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• To determine the effects of different aromatase inhibitors on aromatase activity
• To assess aromatase activity in response to primary endocrine therapy
These aims are addressed sequentially by:
[i] Assessing validation and reproducibility of the methodology to determine aromatase
activity.
[ii] Determining the potency of different aromatase inhibitors - type I (exemestane,
formestane) and type II (aminoglutethimide, letrozole, anastrozole, fadrazole) in a
mammary adipose tissue fibroblast culture model and the time scale needed for the
effects.
[iii] Measuring aromatase activity before and during primary endocrine therapy in
malignant and nonmalignant tissue specimens from postmenopausal women with breast
cancer.
[iv] Assessing changes in molecular expression associated with letrozole treatment by
measuring mRNA, the type of transcripts expressed and the changes in expression of
transcripts before and after treatment.
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ABSTRACT
Certain breast cancers require oestrogen for their continued growth. In postmenopausal
women, in whom most breast cancers arise, oestrogen is primarily synthesised in
peripheral sites such as adipose tissue, muscle and within the breast cancers themselves.
As these sites are not amenable to surgical removal the concept of inhibiting oestrogen
biosynthesis with drugs is an attractive treatment option. Consequently, aromatase
inhibition has become a major treatment strategy for postmenopausal women with
oestrogen-dependent breast cancer.
The aims of this study were to determine the effects of both type I (exemestane,
formestane) and type II aromatase inhibitors (letrozole, anastrozole, fadrazole,
aminoglutethimide) on aromatase activity. Studies based on invitro incubations of
cultures of mammary adipose tissue fibroblasts demonstrate that the new aromatase
inhibitors are highly effective, with IC50 values in the lower nanomolar range (1-50
nm). Aromatase inhibitors such as letrozole (lOOnm) produced almost total inhibition of
aromatase activity (97%) demonstrating its remarkable potency.
The fibroblast cultures were induced to display aromatase activity by preincubation with
either dexamethasone or dibutyryl cyclic AMP. The induced aromatase activity showed
classic sensitivity to aromatase inhibitors. However, if aromatase inhibitors were
included in the culture media during the preincubation period, enhanced activity was
displayed with type II inhibitors (letrozole, anastrozole, aminoglutethimide) but not with
type I inhibitors (exemestane, formestane). This effect may reflect the possibility of
developing resistance with the long term use of type II inhibitors and suggests the
sequential use of type II followed by type I aromatase inhibitors in the treatment of
breast cancer.
Sixteen postmenopausal patients with large (>3cm), oestrogen receptor positive (>20
fmol/mg cystosol protein), primary breast cancers (stages T2, T3, NO, Nl) were treated
with aromatase inhibitors - letrozole, anastrozole and exemestane prior to surgery and
aromatase activity was measured (invitro) before and after 3 months of treatment.
Significant reduction in the aromatase activity was found following treatment in
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malignant tissues. The changes following treatment with letrozole, anastrozole and
exemestane were statistically significant between pre and post treated tumour samples
(p=0.017, p=0.01, p<0.05). This demonstrates the potency of the third generation
aromatase inhibitors in reducing aromatase activity in tumour tissues. The nonmalignant
tissues had a variable response with some displaying enhanced aromatase activity
following treatment.
Molecular changes underlying the mechanism associated with letrozole treatment was
also studied. The coding part of the aromatase gene was expressed in all the samples
studied. Possible induction of the exon I variant 1.1 and 1.4 following treatment was
demonstrated, although this was not totally reproducible. These findings suggest that
there may be a switch in the regulatory mechanism of aromatase activity from normal
breast tissue to cancerous tissue.
This study has demonstrated the effects of aromatase inhibitors on aromatase in both
response and resistance to therapy. T he new generation of aromatase inhibitors are
potent agents capable of profoundly influencing endocrine events within the breast.
Paradoxical response observed with type II aromatase inhibitors under certain
circumstances may have important implications for their long term and sequential use.
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INTRODUCTION
The epidemiology of breast cancer, anatomy and physiology of breast and relevance of
steroid hormones are discussed. The biology of oestrogen as applied to the development
and progression of breast cancer has been reviewed.
Further consideration has been given to
[i] The patterns of endogenous oestrogen within the breast.
[ii] The sources by which the breast and tumours may be supplied with oestrogen and
mechanisms by which oestrogen may exert its action.
[iii] The methods of hormonal deprivation, the molecular events which may follow
oestrogen deprivation leading to hormone independence.
[iv] The role of aromatase and aromatase inhibitors.
6
BREAST CANCER
Breast cancer is the most common female cancer, with a worldwide yearly estimate of
one million new cases and accounts for 22% of all cancers in women [Shibuya K],
Incidence rate varies between populations, with the highest rates in Western countries
(over 100 cases per 100,000 women) and the lowest in Asian countries (10 - 15 per
100,000 women). In the UK, there are over 38,000 new cases of breast cancer diagnosed
each year and accounts for 17% of all cancer deaths [National Statistics, 2001]. In the
United States, approximately 180,000 new cases of breast cancer are diagnosed annually
and accounts for 48,000 deaths per year [Jemal A], Approximately 1% of breast cancers
occur in males with about 250 cases diagnosed each year in the UK [National Statistics,
1999],
The incidence of breast cancer increases with age, with 80 % of cases occurring in
postmenopausal women. Several well-established risk factors are associated with the
development of breast cancer, primarily age and female sex [Fentiman IS].
Breast cancer is the most common cause of cancer related mortality among women
[Flortobagyi GN], The age-standardised mortality has been increasing steadily ever since
the 1960s, suddenly in the late 1980s it flattened out and then during the 1990s it
decreased substantially [Beral V]. Data has revealed a significant improvement in
survival during the last 5-year period (1989-1994) compared with the previous 15 years
[National Statistics, 2001]. The decrease strongly suggests that the improvement is
chiefly due to the changes in the way breast cancer has been diagnosed and treated. Peto
et al have suggested that the reduced mortality was due to the use of tamoxifen and
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adjuvant treatment, whereas Tabar et al have attributed it to widespread screening with
mammography. Although overall survival has improved with earlier diagnosis, breast
cancer still represents a leading cause of cancer-related death.
During the last two decades, significant advances have been made including the
development of early detection methods, less radical surgery, new adjuvant therapies
and improved supportive care [Botha JL], Management of breast cancer has traditionally
been based on the stage of the disease: early disease stages I and II and advanced stages
III and IV. The treatment of patients with early breast cancer is curative and has two
main aims - to achieve local disease control and to treat micrometastatic disease. The
treatment of patients with advanced disease is to control the disease while maintaining
the quality of life. Local disease control is achieved by surgery to breast and axilla and
adjuvant therapy with either cytotoxic drugs or endocrine agents or both is
recommended for patients with node-positive disease [McArdle CS], Radical surgery
has been replaced by breast conservation surgery as both have similar survival rates
[Veronesi U, 1981], For locally advanced disease multimodality therapy is
recommended with the sequence of chemotherapy, surgery and radiotherapy largely
dependent on the operability of the primary disease. Wide ranges of systemic, local and
supportive therapies are available for the palliation of metastatic breast cancer.
Successful delivery of effective adjuvant systemic therapy acts as a complement to
surgical management of breast cancer [Peto R]. The absolute benefit will be a function
of the patient's risk of relapse at the time of diagnosis. The Early breast cancer Trialists
Collaborative Group (EBCTCG) has provided the foundation for consensus statements
regarding selection of cases in which adjuvant therapy is likely to be beneficial. The
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National Surgical Adjuvant Breast Project (NSABP) protocols B-13 and B-14
documented the survival advantages associated with adjuvant chemotherapy and
endocrine therapy for patients who have node negative, endocrine resistant or endocrine
sensitive disease. Chemotherapy is now recommended for high-risk endocrine
responsive disease and for any endocrine resistant breast cancer that is deemed
appropriate for systemic treatment. Patients who have node positive breast cancer have
the largest magnitude of benefit from adjuvant therapy [EBCTCG, 2005], The toxicity
of adjuvant therapy must be carefully, balanced against the relapse risk. Genetic
profiling and assignment of a recurrence score via the Oncotype DX test can be helpful
in determining the benefit from adjuvant therapy [Olivotto IA].
Although the ultimate goal of treatment remains improved survival, increasing emphasis
is now placed on less morbid treatments and enhancing quality of life. The resurgence of
interest in endocrine strategies can be attributed to low toxicity profiles of effective
hormonal agents. This thesis has mainly focused on endocrine therapy for breast cancer,
as discussed in the following sections.
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NORMAL BREAST
STRUCTURE AND FUNCTION OF BREAST
Structure
The human breast is a modified apocrine gland and develops as a dermal-derived organ
lying within the subcutaneous tissue. The breast rests on the pectoralis muscle and on a
thin layer of loose areolar tissue the retromammary space, containing lymphatics and
small vessels. The mature breast is composed of three principal tissue types: glandular
epithelium, fibrous stroma and fat. The lobule is the basic structural unit of the
mammary gland. The number and the size of the lobules vary enormously. In youth, the
predominant tissues are epithelium and stroma, which are replaced by fat in older
women.
Function
The breast undergoes changes throughout reproductive life. In adolescence, the breast is
composed primarily of dense fibrous stroma and scattered ducts lined with epithelium.
With puberty there is increased deposition of fat, formation of new ducts and the first
appearance of lobular units. This process of growth entails cell division and is under the
control of hormones. After the third decade, the ducts and lobules atrophy with
shrinkage of the intralobular and interlobular stroma. Menopause results in involution
and a generalised decrease in the epithelial elements of the resting breast. These changes




Postnatal mammary gland development is highly dependent on the ovarian steroids,
oestrogen and progesterone [Woodward TLj.The mammary gland sequentially acquires
and cyclically exhibits proliferative responses to oestrogen and progesterone from birth
to postmenopause [Fendrick JL]. Oestrogen and progesterone act in an integrative
fashion to stimulate normal adult female breast development. Although oestrogen and
progesterone are vital to mammary growth, they are ineffective in the absence of
anterior pituitary hormones [Fendrick JL]. Oestrogens are considered to play a major
role in promoting cell proliferation, while progesterone influences its differentiation
[Russo J].
The initiation and progression of breast development involves a coordinated effort of
pituitary and ovarian hormones, as well as local mediators [De Bortoli M]. These
hormones guide mammary gland development and differentiation by regulating the
expression of local growth factors and their receptors at the cell surface [De Bortoli M],
The mammary epithelial proliferation is also probably mediated through stromal-derived
factors [Xie J], Walden et al demonstrated that GH-stimulated production of IGF-1
mRNA in the mammary gland itself, suggesting that IGF-1 production in the stromal
compartment of the mammary gland acts locally to promote breast development.
Stromal cells appear to influence behaviour by the secretion of growth factors and by
altering the composition of the extracellular matrix (ECM) in which epithelial cells
reside. The regulation and action of autocrine and paracrine growth factors (including
the epidermal, insulin-like, hepatocyte and fibroblast growth factor families) are
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probably involved in ovarian steroid mediated epithelial stromal interactions [Woodward
TL, 2000]. Hansen et al have suggested that the coordinated regulation of ovarian
hormone responsiveness and extracellular matrix / integrin expression may be critical to
normal mammary gland development and breast cancer growth and progression. Over
the last decade, studies have revealed that basement membrane, extracellular matrix,
proteins and their cellular receptors regulate cell proliferation and differentiation and are
regulated by complex epithelial stromal interactions regulated by ovarian steroids
[Haslam SZ], Thus, development and regulation of breast is critically dependent upon




Steroid hormones comprise families of structurally related compounds, which include
progesterones, corticosteroids, androgens and oestrogens. All share common precursor
molecule cholesterol from which they are derived.
Mode of action
Biologically active steroids are classically produced and secreted from endocrine organs
such as ovary, testis and adrenal cortex. They are then transported through circulation
and act on target tissues in which their specific nuclear receptors are present [Miller WR,
1996]. The biological features of steroid dependent target tissues are influenced by
serum or plasma concentration of the hormones [Suzuki T, 2005], The biochemical
actions of steroid hormones are diverse. In the target tissues steroids may increase the
rate of messenger ribonucleic acid (mRNA) synthesis and regulate mRNA stability,
increase nucleotide incorporation into deoxyribonucleic acid (DNA), DNA synthesis and
cell numbers, enhance the synthesis of specific proteins, member trafficking and
mobilisation of lipids. Steroids have pleiotropic effect and are able to induce synthesis
and secretion of peptide growth factors, which have autocrine and paracrine influences
including proliferative responses [Sasano H, 2007]. Consequently steroids are able to
regulate tissue growth, differentiation and metabolic activity. Action of steroid
hormones is mediated through receptors, which are essentially nuclear transcription
factors [Baniahmad A]. Binding of ligand to receptor causes disassociation of the
receptor from chaperone proteins, conformational changes and increase phosphorylation
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of the receptor molecule. This, results in transactivation of the receptor promoting
transcriptional events necessary for transcription and as a result new species of mRNA
appear which may be specific for the interaction of steroids with receptors.
Synthesis
Cholesterol has a phenanthrene structure composed of one five membered and three six
membered ring. Steroid biosynthesis comprises a series of degradative steps (fig la)
whereby, C27 sterol is converted [i] to corticoids by partial removal of the side-chain of
the D-ring into progestins and its hydroxylation [ii] to androgens by total removal of the
D-ring side-chain [iii] to oestrogens by removal of the side chain between A and B rings.
Only the synthesis and relevance of steroids to breast are discussed in this chapter.
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The ovary secretes a variety of C19 steroids, including dehydroepiandrosterone (DHEA),
androstenedione, testosterone, and dihydrotestosterone [Labrie F, 2003]. They are
produced by the thecal cells and to a lesser degree by the ovarian stroma. The major C19
steroid androstenedione is partly secreted directly into plasma, while the remainder is
converted to oestrogen by the granulosa cells [Suzuki T, 2007]. Androstenedione can be
converted to oestrogen or testosterone in the ovary and in extraglandular tissues.
Oestrogens
The naturally occurring oestrogens are Cis steroids characterised by the presence of an
aromatic A- ring, a phenolic hydroxyl group at C-3 and either a hydroxyl group
(oestradiol) or a ketone group (oestrone). In women oestrogens originates from different
sources; the ovaries and extragonadal sites are its main sources in the pre and
postmenopausal periods respectively. The most potent oestrogen secreted by the ovary is
17 beta oestradiol [Chappel SC]. Oestriol (16-hydroxyoestradiol) is produced by the
metabolism of oestrone and oestradiol and is the most abundant oestrogen in urine.
Oestrone sulfate is formed by peripheral conversion of oestradiol and oestrone and it is
the most abundant oestrogen in blood, though not physiologically active [Vignon F],
Oestrone is mainly derived from extraglandular conversion of androstenedione in
peripheral tissues [Lipsett M],
The conversion of androgen to oestrogen in postmenopausal women has shown to occur
principally in peripheral tissues including skin, muscle, fat and bone [Longcope C], The
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conversion is catalysed, by the aromatase enzyme complex. C19 steroids produced by
the adrenal cortex include androstenedione, dehydroepiandrosterone (DHEA) and
dehydroepiandrosterone sulfate (DHEAS). DHEA must be first converted to
androstenedione before aromatisation. Another major step is reduction of the 17 keto
group to 17 hydroxyl catalysed by 17 p hydroxysteroid type I which is essential for the
formation of oestrogen (oestradiol).
The extragonadal sites of oestrogen biosynthesis differ from the ovaries in many ways.
Although they have the capacity to convert C19 steroids to CI8 steroids, unlike the
ovaries they lack the ability to synthesise C19 precursors. They are therefore dependent
on circulating C19 steroid precursors for oestrogen biosynthesis. Oestrogens synthesised
extragonadally are probably only biologically active in local tissues in either an
intracrine or a paracrine fashion [Labrie F]. The total amount of oestrogen synthesised
by the extragonadal sites may be small but may exert significant biological influence
locally.
The major routes of metabolism of oestrogen are [i] interconversion of oestrone and
oestradiol [ii] the formation of catechol oestrogen by 2 hydoxylation and [iii]
conjugation of oestrogen with sulfate or glucuronic acid. Oestrogen is metabolised
almost exclusively by oxidation, in both men and women [Lippert TH], The first stage
involves transformation of oestradiol into oestrone by oxidation at the C17 position, a
process that is reversible. Further metabolism, from oestrone takes place in two different
ways - by hydroxylation at either the A or D ring. The products of both pathways are
catalysed by different enzyme systems. Metabolism of A-ring results in the metabolites
2 and 4 hydroxyoestrone and metabolism of the D ring leads to 16 hydroxyoestrone and
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oestriol. In men and postmenopausal women, oestrogen is formed predominantly via
aromatisation of adrenal steroids resulting in oestrone and metabolism starts from
oestrone [Siiteri PK, 1973].
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Fig 1b: Origin of oestrogen in breast cancer
HSD -Hydroxy steroid dehydrogenase, STS- Sulfotransferase
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Intratumoral production of oestrogens in breast
Studies, have suggested that local formation of oestrogens in the breast tumors is more
important than circulating oestrogen in plasma for the growth and survival of oestrogen-
dependent breast cancer in post-menopausal women [Foster PA; Russo J; Bulun SE,
2008]. The rationale for the importance of local formation of oestrogens is based on the
following; (i) Oestradiol (E2) levels in breast tumors are equivalent to those of pre¬
menopausal patients, although plasma E2 levels are 50-fold lower after menopause. E2
concentrations in breast tumors of post-menopausal women are 10-40 times higher than
serum level [Nakata T, 2003] (ii) breast tissues are able to concentrate oestrogen from the
circulation against a gradient [Miller WR, 1997] and (iii) mammary adipose tissue and breast
cancers are capable of oestrogen biosynthesis [Varela RM],
Local potential for oestrogen production within the breast is relevant to the natural
history of breast cancer. Both normal and diseased breast can produce steroid hormones,
which can influence the growth and development of breast tissues [Varela RM]. Perel
and Miller et al independently demonstrated the ability of human breast and its
neoplasms to produce 17|3 oestradiol (invitro) [1982],
Biosynthesis of oestrogens in breast tumors tissues occurs via two major different routes,
(Fig lb) one is aromatase pathway and another is steroid-sulfatase (STS) pathway.
Intratumoral aromatase plays as important role converting serum androgens to
oestrogens in situ and serves as a major source of oestrogen. However, other enzymes
such as the 17 beta-hydroxysteroid dehydrogenase isozymes (17beta-HSD), oestrogen
20
sulfatase (STS) and oestrogen sulfotransferase may also play pivotal roles in
intratumoral oestrogen production [Sasano H, 2006].
High concentrations of circulating inactive steroids, such as androstenedione and
oestrone sulfate, are considered major precursor substrates of local oestrogen production
[Suzuki T, 2006]. The relative contribution of uptake into the breast and local biosynthesis of
endogenous oestrogens within breast tumours can be assessed from infusion studies [Reed MJ,
1991], These suggest substantial inter-subject variation; in some breasts, oestrogen levels are
largely accounted for by uptake, whereas in others most oestrogen appears to be derived from
local intratumoural synthesis [Bulun SE, 1994; Miller WR, 2006]. Furthermore, tumours
with highest levels of oestrogen are invariably those with the greatest in situ synthesis [Reed
MJ, 1991; James VHT, 1989], If intratumoural aromatase activity is the source of oestrogen,
which maintains malignant growth, treatment with drugs, which inhibit that activity, would be
particularly effective in these tumours.
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OESTROGEN AND BREAST CANCER
Breast cancer risk is related to the cumulative exposure of the normal breast epithelium
to the sex hormones, mainly oestrogen. It has been well documented to play a central
role in the aetiology of breast cancer [Travis RC].
Several endogenous and exogenous variables, which alter oestrogen status, affect the
risk of breast cancer [Henderson BE, 1981, 1984], The most consistently documented
hormonal risk factors are early menarche, late menopause and at first full-term
pregnancy [Brinton LA, 1988; Henderson BE, 1985; Trichopoulas D], The intense
differentiation of the terminal duct lobular unit associated with each full term pregnancy
and release of various hormones, autocrine and paracrine growth factors during lactation
may explain the protective effects of early age at first full term pregnancy, parity and
lactation of breast cancer risk [Okobia MN, 2005]. Observations suggest that regular
ovulatory cycles increase the risk of developing breast cancer [Henderson BE, 1985].
Women with early menarche and rapid establishment of regular cycles had an almost
four-fold increased risk of breast cancer compared to women with late menarche and
long duration of irregular cycles [Vihko RK], Rate of breast cancer increases rapidly in
the premenopausal years, but slows sharply at the time ofmenopause, when endogenous
hormone levels decline rapidly [Sasco AJ], The rate of breast cancer in the
postmenopausal period is only about a sixth of the rate in the premenopausal period.
This age incidence curve appears to be shaped in a major way by the effects of ovarian
activity [Henderson BE, 1993],
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Hormone replacement therapy and oral contraceptives, the exogenous sources of
oestrogens, are also potential contributors to breast cancer risk [Collaborative Group,
1997], The Million Women Study (MWS) and the Women's Health Initiative (WHI)
study demonstrated an increase in breast cancer risk in women on hormone replacement
therapy (HRT) in comparison with control groups. In the Million women study current
users of HRT were associated with an increased risk of incidents (RR 1.66, pO.OOOl)
and fatal breast cancer (RR 1.22, p=0.05). Incidence was significantly increased for
current users of preparations containing oestrogen only (RR 1.30, pO.OOOl), oestrogen
progesterone (RR 2.00, pO.OOOl), but the magnitude of the associated risk was
substantially greater for oestrogen- progesterone than other types of HRT (pO.OOOl).
Results varied little between specific oestrogens and progesterone or their doses; or
between continuous and sequential regimens. In current users of each type of HRT, the
risk of breast cancer increased with increasing total duration of use. 10 years use ofHRT
is estimated to result in five additional breast cancers per 1000 users of oestrogen only
preparations and 19 additional cancers per 1000 users of oestrogen-progestrone
combinations. In the WHI trial women randomised to oestrogen and progesterone, had
an elevated risk of breast cancer (RR = 1.29) after 5 years of follow-up.
The relationship between weight and breast cancer risk is critically dependent on age. In
postmenopausal women, a 10 kg increment in body weight results in an approximately
80% increase in the risk of breast cancer [den Tonkelaar I]. This is due to the higher
circulating oestrogen level from conversion of the adrenal androstenedione to oestrone
by enzymes present in body fat.
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In premenopausal women, the relationship between weight and breast cancer risk is less
clear-cut, but may be inverse [Waard F], Nutrition probably influences breast cancer
occurrence by modifying age at menarche and body weight. Howe et al found that the
breast cancer risk of postmenopausal women was positively associated with both total
fat and saturated fat intake [Brinton LA, 1995], However, analysis of cohort studies has
found little or no difference in breast cancer-risk and intake of fat [Hunter DJ],
A large and compelling body of epidemiological data, animal studies and clinical trials
implicate oestrogen in the aetiology of breast cancer [Henderson BE, 1988]. It is well
known that synthesis and metabolism of oestrogen takes place in both tumour and
surrounding tissues [Santen RJ, 1999], Administration of steroids in patients with breast
cancer can increase tumour cell proliferation [Dao TL]. Experimentally this is
manifested by the proliferative effect on cultured breast tumour cell lines and
development ofmammary tumours in rats exposed to high doses of oestrogen [Rudali G;
Lippman ME, 1975]. Higher plasma oestradiol levels have been reported several years
before diagnosis in women with breast disease compared with matched controls
[Toniolo PG]. An inverse relationship between plasma oestrogen and disease free
interval has been demonstrated in premenopausal breast cancer patients after primary
treatment [Lonning PE, 1996],
The most convincing data that oestrogens play a major role in the natural history of
breast cancer are from treatment aimed at inhibiting oestrogen production by ovarian
ablation or administration of antioestrogens [Veronesi U, 1975]. Artificial menopause
induced by either bilateral oophorectomy or pelvic irradiation, also markedly reduces
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breast cancer; this effect appears to be slightly greater than that of natural menopause
[Parazzini F],
Endocrine therapy has shown that surgical, radiological or medical oophorectomy causes
regression of about 30% of breast cancers in premenopausal women [Ward HWC],
Remission is noted in a similar proportion of postmenopausal women treated by
adrenalectomy, hypophysectomy, antioestrogens and aromatase inhibitors.
Evidence suggests that the genotoxic transformation can be initiated by binding of the
electrophilic metabolite of oestradiol or oestrone to deoxyribonucleic acid (DNA),
initiating the critical step in the pathway leading to tumour formation [Cavalieri EL],
Studies indicate that metabolites of both oestradiol metabolism pathways can potentiate
carcinogenesis [Theodor HL]. Oestrogens are considered typical tumour promoters; due
to their oestrogen-receptor mediated mitogenic activity that increases the probability of
spontaneous mutations [Emons G]. Oestrogens may also exert paracrine effects on
tumour development and growth by increasing the expression and activity of other
regulatory proteins including transforming growth factor-alpha, cyclin-dependent




Normal breast growth and development are regulated by the complex interaction of
hormones and growth factors [Dickson RB, 1988; Osborne CK, 1990], Abrogation's in
hormonal regulation (endocrine, paracrine, autocrine and intracrine) contribute to breast
tumourigenesis by promoting inappropriate growth and survival of cells. Studies indicate
that breast cancer cells under oestrogenic control synthesise and secrete their own
growth factors, which may auto stimulate themselves or adjacent stromal tissues through
autocrine or paracrine mechanism [Lippman ME, 1987], Therefore, it is important to
understand the direct and indirect effects of oestrogen on breast, as it influences the
natural history of breast cancer.
Mechanisms of oestrogen action
The major effects of oestrogen are probably mediated directly on tumour cells
through the oestrogen receptors, which programme genomic responses
[Yamamoto KR]. Oestrogen can also indirectly affect the growth of breast cancer
by influencing polypeptide hormones and secretion of mitogenic factors [Freiss
G]. It is unclear whether receptor-genome interaction directly modifies cellular
proliferation or if growth effects are mediated via secondary response modifiers.
However, in oestrogen-sensitive cell lines of breast cancer, oestrogen may (i)
induce the secretion of mitogenic factors and (ii) stimulate the production of
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proteases, which may degrade extracellular matrix and thereby accelerate tumour
invasion and metastasis.
Hormone receptors
Reproductive and hormone sensitive tissues possess high-affinity protein receptors for
oestrogen and progesterones. Receptors may be expressed in normal and tumour tissue
of mammary origin [McGuire WL, 1975]. Isolation of the steroid receptors has led to
understanding of the molecular mechanism of action of the steroid hormones. Hormone
receptor proteins are activated when occupied by their specific hormone ligand receptor,
leading to induction of numerous cellular genes, including those that may encode critical
enzymes and secrete peptide growth factors [Mclnerney EM], Intranuclear binding of
the steroid-receptor complex to DNA at different promoter regions of numerous
oestrogen-responsive elements results in several biologic effects including stimulation of
mammary gland growth [Kelloff GJ]. Therefore, it is likely that the proliferative effect
of steroids on tumour cells is also mediated through the receptor proteins.
Oestrogen receptors
Oestrogen receptors (ER) have two isoforms: the initially cloned oestrogen receptor
alpha and the more recently cloned oestrogen receptor beta [Mosselman S]. Oestrogen
stimulates cell growth by binding to the oestrogen receptor, which causes oestrogen
receptor homodimer formation [Read LD], This receptor-ligand complex binds to
specific DNA sites called oestrogen-responsive elements and serves as a transcription
factor, activating oestrogen-responsive genes that regulate the cell growth [Green S].
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Thus oestrogen signal transduction plays an important role in both normal and neoplastic
mammary tissue [Vorherr H]. However, perturbations of oestrogen receptor signal
transduction are thought to contribute to tumour progression and the eventual
development of a hormone-independent and more aggressive phenotype [Schmitt FC].
Progesterone receptor
Progesterone receptor may be an indicator of a functional oestrogen receptor, which may
explain why progesterone receptor-positive breast cancers respond to hormonal
treatment, despite very low or absent oestrogen receptor [Horowitz KB]. The predictive
value of PR has long been attributed to the dependence of PR expression on ER activity,
with the absence of PR reflecting a nonfunctional ER and resistance to hormonal therapy
[Wilson CA], However, recent clinical and laboratory evidence suggests that ER
positive/PR negative breast cancers may be specifically resistant to SERMs, where as
they may be less resistant to oestrogen withdrawal therapy with aromatase inhibitors,
which is a result inconsistent with the nonfunctional ER theory [Arpino G; Howell A,
2005]. Novel alternative molecular mechanisms potentially explaining SERM resistance
in ER positive/PR negative tumors has been suggested by experimental indications that
growth factors may down regulate PR levels [Cui X, 2005]. Thus, the absence of PR
may not simply indicate a lack of ER activity, but rather may reflect hyperactive cross
talk between ER and growth factor signaling pathways that down regulate PR even as
they activate other ER functions.
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Growth factors
Tissue regulation is modulated in a very complex fashion by locally acting polypeptide
hormones (growth factors). Growth factors include epidermal growth factor (EGF),
insulin-like growth factor (IGF), fibroblast growth factor (FGF) and transforming
growth factors (TGF family). The EGF family includes four transmembrane tyrosine
kinase receptors, HER 1-4 and several growth factors including EGF and TGF-alpha.
Multiple aspects of breast biology, including survival, proliferation and differentiation
are modulated by the EGF family through complex receptor heterodimerization pattern
[Earp HS]. TGF-alpha and related growth factors may also mediate the stromal epithelial
interactions involved in the indirect growth response of normal mammary epithelial cells
(MECs) to oestrogen. Thus antibodies against TGF-alpha or its receptor (EGFR) can
block oestrogen induced growth [Dickson RB, 1998], Studies suggest that oestrogen
receptor negative breast cancer cells are more sensitive to TGF-P [Arteaga CL]. The
malignant potential of breast cancer is likely to depend on the balance between the
stimulators and inhibitors of growth produced by the tumours. TGF-P may inhibit the
proliferation of epithelial tissues and stimulate the proliferation of stromal tissues via
interdependent serine-threonine kinase receptors [Relf M], Insulin-like growth factor 1
plays a central role in normal mammary gland development. Insulin-like growth factors
1 and 2 are both potent mitogens for breast cancer cells invitro [Surmacz E], Expression
of several fibroblast growth factor (FGF) ligands and receptors has been observed in
normal and malignant breast tissue [Kern FG], Fibroblast growth factors (FGF) have
pleiotrophic effects on breast tumour cells including increased metastatic ability (invivo)
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and angiogenesis [Lee AV], The epithelial and/or stromal cells within the tumour also
secrete proteases, such as the cathepsins, stromelysin, gellatinases or urokinase
plasminogen activator, which may contribute to tumour invasiveness and metastatic
potential [Noel A; Thomssen C]. In oestrogen receptor positive breast cancer cells,
expression and secretion of certain autocrine growth factors, such as TGF-a and IGF-2,
are stimulated by oestrogen and inhibited by antioestrogens while oestrogen receptor
negative breast cancer cells are autonomous [Lippman ME, 1987], Thus changes in the
expression of these secreted factors can mediate the growth effects of oestrogen and
antioestrogen. If the actions of oestrogen are mediated by growth factors,
oestrogenic responses should be mimicked by growth factors. Conversely,
anti-growth factor strategies should cause regression of oestrogen-dependent
tumours. Experimental systems do not completely support these concepts. The full
growth-promoting effects of oestrogen seem to require other agents besides
secreted growth factors. The sequelae from the observations are that therapies
directed against oestrogen-induced growth factors are unlikely to be as effective in
causing tumour regression as antioestrogen and conversely, successful
antioestrogen therapy is not simply mediated via antagonism of growth factor
production, but embodies full panoply of actions.
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ENDOCRINE DEPRIVATION
Tumours of target organs for steroid hormones, most notably breast cancer, often need
oestrogen for their continued growth and will regress if deprived of such hormones
[Bulbrook RD; Miller WR, 1996], In contrast to prostatic cancer, in which the majority
of patients respond to endocrine therapy, only a third of the patients with advanced
breast cancer respond to hormonal manipulation [Masamura S]. Endocrine blockade
aims to deprive hormone responsive cancer cells of mitogenic stimulation by oestrogen.
Before the menopause the ovary is the principle source of oestrogen; it explains the
beneficial effects of surgical or radiation induced oophorectomy in premenopausal
women with breast cancer [Clarke MJ], The glandular production of oestrogen becomes
negligible after menopause and biosynthesis in peripheral sites becomes physiologically
important [Poortman J]. Oestrogen deprivation therapies aim to destroy hormone
producing tissues either by surgical intervention or by the use of drugs, which inhibit the
enzymes involved in oestrogen biosynthesis at the oestrogen receptor. Endocrine
deprivation may also induce growth inhibitory factors or reduce the production of
growth stimulatory factors [Hulka BS].
Endocrine therapies can be classified as ablative, additive, inhibitive and competitive
therapy. Most of them affect tumour growth, either by inhibiting the synthesis of
oestrogen or its action at the level of the tumour cell [Goldhirsch A]. Other postulated
mechanisms include direct cytotoxicity, effect on autocrine growth factors, apoptosis
and cell cycle arrest. The choice of endocrine therapy is influenced by the menopausal
status. In premenopausal women, oestrogen synthesis is reduced by ovarian ablation
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with surgery, radiotherapy, or luteinizing hormone-releasing hormone (LHRH) agonists
[Gradishar WJ]. Aromatase inhibitors are largely ineffective in this group as peripheral
suppression is overcome by the intact hypothalamic-pituitary-ovarian axis [Santen RJ,
1980]. In postmenopausal women, antioestrogens, aromatase inhibitors and progestins
are effective [Miller WR, 1990]. Table - 1 considers different strategies employed for
oestrogen deprivation.
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Table-1: Oestrogen deprivation strategies
Primary Effect Strategy
Decrease oestrogen production Irreversible surgical ablation:
oophorectomy, hypophysectomy,
adrenalectomy
Reversible medical ablation: luteinizing
hormone-releasing hormone agonists
Inhibitive strategies: selective
aromatase inhibitors and non selective
aromatase inhibitors
Antagonise oestrogen effects Competitive: antioestrogens
Mechanism unclear: progestins, androgens
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Oestrogen deprivation and transition to hormone
independence
Antihormones continue to be a mainstay in the management of breast cancer disease,
promoting worthwhile tumour remissions and significant survival benefits in many ER
positive patients [Santen RJ, 2004]. Some of these agents act by competing with
oestrogen for binding to its target receptor in breast cancer cells, exemplified by partial
antioestrogens (Tamoxifen) and also pure antioestrogens (Faslodex) that additionally
reduce ER level. Other agents, notably aromatase inhibitors, act to severely deplete the
oestrogenic environment. The efficacy of all antihormones present to date is
compromised not only by a proportion of ER positive patients exhibiting de novo
antihormone resistance, but also by the many more who acquire resistance following an
initial therapeutic response [Gee JMW; Johnston SR].
Deprivation of oestrogen causes breast tumors in women to adapt and develop enhanced
sensitivity to steroids [Santen RJ, 2008], Following successful endocrine treatment,
most hormone-dependent tumours may become independent and resume growth.
It is therefore important to define mechanisms by which autonomy occurs and to
characterise the events, which may follow oestrogen deprivation. In oestrogen,
deprived environment the endocrine system may compensate by producing
oestrogen from alternate sources [Miller WR, 1999]. But in most patients, relapse
after successful endocrine treatment is not associated with an increase in
oestrogen and when raised levels occur they seem to be the consequence rather
than the cause of progressive disease.
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The concept that hormone independence results from constitutive production of the
growth factors, which are normally induced by oestrogen, has received
considerable attention. Studies in which breast cancer cells have been engineered to
overproduce growth factors in the absence of oestrogen failed to demonstrate that this
could lead to an oestrogen-independent phenotype [Clarke R]. Preliminary results in
primary breast cancers did not support the theory that oestrogen-independent
tumours are autonomous on account of enhanced growth factor synthesis [King
RJ]. There is a growing body of literature suggesting that cross-talk between growth
factors and oestrogen receptors may contribute to endocrine resistance [Massarweh
S].Based on studies primarily with tamoxifen (but now emerging with oestrogen
deprivation), altered growth factor receptor signalling and its cross-talk with the ER
pathway has been heavily implicated as a resistance mechanism [Hutcheson IR]. Of
particular interest is the recent finding with respect to human epidermal growth
factor receptor 2 over expression, suggesting this may reduce responsiveness to
tamoxifen but not to aromatase inhibition [Jones HE],
During oestrogen deprivation renewed growth may likely result from adaptive
changes within the tumour either from outgrowth of oestrogen-resistant cell clones
(which were present from the outset of therapy) or from cell genetic changes
resulting in autonomous phenotype [Powers MV]. These phenomena need not be
mutually exclusive and there is supportive evidence for both. Firstly, cellular
heterogeneity exists within tumours with regard to hormone sensitivity and
successful hormone therapy can produce selective cell kill. Secondly, adaptive
changes occur in oestrogen-dependent breast cancer cells maintained in a steroid
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free environment; in time, an oestrogen-resistant phenotype develops [Darbre PD],
Loss of sensitivity to oestrogen can also occur without concomitant loss of
oestrogen receptors or oestrogen-inducible molecular markers. The exact molecular
changes essential for autonomy have not been determined although different
patterns of mRNA expression may be observed in oestrogen-dependent and
independent cells. The acquisition or increased capacity of tumour cells to
synthesise oestrogen would theoretically confer independence from an external
source of oestrogen. In addition, recent findings by Modlich et al suggest that it is
important to assess changes in gene expression that might occur after the initiation
of therapy. Thus, prolonged endocrine therapy can be associated with an acquired
increase in peptide growth factor signaling (EGFR, HER2), together with cross talk,
activation of ER dependent gene transcription and cell growth, all of which may lead to
endocrine resistance [Johnston SR], All in all, a better understanding of the
multidirectional cross-talk between growth factor pathways, the oestrogen receptors
(both at the genomic and nongenomic level), and oestrogen receptor cofactors is
vital to overcome endocrine resistance [Santen RJ, 2006].
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ENDOCRINE THERAPY
Background to endocrine therapy
Hormonal therapy for breast cancer has changed radically from ablative surgical
procedures to medical therapy. In 1886, Beatson first demonstrated that bilateral
oophorectomy leads to regression of metastatic breast cancer. Surgically induced
menopause became the first effective means to control advanced breast cancer,
producing a beneficial regression in 25 - 40% of premenopausal patients [Beatson G,
1901]. In 1922, DeCourmellers administered radiotherapy to the ovaries; its antitumour
effect was similar to surgical oophorectomy, except for the delay in tumour regression.
In 1952, Huggins demonstrated the effectiveness of adrenalectomy in the treatment of
postmenopausal metastatic breast cancer. In 1953, Luft proved that hypophysectomy
which deprives pituitary polypeptide hormones, caused palliative remission in upto 40%
of patients. These procedures have largely been abandoned due to their associated
morbidity.
A greater understanding of oestrogen action on tumour growth evolved with time and
new medical treatments were developed (table-2). Over the last few decades,
antioestrogen therapy has almost replaced endocrine organ ablation. The first experience
of using, androgens, oestrogen and progestins as additive therapies were reported in the
1950s [Ulrich P, Stoll BA], Tamoxifen, an oestrogen agonist-antagonist was introduced
in 1970 and used in treatment of oestrogen-sensitive breast cancer [Cole MP]. In 1970s
aminoglutethimide, an aromatase inhibitor, replaced adrenalectomy in the treatment of
advanced breast cancer [Griffiths CT], In the last decade, aromatase inhibitors of the
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second generation (fadrozole, formestane) and third generation (anastrozole, letrozole,
exemestane) and new anti-oestrogens (toremifene, raloxifene, droloxifene) have been
developed. Newer generation aromatase inhibitors are far more enzyme specific with
minimal side effects and have almost replaced tamoxifen in the treatment of hormone
sensitive breast cancer.
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1952 Pituitary irradiation Douglas
1953 Pituitary removal Luft
1971 Antioestrogen Cole
1973 Aromatase inhibitors Griffiths




1993 Pure antioestrogen Howell
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METHODS OF ENDOCRINE DEPRIVATION
All endocrine therapies aim to reduce oestrogen dependent tumour growth. Surgical
procedures such as oophorectomy ablate oestrogen synthesis by the ovary [Veronesi U,
1975], Antioestrogens act at the cellular level by interfering with the action of oestrogen
on the hormone receptors, while aromatase inhibitors inhibit the peripheral conversion
of steroid precursors into oestrogen [Jordan VC, 1997]. The mechanism of action of
additive therapies such as progestins, androgens and oestrogens are not clearly
understood. Table - 3 illustrates the different mechanisms of action.
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Table-3: Mechanism of action of endocrine therapies
THERAPY MECHANISM OF ACTION
Oophorectomy Ablation of oestrogen synthesis in premenopausal women
Adrenalectomy Decreased androgens leading to decrease in their
aromatisation to oestrogen
Hypophysectomy Decreased FSH, LH, and corticotropin leading to
decreased oestrogen synthesis
Ovarian radiation Primary site of oestrogen synthesis in premenopausal
women removed; decreased oestrogen synthesis
Antioestrogens Competition with oestrogen for binding to oestrogen
receptor
Aromatase inhibitors Aromatisation of androgens into oestrogen inhibited in
postmenopausal women
LHRH agonists Gonadotropin stimulation of hypothalamus blocked,
thereby decreasing release of FSH/LH; oestrogen
synthesis decreased in premenopausal women
Progestins Unclear
FSH-folIicle stimulating hormone; LH-luteinizing hormone; LHRH-luteinizing hormone
releasing hormone
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Predictive markers to endocrine therapy
Oestrogen receptor (ER) has been studied in clinical breast cancer for more than 20 years
[Love RR, 1990] and is widely used to select patients for adjuvant hormonal therapy
[Allred DC, 1998; Harvey DC, 1999], It is clear that ER status (ER positive or negative)
remains the most logical and reliable predictor of response to endocrine therapy in the
primary (neoadjuvant), adjuvant and metastatic settings [Pritchard KI.]. Approximately
50%-60% of women with ER-positive breast cancer benefit from endocrine therapy
[EBCTCG, 1992], Research carried out in the early 1970s showed that the ER protein
was present in 50-70% of invasive breast cancers [Jordan VC]. Based on a pooled
analysis of 400 patients with advanced breast cancer, McGuire et al showed that 50-60%
of women possessing ER positive tumors responded to endocrine therapy. In contrast,
only 5-10% of ER-negative tumors regressed with this treatment. It was later shown that
70-80% of breast cancers containing both ER and PR regressed with hormone therapy
[McGuire WL, 1980], Bardou et al demonstrated that the combined measurement of ER
and PR is superior to ER alone in predicting benefit from adjuvant hormone therapy.
Although response rates progressively decline, they remain in the 20-40% range
[Cheung KL, 1997]. Irrespective of the type of hormone therapy used, only 30% of
unselected patients with metastatic breast cancer respond [Buzdar AU, 1998],
Approximately 50 to 60% of all advanced breast cancer in postmenopausal patients will
have hormonally responsive disease [Osborne CK, 1991]. Eventually approximately
half of patients with acquired resistance obtain a clinical benefit from other endocrine
therapies. The National Institutes of Health panel, the European Group on Tumor
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Markers, and the European Society ofMastology have recommended that ER and PR be
assayed on all primary breast cancers [Blarney RW, 2002]. Currently, most investigators
use immunohistochemistry to measure ER and PR [Duffy MJ, 2005]. Baseline tumor
ER expression should be present in at least 10% of infiltrating cancer cells and
preferably should score in the 7 to 8 range by the Allred scoring method. The Letrozole
P024 study required the ER to be expressed in at least 10% of the malignant infiltrating
component of the tumor, but in the IMPACT study, only 1% of the cells were required to
express ER. It is very clear that neoadjuvant endocrine therapy response rates are closely
related to oestrogen-receptor expression [Ellis MJ, 2003].
70% of tumors that have ER or PR do regress in response to these preoperative hormone
therapies [Litherland S]. Although 60-70% of patients with ER positive tumours
respond, only 30-40% sustains response beyond 2 years [Pritchard KI]. In patients who
develop recurrent metastatic disease, it has been a concern as to whether hormone
sensitivity due to the presence of ER in the original primary tumor is lost over time.
This could account for lower response rates see with tamoxifen in advanced metastatic
breast cancer compared with recent studies when given as primary medical therapy, as it
is recognized that 30-40% of metastases from original ER-positive primary breast cancer
fail to respond to endocrine therapy [Duffy MJ, 2005].
Expression of ERa is the main predictor of response to endocrine therapy, lack of
expression of ER is clearly the main mechanism of de novo resistance to treatment with
hormonal agents [Weippl SK, 2005], Because the presence of ER does not guarantee
response, optimal management with endocrine therapy requires the identification of
further markers by which to subdivide ER-rich tumours into responders and non
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responders [Speirs V, 2004], Other markers may only be predictive effects for certain
types of endocrine therapy. Thus in the P 024 study in which patients were randomised
to receive either tamoxifen or letrozole, high expression of epidermal growth factor
receptor and c-erbB2 was associated with a decreased likelihood of the response to
tamoxifen but an increase of the response rate to letrozole. In results from Edinburgh, in
which patients were treated with a third-generation inhibitor (anastrozole, letrozole or
exemestane) over expression of c-erbB2 did not appear to be associated with resistance
to any of the aromatase inhibitors [Dixon JM, 2005]. Overall, response rates were
similar irrespective of c-erbB2 expression. High expression of c-erbB2 did not reduce
tumour responses to neoadjuvant treatment with aromatase inhibitors, but was associated
with high tumour proliferation before and during treatment. It remains to be determined
whether these characteristics may confer subsequent resistance to treatment and early
relapse in the adjuvant setting.
Additional factors, which might characterise hormone sensitive versus hormone resistant
tumors, might improve on the predictive power ofER status alone for response to
endocrine therapy. In particular, the ER phenotype manifested by coexpression of
oestrogen-dependent proteins such as pS2 and bcl-2 are thought to represent functional
receptor pathway [Horowitz KB], Arpino et al demonstrated that patients with HER-2
amplification had lower ER levels and were modestly less responsive to tamoxifen,
suggesting that molecular events in addition to those involving the ErbB receptors are
important in determining the endocrine-resistant phenotype. Significantly lower rate of
response to endocrine therapy were seen in patients with high vascular endothelial
growth factor (VEGF) levels and high levels of urokinase-type plasminogen activator
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[Manders P, 2003, 2004]. Studies using gene expression profiling have demonstrated
the distinct genetic patterns of different breast tumors, including at least two subtypes of
hormone receptor positive disease, often referred to as luminal A and B [Sorlie T], More
recently, investigators from the NSABP and Genomic Health have demonstrated a 21
gene ass ay, which can help predict response to endocrine therapy [Paik S]. Specific
genes in the expression profile can predict response to preoperative endocrine therapy
more accurately and may themselves be candidates as direct targets for future therapies.
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Antioestrogens
Antioestrogens fall into at least 2 distinct categories: mixed or partial agonists
antagonists such as tamoxifen and pure antagonists such as Fulvestrant. Although both
oestrogen and antioestrogen bind within the hormone-binding domain of the oestrogen
receptor (ER), the association must differ because oestrogen binding activates
transcription, whereas antioestrogens partially or completely fail in this role [Tzukerman
M], The partial agonist-antagonist compounds form complexes with the oestrogen
receptor (ER) that bind as dimers to oestrogen-response elements; there they block
ligand-dependent transcription activation [Wolf D). In the case of the more complete
antagonists, ER binding to DNA and reduction of the ER content of target cells appear
to contribute to, but may not fully explain, the pure antagonist character. The antitumour
effect of tamoxifen is mediated primarily through the ER, although there maybe other
potential mechanisms of action [Jordan VC, 1997].
Tamoxifen
It was first approved for use in 1977 for the treatment of advanced breast cancer in
postmenopausal women. The selective oestrogen receptor modulator, tamoxifen, has
been the mainstay endocrine therapy for hormone receptor-breast cancer for several
decades. Gradually, tamoxifen is being replaced by the third-generation aromatase
inhibitors [Nabholtz JM, 2008].
Data from the Nolvadex Adjuvant Trial Organisation (NATO) study, the Scottish
Tamoxifen trial, the Early Breast Cancer Trialists Collaborative Group (EBCTCG) and
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the National Surgical Adjuvant Breast and Bowel Project (NSABP) demonstrate the
efficacy of tamoxifen in the adjuvant setting. Tamoxifen was considered, as first-line
endocrine therapy for all stages of breast cancer and in chemoprevention in high-risk
population [Fisher B, 1998], It was recommended as adjuvant therapy, for early and late
stage oestrogen receptor (ER) / progesterone receptor (PR) positive breast cancer and
metastatic breast cancer in postmenopausal women and men. The NATO study
demonstrated a decrease in the risk of relapse and mortality with tamoxifen as adjuvant
treatment in postmenopausal women. The NSABP B-14 [Fisher, 1989] and the
EBCTCG meta-analysis update have demonstrated improvement in overall survival in
oestrogen receptor-positive women in the premenopausal and the node-negative setting
[EBCTCG, 1998], Regardless of nodal status, tamoxifen has been shown to improve
both disease free and overall survival. This benefit is most significant in postmenopausal
patients, but benefits were also noted in women less than 50 years of age [EBCTCG,
2005], Tamoxifen offers the greatest benefit to patients whose tumours are most strongly
ER positive [EBCTCG, 1998]. Tamoxifen reduced the risk of recurrence by almost 50%
and that of death by 30% when used for 5 years in the adjuvant setting [EBCTCG,
1998], A secondary benefit of tamoxifen is an approximate 50% decrease in the risk of
second primary breast cancers.
The optimal duration of tamoxifen therapy was investigated. The Swedish Breast Cancer
Cooperative Group noted that 5 years of adjuvant tamoxifen was more beneficial than 2
years in the treatment of postmenopausal women with oestrogen receptor-positive,
breast cancer. The NSABP B-14 trial has shown that the benefit of 5 years of tamoxifen
persists through 10 years of follow-up and that no additional benefit is obtained by
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continuing tamoxifen for more than 5 years [1996, 2001], Thus, the standard adjuvant
therapy was for five years.
The most frequent adverse reactions to antioestrogens, such as tamoxifen, include hot
flushes, nausea and vomiting [Fisher B, 1996]. These may occur to some degree in up to
50% of patients but are rarely sufficiently severe to require discontinuation of therapy.
Menstrual irregularities, vaginal bleeding and discharge, pruritis vulvae and skin rashes
have occurred less frequently. An increase in risk of tumour flare, thromboembolic
events, ocular disturbances, hypercalcaemia and endometrial cancer has also been
reported following tamoxifen [van Leeuwen F; Nevassaari K],
A troubling aspect of tamoxifen use as early adjuvant treatment is the development of
de novo resistance and thus relapse during the first few years of the planned 5-year
course of treatment [Ring A], However, more than half of hormone-sensitive patients
will relapse after 5 years of treatment and two thirds of deaths will occur after
completion of the hormonal treatment [Ring A], This has led to the search for new
hormonal agents with the specific goal to improve the therapeutic ratio.
The adjuvant treatment of patients with endocrine-sensitive breast cancer has been
dominated for several decades by the gold-standard tamoxifen. In the metastatic setting,
superior efficacy over tamoxifen has led to the Aromatase Inhibitors becoming the
agents of choice in postmenopausal women with receptor-positive metastatic disease.
They now show consistent improvements over tamoxifen in the treatment of early breast
cancer, in both the neoadjuvant and adjuvant settings. Thus, the choice of adjuvant
endocrine treatment for early breast cancer (EBC) has now evolved from tamoxifen to
the AIs. Five years of tamoxifen, the standard adjuvant, endocrine therapy, is now
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known to be inferior to treatment with the third-generation aromatase inhibitors (AIs),
which are approved for treatment in a variety of adjuvant settings.
Selective oestrogen receptor modulators
The selective estrogen receptor modulators (SERMs) are molecules that block oestrogen
action in breast cancer but can still potentially maintain the beneficial effects of
oestrogen in other tissues, such as bone and cardiovascular system [Jordon VC, 2008].
Tamoxifen, the prototypical drug of this class has been used extensively for the past 30
years to treat and prevent breast cancer.
Several new antioestrogens have been developed over the recent past, which includes
Toremifene, droloxifene, raloxifene, and idoxifene. Toremifene is a chlorinated
analogue of tamoxifen and has similar site-specific oestrogen and antioestrogen activity.
It has shown similar efficacy to tamoxifen with a response rate of 21% and a median
survival of 38 months [Hayes DF], However, substantial cross-resistance has been
demonstrated with toremifene and tamoxifen [O'Regan RM]. Droloxifene, raloxifene
and idoxifene are antioestrogens that are in clinical trials and all have binding profiles
different from tamoxifen. Idoxifene has a binding capacity twice that of tamoxifen for
oestrogen receptors and has been studied in phase I trials with partial response of about
14% with minimal toxicity [Coombes RC, 1995], In animal models idoxifene use,
decreased uterine weight, prevented bone loss, and lowered serum cholesterol levels
[Nuttall ME]. Its role in the treatment of metastatic breast cancer needs further
investigation. Raloxifene is a nonsteroidal benzothiophene derivative that binds to the
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ER and has been classified as a SERM because it has been shown to have
antioestrogenic effects in the uterus and breast as well as oestrogenic effects on bone and
cholesterol [Black LJ], Raloxifene though originally developed for breast cancer therapy
was disappointing, but showed significant activity in the treatment and prevention of
osteoporosis [Delmas PD], However, the Multiple Outcomes of Raloxifene Evaluation
(MORE) trial shows a reduced incidence of breast cancer in raloxifene-treated patients
[Cummings SR]. Raloxifene reduces risk of invasive ER-positive breast cancer
regardless of a woman's baseline breast cancer risk but does not reduce risk of
noninvasive or ER-negative breast cancers. These results confirm those of the Multiple
Outcomes of Raloxifene Evaluation, a previous randomised trial among women with
osteoporosis [Grady D],
Fulvestrant (Faslodex) is an oestrogen receptor antagonist used in locally advanced or
metastatic breast cancer following progression or recurrence on anti-oestrogen therapy.
The Evaluation of Faslodex and Exemestane Clinical Trial (EFECT) evaluated the
efficacy and tolerability of fulvestrant and exemestane, in patients with locally advanced
or metastatic breast cancer. Similar efficacy was seen in both treatment groups and there
were no significant differences in reported adverse events between fulvestrant and
exemestane [Gradishar W], Three Phase III trials found no significant difference
between fulvestrant and control, either anastrozole or exemestane, across efficacy and
safety endpoints following prior endocrine therapy failure. Fulvestrant can therefore be
considered as alternative therapy to AI in postmenopausal women with locally advanced




Castration has been observed as an effective therapy for metastatic breast cancer for
more than 100 years. Several different methods are available: surgical oophorectomy,
radiation ablation and LHRH agonists [Block GE]. Oophorectomy is an irreversible
surgical procedure, associated with morbidity and psychological trauma [Boyd S],
Ovarian irradiation is associated with delayed onset of action (up to 6 weeks) and a
potential for damage to adjacent organs and tissues. Ovarian ablation reduced the annual
odds of recurrence and death in breast cancer by approximately 25% [EBCTCG, 1996],
Studies have suggested temporary amenorrhea can confer benefit in early breast cancer,
giving luteinizing hormone-releasing hormone (LH-RH) agonists an advantage over
oophorectomy or radiation [Lonning PE, 2007]. Increasing interest has emerged in the
role of ovarian function suppression, which has shown equivalence to adjuvant
chemotherapy whether achieved by surgery or irradiation, [Tan SH], The ABC Ovarian
Ablation or Suppression Trial randomly assigned pre and perimenopausal patients with
early-stage breast cancers, who were receiving prolonged (5 years) tamoxifen treatment
with or without chemotherapy to ovarian ablation or suppression (by oophorectomy,
ovarian irradiation, or treatment with luteinizing hormone-releasing hormone agonist)
versus no ovarian ablation or suppression [ABC trial group, 2007]. Overall, no added
effect of ovarian ablation or suppression was seen on relapse-free survival or overall
survival of premenopausal women who were treated for early-stage breast cancer
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Luteinizing hormone releasing hormone (LHRH) agonists
LHRH analogues are an alternative to oophorectomy. These agents induce chemical
castration and are effective in premenopausal patients with metastatic breast cancer
[Filicori M], Goserelin has been approved for therapy while buserelin and tryptorelin are
under investigation. The continuous administration of LHRH agonists overstimulates the
LHRH receptors in the anterior pituitary, causing an initial rise in follicle stimulating
hormone (FSH) and luteinizing hormone (LH), followed by desensitisation of the
receptors (1 to 2 weeks), leading to decrease in the release of the hormones [Dlugi AM],
Thus the decrease in gonadotrophins levels results in reduced drive to the ovaries,
reducing the synthesis of oestrogen to postmenopausal level, within 4 weeks of starting
an LHRH agonist and with discontinuation of treatment, serum oestradiol levels return
to normal within 12 weeks [West CP]. Goserelin is administered as a monthly
subcutaneous injectable implant that provides continuous release of the drug. Objective
response rates have ranged from 31 - 63% in premenopausal women with advanced
breast cancer. However, no difference in disease-free survival or overall survival rates
has been shown in premenopausal patients treated with either goserelin or oophorectomy
[Jonat W]. Toxicities associated with goserelin acetate are those consistent with a
menopausal state, including hot flush, loss of libido, vaginal dryness and decreased bone
mineral density. Trials are investigating the use of LHRH agonist in combination with




Previously, used treatments such as progestogens (megestrol acetate and
medroxyprogesterone acetate (MPA) are now rarely used or confined to fourth or fifth
line treatments [Howell A, 2001]. Intermittent tamoxifen or intermittent/ alternated
tamoxifen and MPA had no impact on overall survival as compared to classical
continuous tamoxifen in patients with advanced breast cancer [EORTC study, 2006].
Two randomised, multicenter trials were conducted, involving a total of 764 patients
comparing the efficacy and tolerability of anastrozole, and megestrol acetate in the
treatment of postmenopausal women with advanced breast carcinoma whose disease had
progressed after treatment with tamoxifen. Results demonstrated treatment with
anastrozole 1 mg once daily results in a statistically and clinically significant advantage
over a standard treatment, megestrol acetate [Eiermann W, 1998].
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AROMATASE
Aromatase also called cytochrome P-450 arom or oestrogen synthetase is a unique
member of the cytochrome P450 superfamily. The enzyme is complex and consists of
cytochrome P-450 haemoprotein and an NADPH reductase [Thompson EA],
Distribution
Aromatase is mainly located in the endoplasmic reticulum of oestrogen producing cells.
The enzyme is expressed in variety of cells and tissues including ovarian granulosa,
testicular Sertoli and leydig cells, placenta, adipose tissue, liver, muscle, skin fibroblasts,
gonads and brain [Siiteri PK; Grodin JM], A number of studies have reported aromatase
activity both in normal breast tissue and in tumours [James VHT, Miller WR, 1987,
Lipton A, 1987],
Mechanism of aromatisation
Aromatase mediates the conversion of androgen into oestrogen, which is a last step in
oestrogen biosynthesis. Aromatase catalyses the steroid hydroxylations involved in the
conversion of androstenedione to oestrone or testosterone to oestradiol [Fishman J]. The
two major androgens, androstenedione and testosterone serve as substrates for
aromatase. The conversion of androgens to oestrogen involves three hydroxylation steps.
The first two give rise to 19 hydroxy and 19 aldehyde structures and the third probably
involves the CI9 methyl group with release of formic acid. This enzymatic reaction
results in desaturation of the A ring of the steroid molecule to produce an aromatic
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structure and hence the enzyme is known as aromatase and reaction called aromatisation.
Despite intense investigations, the precise mechanism involved in the final step has not
been established definitively. The NADPH reductase is responsible for transfer of
reducing equivalents from NADPH to cytochrome P450. The whole reaction requires
3mol molecular oxygen and 3mol NADPH per mol C19 steroid substrate metabolised.
Two oxygen molecules are required for oxidation of CI 9 angular methyl group and the
site of action of the third molecule is uncertain.
Aromatase gene
Aromatase is expressed throughout the entire spectrum of the vertebrate phylum. The
aromatase gene belongs to a separate gene family designated CYP19 as its overall
homology to other members of the family is low [Harada N, 1990a], The gene has been
mapped to chromosome 15 and the structural organisation of CYP19 was studied by
isolating and characterizing genomic DNA fragments containing the gene. The gene is
larger than other members of the cytochrome P-450 super family and consists of 10
exons and spans at least 70Kb [Harada N, 1993]. It is now believed that that the gene
exists in the human haploid genome as a single copy [Means GD], The cDNA of the
aromatase gene is 3.4 kb in size and encodes a polypeptide of 503 amino acids with a
molecular weight of 55 kb.
Regulation
There is only one gene for the aromatase but its expression is regulated in a tissue
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specific manner, by the use of a number of different promoters [Simpson ER, 1993].
Aromatase transcripts are tissue specifically spliced by alternative usage of multiple
exons I. Aromatase has been suggested to have multiple promoters attached to multiple
exons 1 and to use tissue specific exons 1 and promoters, by alternative splicing
mechanisms [Harada N, 1993]. The tissue specific exons 1 of the human aromatase gene
are flanked with a unique promoter region containing the basic promoter sites and
regulatory promoter or enhancer sites. Transcripts from placenta contain sequences that
are at 35 kb upstream from the start of translation, under the regulation of distal
promoter 1.1. Transcripts from adipose tissue contain two different 5'termini - exon 1.3
and exon 1.4. Exon 1.4 is situated just 100 bp upstream of exon II and exon 1.4 20 kb
downstream from exon 1.1.
The tissue specific utilisation of alternative exons I can explain the complex regulatory
mechanism of tissue specific expression of aromatase [Utsumi T]. In humans use of
alternative and partially tissue-specific promoters in the placenta (promoter 1.1), adipose
tissue (promoters 1.4, 1.3, and II), skin (promoter 1.4) and ovary (promoter II) regulates
aromatase expression and is shown in table-4. Activation of these promoters and thus
aromatase expression in these tissues is controlled by various factors [Simpson ER,
1993]. These include cytokines, cyclic AMP, glucocorticoids, phorbolesters and growth
factors [Simpson ER, 1997]. In ovarian granulosa cells, follicle-stimulating hormone
(FSH) stimulates the activation of promoter II via a cyclic adenosine monophosphate
(cAMP)-dependent signaling pathway [Bulun SE, 1999a], In adipose fibroblasts,
glucocorticoids together with members of the interleukin-6 cytokine family give rise to
activation of promoter 1.4, whereas treatment with cAMP analogs or prostaglandin E2
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(PGE2) switches the promoter use to 1.3 and II in these cells [Chen S, 1999]. In the brain,
a tissue-specific promoter IF is used along with fibroblast (I.4)-type and ovarian (II)-
type promoters [Sasano H, 1998b]. Cellular and molecular mechanisms responsible for
the regulation of brain aromatase expression are not yet clear. However, regardless of
the promoter used the encoded aromatase protein is identical in all these cells.
Consequently, alternative promoter use, does not affect the structure of aromatase
enzyme that catalyses the oestrogen formation. Thus an alternative splicing mechanism
plays an important role not only in tissue specific expression but also in alteration of
aromatase expression through developmental or neoplastic process of the same tissue
[Utsumi T],
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Table 4: Tissue specific utilisation of alternative exons I of the
human aromatase gene
TISSUE Exon 1A Exon1B Exon 1C Exon 1D Exon1F
[11] [1.2] [1.3] [1.4] [1.5]
ADIPOSE TISSUE





- - i i i i ++++
+
TESTIS - - - +
FOETAL LIVER + i i i i + + +
ADULT LIVER - - - +
FOETAL BRAIN - + - +++
ADULT BRAIN - - - +
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Adipose tissue expression and regulation
MacDonald et al demonstrated that human adipose tissue was a major source of
oestrogen production [1978], Oestrogen production by adipose tissue increases as a
function of obesity and aging. In both women and men with advancing age, there is a
progressive increase in the efficiency of conversion of circulating androstenedione to
oestrone [Hemsell DL]. In post reproductive years the degree of oestrogenisation is
mainly dependent on the extent of adiposity, as the adipose tissue is the main source of
oestrogen. The production of oestrogen correlated positively in both pre and
postmenopausal women with excess body weight and increased as much as tenfold in
morbidly obese postmenopausal women [MacDonald PC, 1978], The messenger RNA,
levels of aromatase and the activity per cell increased with advancing age [Bulun SE,
1999b; Cleland WH], Both cell types found in adipose tissue, namely adipocyctes and
adipose stromal cells, express aromatase although much higher levels of expression has
been observed with the latter [Sasano H, 1994a; Santen RJ, 1994], Ackerman et al
demonstrated aromatase expression in adipose stromal fibroblasts. Aromatase activity is
higher in adipose tissue in patients with breast cancer than in women without the disease
[Utsumi T] and highest in regions proximal to the tumour [Miller WR, 1991],
A number of agents alter aromatase expression in human adipose stromal cells in culture
including glucocorticoids, cyclic AMP, phorbol esters and growth factors [Mendelson
CR 1987]. The stimulatory effects of dexamethasone, requires the presence of foetal calf
serum in the medium while dibutryl cAMP manifests an increase in activity only in the
absence of foetal calf serum. Aromatase regulation by these agents is tissue specific
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since glucocorticoids have no effect and phorbol esters inhibit cAMP induced aromatase
activity in ovarian granulosa cells. Mahendroo et al have identified four P450 arom with
unique 5'termini in adipose tissue and stromal cells in culture by RACE [rapid
amplication of cDNA ends]. 1.3 specific sequence was expressed in cells in all
conditions as well as in adipose tissue, 1.4 specific sequence was present only in
tissue/cells stimulated with glucocorticoids and p II sequence was present only in cells
stimulated with cAMP analogues as shown in table 5. Thus glucocorticoid stimulation
of expression is mediated by promoter 1.4, which would lead to the formation of
transcripts containing exon 1.4 in their termini and in contrast expression of promoter II
specific sequences would be cAMP mediated [Mahendroo M]. It is uncertain whether
additional factors are also required to produce the determined splicing pattern. Thus the
5'upstream region of this promoter contains a glucocorticoid response element and a
gamma activating sequence (GAS) element, which can bind transcription factors for the
signal transducer and activator of the transcription (STAT) family [Zhao Y], Cytokines
in the presence of glucocorticoids regulate aromatase gene expression via PI.4. Chen et
al have proposed that in normal breast adipose tissue and fibroblasts, aromatase
expression is driven by promoter 1.4 (glucocorticoid-dependent) and the action of
promoters 1.3 and II is suppressed by the silence negative regulatory element. In cancer
cells and surrounding tissue, the cyclic AMP level increases and aromatase promoters
are switched to cyclic AMP dependent promoters 1.3 and II. Thus, regulation of
aromatase in breast adipose tissue becomes abnormal during carcinogenesis due to
switching of exons I and promoters, resulting in overproduction of oestrogen under
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control of a new promoter. The role of alternative splicing pathway and the normal
regulatory splicing can function as an on / off switch in gene expression.
61
Table 5: Summary of major 5'termini in adipose cells and
tissues
TISSUE CELLS MAJOR 5' TERMINUS
Adipose tissue 1.4,1.3
Adipose stromal cells in culture 1.3
Control - serum 1.3
Control + serum 1.3
Dex + serum 1.4,1.3
cAMP - serum PII / 1.3




Aromatase in oestrogen biosynthesis
The conversion of androgens to oestrogen by aromatase is the last step in one of the
three major steroidogenic pathways. In the premenopausal state, the major source of
aromatase and of its substrates is the ovary. Extraglandular aromatisation of adrenal
substrates also provide substantially to the oestrogen pool in the early follicular and
luteal phases of the menstrual cycle [McNatty KP]. In the postmenopausal state, the
ovary loses its complement of aromatase, although it does continue to secrete
androstenedione [Naftolin F], The adrenal gland provides the substrate for aromatase by
directly secreting testosterone, androstenedione and dehydroepiandrosterone and its
sulfate [Baird DT], The peripheral tissues form the principal source of oestrogen after
menopause [Grodin JM], Unlike in the ovary, oestrogen production in adipose tissue is
continuous and not cyclic. Synthesis of ovarian aromatase is regulated by an ovarian-
pituitary (oestrogen-follicle-stimulating hormone) feedback loop, although a similar
mechanism of aromatase expression in peripheral tissue has not been reported [Chen S,
1988],
Aromatase in breast cancer
The association between increased aromatase expression and human breast cancer has
been demonstrated previously [Miller WR, 1991; Macaulay VM; Sasano H, 1998c].
Approximately two-thirds of human breast cancers contain appreciable levels of
aromatase activity [Silva MC] and synthesise biologically significant amounts of
oestrogen locally within the tumour [Miller WR, 1987]. Reported aromatase activity
63
ranges between 5 and 80 pmols/g protein/hour equivalent to 0.02 - 0.9% conversion of
androstenedione to oestrone [Dowsett M, 1996]. Demonstration that aromatase activity
contributes significantly to intratumoural oestrogen concentrations of breast carcinoma
has been directly obtained by injection of 3H androstenedione and 14C oestrone prior to
surgical sampling of the tumour [Reed MJ], There is evidence that aromatase expression
is increased in the breast quadrant in which the tumour is located [O'Neill; Purohit A],
Therefore breast tumours may arise in quadrants with high aromatase activity or they
may secrete factors which stimulate aromatase activity in tissues proximal to the tumour.
The cell type and their relative contribution to aromatase activity in human breast tissue
remains a controversial issue with evidence of aromatase either in epithelial cells,
stromal cells or both cell types. Santen et al observed, the highest degree of aromatase
expression occurred in stromal spindle cells, while tumour epithelial, stromal,
inflammatory and normal breast elements contained lesser amounts [1994], Furthermore,
a statistically significant correlation was found between biochemical measurements of
aromatase and the stromal spindle cell histological score [Santen RJ, 1998],
Immunocytochemical studies revealed that aromatase is mainly expressed in the stromal
adipocyctes [Lu Q]. Heterogeneity in aromatase expression by human breast cancers has
also been reported by other investigators [Harada N, 1995, Lu Q, Zhang Z]. Increase
aromatase protein expression in tumours was observed by Lu et al, while Bulun et al
found highest mRNA transcript levels of aromatase in the tumour bearing quadrant
[1994b], In aggregate, observations provide further support for the possibility that
human breast tumours may contain biologically relevant amounts of aromatase,
producing oestrogen exerting autocrine or paracrine effects [Eppenberger US]. The
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interest in intratumoural aromatase activity is that it could form the most important
source ofoestrogen for the tumour and thus the most important target for inhibition.
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AROMATASE INHIBITORS
Recently, several new aromatase inhibitors have been developed with greater clinical
efficacy and improved tolerability [Miller 2005]. These agents including exemestane,
letrozole and anastrozole are highly selective and potent inhibitors of aromatase.
Promising results on the third-generation aromatase inhibitors (AIs), anastrozole,
letrozole and exemestane in advanced disease, led to the development of these agents in
the treatment of early breast cancer in both adjuvant and neoadjuvant setting.
Classification
Aromatase inhibitors are classified into steroidal (type I) and non-steroidal inhibitors
(type II). They differ in their mode of interaction with the aromatase enzyme. Aromatase
inhibitors can also be classified based on their generation (table- 6). The third
generation nonsteroidal aromatase inhibitors are triazoles. The new inhibitors have
greater specificity and potency than earlier generations.
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Type I inhibitors interact with the substrate binding site of the enzyme and invariably
have an androgen structure while type II inhibitors interfere with the cytochrome P450
moiety of the system [Miller WR, 1989].
Steroidal inhibitors
Steroidal inhibitors include: exemestane and formestane. Steroidal inhibitors compete
with the endogenous substrates, androstenedione and testosterone for the active site of
the enzyme, where they act as a false substrate and are processed to intermediates that
bind irreversibly to the active site, causing irreversible enzyme inhibition. This type of
inhibition is mechanism based inhibition or suicide inhibition. Because the inhibitor
needs to be activated by the enzyme, the inhibition is time dependent, but the effect is
generally long term and specific.
Nonsteroidal inhibitors
Nonsteroidal (type II) compounds are structurally imidazoles and triazoles and include:
aminoglutethimide, fadrozole, letrozole and anastrozole. Nonsteroidal inhibitors
interact with the cytochrome P450 moiety of the aromatase enzyme complex at the same
time excluding the endogenous substrate from the active site, where they form a
coordinate bond to the haem iron atom. The drugs bind reversibly and inhibition is
maintained only in the continuous presence of the drug. Imidazoles have a shorter half
life than the triazoles, potentially resulting in lower invivo efficacy, despite similar
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invitro potency [Brodie AMH, 1994], Many type II drugs have the disadvantage of poor
specificity, in that a variety of enzymes possess cytochrome P450 prosthetic groups and
may be inhibited [Santen RJ, 1981]. However, the amino acid sequence of P450 arom
shows it to be quite distinct from other members of the cytochrome family and more
specific aromatase inhibitors are available now.
Aminoglutethimide
Aminoglutethimide was first used as an anticonvulsant in 1967 [Cash AJ]. It was later
used to for medical adrenalectomy in breast cancer patients [Santen RJ, 1981], This
inhibitor lacks selectivity for the aromatase enzyme and has effects on other cytochrome
P450 enzymes. Aminoglutethimide therapy is associated with many drug interactions
and also causes adrenal insufficiency, requiring the concurrent administration of
glucocorticoids [Johanessen DC]. This along with other adverse effects including
somnolence, rash and nausea served to limit the usefulness of aminoglutethimide
[Goldhirsch A],
Anastrozole
Anastrozole (Arimidex: ICI-D1033; 2, 2'-5-lH-2, 4-triazol-l-ylmethyl-l, 3-phenylene
bis 2-methyl-propioononitrile) is a potent and selective benzyl triazole derivative
[Buzdar AU, 1996b], It is well absorbed from the gastrointestinal tract, excreted through
hepatic metabolism (85%) with a half-life of 50 hours. It has no effect on Cortisol or
aldosterone secretion and requires no steroid replacement therapy [Plourde PV, 1995],
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Geisler et al examined the effect of anastrozole on invivo aromatisation and plasma
oestrogen levels. Both 1 and lOmg doses inhibited invivo aromatisation by 96.7% and
98.1% respectively. The drug also significantly suppressed plasma oestradiol (84%),
oestrone (87%), and oestrone sulfate (94%), irrespective of the dose studied. Kleeberg
compared the effects on oestrogen suppression between anastrozole and formestane in
postmenopausal women with advanced breast cancer and observed that it was more
consistent with anastrozole. Two large randomised phase III trials have compared
anastrozole to megestrol acetate in the treatment of advanced breast cancer in
postmenopausal women who had failed tamoxifen therapy [Buzdar AU, 1996a]. The
combined analysis demonstrated a statistically significant survival advantage with lmg
dose of anastrozole compared with megestrol acetate (HR 0.78, p < 0. 025). The lOmg
daily dose of anastrozole also had a survival advantage, but not statistically significant.
The incidence of adverse drug effects in these trials was low, but weight gain and
dyspnoea were significantly greater in the megestrol acetate group compared to the
anastrozole group (p= 0.045 for weight gain, p= 0.022 for oedema/ The lmg dose was
selected for FDA approval and for future trials, as the lOmg dose had more adverse
effects with no increased clinical efficacy.
Adjuvant setting
Anastrozole was compared with tamoxifen for 5 years in 9366 postmenopausal women
with localised breast cancer in the Arimidex, Tamoxifen Alone or in Combination
(ATAC) study [ATAC trial]. After a median follow-up of 68 months, anastrozole
significantly prolonged disease-free survival (575 events with anastrozole vs 651 with
tamoxifen, HR 0.87, p=0.01), time to recurrence (402 vs 498, HR 0.79, p=0.0005),
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significantly reduced distant metastases (324 vs 375, HR 0.86, p=0.04) and contralateral
breast cancers (35 vs 59, 42% reduction, p=0.01). Anastrozole was associated with
fewer side-effects than tamoxifen, especially gynaecological problems and vascular
events; but were associated with increase in arthralgia and fractures. The ATAC trial
demonstrated that adjuvant endocrine therapy for postmenopausal patients with early
stage breast cancer, anastrozole was superi or to tamoxifen in terms of disease-free
survival (DFS), time to recurrence (TTR), and incidence of contralateral breast cancer
(CLBC). A recent analysis of annual recurrence rates at 2.5 and 5 years found that the
majority of excess first events in patients receiving tamoxifen occurred during the first
2.5 years of therapy, and although the greatest difference between anastrozole and
tamoxifen appeared early at about 2 years, the data indicate that most of the early
difference is not in reduction of distant metastatic events and the difference in distant
disease is greater at 5 years than at 2.5 years (16% vs. 7%) [Houghton J]
Sequential therapy
TheABCSG8 trial randomised patients to either 5 years of tamoxifen or 2 years of
tamoxifen followed by 3 years of treatment with anastrozole. Although there was a 24%
relative reduction in recurrence risk with anastrozole, the difference between anastrozole
and tamoxifen treatment arms for the primary end point, event free survival, was not
statistically significant ( p = 0.07) at 30 months follow-up [Jakesz R],
Letrozole
Letrozole (4, 4'-lH-l, 2, 4-triazol-a-yl-methylene-bis-benzonitrile) is a potent oral,
reversible, nonsteroidal competitive aromatase inhibitor. It is rapidly and completely
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absorbed from the gastrointestinal tract, metabolised to an inactive metabolite and
excreted renally. The elimination half-life of letrozole is about 2 days and steady-state
plasma concentration is reached in 2-6 weeks. It is a potent inhibitor of peripheral
aromatase activity (> 98%) and suppresses plasma oestrogen levels by greater than 95%
[Klein KO],
Bajetta et al evaluated the effects of two doses of letrozole (0.5 mg and 2.5 mg orally
daily) on oestrogen suppression in a double blind, randomised trial involving
postmenopausal patients with advanced breast cancer progressing after tamoxifen. A
significant suppression of oestrone and oestradiol levels was achieved by both letrozole
doses without affecting adrenal activity. Two large randomised trials have evaluated the
role of letrozole in the second-line treatment of advanced breast cancer. Gershanovich et
al, compared letrozole and aminoglutethimide in 555 postmenopausal women with
advanced breast cancer, previously treated with antioestrogens. Letrozole 2.5 mg was
superior to aminoglutethimide in time to progression, time to treatment failure and
overall survival. Treatment-related adverse events occurred in 33% of letrozole patients
compared with 46% of aminoglutethimide patients. In another large phase III trial,
letrozole was compared to megestrol acetate as second-line therapy in postmenopausal
women with advanced breast cancer previously treated with antioestrogens
[Dombernowsky P], The differences in overall recurrence rate were statistically
significant between the letrozole 2.5 mg group compared with both the megestrol acetate
group (p =0.04) and the letrozole 0.5 mg group (p=0.004). The duration of response was
significantly longer for letrozole 2.5 mg compared with the megestrol acetate group
(p =0.02).
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Letrozole 2.5 mg was also significantly superior to megestrol acetate and letrozole
0.5mg in time to treatment failure. It was significantly better tolerated than megestrol.
Neoadjuvant setting
In a double blind trial, 337 postmenopausal women with hormone receptor positive
locally advanced breast cancer were randomised to either letrozole (2.5mg) or tamoxifen
(20mg daily) for 4 months [Eiermann W], Tumour response rates were higher with
letrozole (55% vs 36%, p<0.001) and more patients on letrozole had sufficient tumour
response to allow breast conserving surgery (45% vs 35%, p= 0.022).
Adjuvant therapy
The Breast International Group (BIG) 1-98 phase 3, double-blind, controlled trial
enrolled 8010 postmenopausal women with early breast cancer. The BIG 1-98 trial had a
unique trial design, as it randomised patients to: 5 years adjuvant tamoxifen, or 5 years
of adjuvant letrozole, or to one of the two sequential arms where therapy was initiated
with either tamoxifen or letrozole and subsequently switched to the alternative treatment
after 2-3 years so that patients received a total of 5years of endocrine treatment. The
primary core analysis included events in the two monotherapy arms as well as events up
to the time when patients were to switch in the two sequential arms. After a median
follow-up of 25.8 months, letrozole significantly increased DFS by 19% when compared
with tamoxifen (HR 0.81; p =0.003), with an absolute benefit of 2.6% at 5 years (84%
letrozole vs. 81.4% tamoxifen). Initial adjuvant letrozole was particularly effective in
reducing the relative risk of distant recurrence by 27% (HR0.73; p = 0.001). Overall, in
the BIG 1 -98 trial, there were fewer deaths in the letrozole group than in the tamoxifen
group (166 or 4.1% vs. 192 or 4.8%, respectively), but survival advantage was not seen.
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After a median follow-up of 2 years, letrozole markedly reduced the risk of distant
metastatic events (87 vs. 125 events, 30% reduction) [Thurlimann B, 2005].
Extended therapy
A double-blind, placebo-controlled trial was conducted to test the effectiveness of five
years of letrozole therapy in postmenopausal women with breast cancer who have
completed five years of tamoxifen therapy [Goss PE], The primary end point was
disease-free survival. A total of 5187 women were enrolled (median follow-up 2.4
years). At the first interim analysis, there were 207 local or metastatic recurrences of
breast cancer or new primary cancers in the contralateral breast; 75 in the letrozole
group and 132 in the placebo group with estimated four-year disease-free survival rates
of 93 % and 87 %, respectively, in the two groups (p< 0.001). A total of 42 women in
the placebo group and 31 women in the letrozole group died (p=0.25 for the comparison
of overall survival). Letrozole therapy after the completion of standard tamoxifen
treatment significantly improves disease free survival. Low-grade hot flush, arthritis,
arthralgia, and myalgia were more frequent in the letrozole group, but vaginal bleeding
was less frequent. Osteoporosis was seen in 5.8 % of the women in the letrozole group
and 4.5 % of the women in the placebo group (p=0.07) but the fracture rates in the two
groups were similar.
Fadrozole
Fadrozole (CGS 16949A: 4-5, 6, 77, 8-tetrahydroimidazole l,5a-pyridin-5yl benzonitrile
monohydrochloride) is an inhibitor of aromatase with an inhibitory constant of K, of
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0.19nm. Fadrozole at a dose of 1 mg twice daily causes maximal suppression of plasma
and urinary oestrogens [Dowsett M, 1990]. It may also cause a degree of inhibition of
Cortisol and aldosterone production, although the clinical relevance of this is unclear
[Dowsett M, 1994]. A phase II study compared fadrozole with megestrol acetate and
approximately 20% of postmenopausal women with metastatic cancer responded to
Fadrozole [Buzdar AU, 1996a]. No significant difference was observed in response rate
and time to progression, response duration or survival. It has also been compared to
tamoxifen as first line of therapy for metastatic cancer, with statistically no significant
difference in response rate and duration [Falkson CI]. Fadrozole has been approved for
treatment in Japan.
Formestane
Formestane (Lentaron; 4-OHA; 4-Hydroxyandrost-4-ene-3, 17- dione) is a structural
analogue of androstenedione and a highly specific aromatase inhibitor [Lonning PE,
1998],
Formestane is a selective inhibitor of the aromatase enzyme and is available only in
injectable form [Coombes RC, 1992], It has low toxicity and adverse effect includes hot
flushes, GI disturbances and alopecia [Coombes RC, 1987]. Parenteral administration
produces 65% oestradiol suppression and 85% peripheral aromatase inhibition [Dowsett
M, 1994], Studies have revealed that formestane has no oestrogenic or antioestrogenic
properties but has androgenic effects under certain circumstances [Brodie AMH, 1986].
Data from phase II clinical trials have demonstrated 33% objective regression rate in
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postmenopausal women previously treated with multiple endocrine therapies [Bajetta E,
1997],
A phase III randomised trial of formestane versus tamoxifen was carried out in 409
postmenopausal women with advanced breast cancer [Perez CR, 1994]. 33% had
objective response to formestane compared to 37% to tamoxifen (p=0.48) with median
response of 15 vs 20 months (p=0.17) and median survival of 35 vs 38 months (p=0.64).
However time to disease progression was longer for tamoxifen (213 vs 294 days) but
both drugs were well tolerated. Formestane is now approved in Europe for the treatment
of metastatic breast cancer in women who have failed tamoxifen therapy.
Exemestane
Exemestane (6methylene-androsta-l, 4-diene-3, 17 dione) is an irreversible aromatase
inhibitor [Evans TR] developed for oral use. Its Ki is 10.2 nmol/1 for competitive
inhibition and 26 nmol/1 for irreversible inactivation. Exemestane is selective and does
not interfere with Cortisol or aldosterone concentration. In general, exemestane is well
tolerated [Lonning PE, 1997].
In phase II trial involving 134 patients with breast cancer resistant to tamoxifen, the
overall response rate was 22% [Kvinnsland S]. Median duration of objective response
was 68 weeks and time to progression was 29 weeks. In a phase III randomised,
multicentre, double-blinded study, exemestane was compared with megestrol acetate
(MA) in 769 postmenopausal women with advanced breast cancer refractory to
tamoxifen therapy [Kaufmann M, 2000], There was no significant difference between
the two groups in neither baseline characteristics nor prognostic factors.
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Exemestane was significantly better than MA in terms of median time to progression
(4.7 vs. 3.8 months), duration of overall success (13.8 vs. 11.3 months) and overall
survival. Furthermore, the study showed that exemestane was better tolerated than MA,
with a withdrawal rate of 1.4% (vs. 2.5% with MA). Reported common side effects
includes, nausea (9.2%), fatigue (7.5%) and hot flushes (6%). The number of patients
gaining weight was significantly lower in the exemestane arm (7.6 vs. 5.1%, p = 0.001).
Switch therapy
The exemestane intergroup study conducted a randomised double blind, trial was
conducted to test whether switching to exemestane, after two to three years of tamoxifen
therapy, was more effective instead of continuing tamoxifen for five years. The primary
end point was disease-free survival. Of the 4742 patients enrolled, 2362 were randomly
assigned to switch to exemestane, and 2380 to continue to receive tamoxifen. After a
median follow-up of 30.6 months, 449 first events (local or metastatic recurrence,
contralateral breast cancer, or death) were reported: 183 in the exemestane group and
266 in the tamoxifen group. The unadjusted hazard ratio in the exemestane group
compared to the tamoxifen group was 0.68 (p<0.001), representing a 32 % reduction in
risk and corresponded to an absolute benefit in terms of disease-free survival of 4.7 % at
three years after randomisation. Overall survival was not significantly different in the
two groups, with 93 deaths occurring in the exemestane group and 106 in the tamoxifen
group. Contralateral breast cancer occurred in 20 patients in the tamoxifen group and 9
in the exemestane group (p=0.04). Severe toxic effects of exemestane were rare.
Exemestane after two to three years of tamoxifen significantly improved disease-free
survival compared to the standard treatment for five years with tamoxifen.
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Conclusion
Third-generation AIs are now an integral part of hormonal therapy for postmenopausal
patients with endocrine-sensitive breast cancer. Gradually, tamoxifen has been replaced
by the third-generation aromatase inhibitors (AIs)—anastrozole, letrozole, and
exemestane. All studies consistently show the superiority of these agents over
tamoxifen. For adjuvant therapy, the recent American Society of Clinical Oncology
guidelines advise that AI treatment should be included in the overall therapy of early
breast cancer but there is no one specific AI, which has been, recommend over the other
[Winer EP]. However, the best therapeutic strategy for AIs in an adjuvant setting
remain to be defined, in particular in terms of the role of the sequential approach and the
duration of therapy beyond 5 years. The overall therapeutic index of AIs appears to be
superior to that of tamoxifen with proven improved efficacy and a better toxicity profile.
In terms of safety, regardless of the adjuvant treatment setting, bone loss, increased
fracture rates, and other musculoskeletal disorders are the most serious side effects
associated with the use of AIs [BIG, ATAC and IES study]. However, studies have
shown that these bone health issues can be easily managed and the impact of AIs on
bone health minimised with concomitant zoledronic acid use if necessary [Bundred N].
By comparison, toxicities commonly associated with tamoxifen, such as
thromboembolic events and endometrial abnormalities, are more serious and less easily
managed.
It is reasonable to offer adjuvant AI therapy at the earliest opportunity due to the higher
rate of recurrences, adverse events, and withdrawals associated with adjuvant tamoxifen
over the first 2 years of treatment [Houghton J], For patients currently receiving
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adjuvant tamoxifen therapy, it is clear that they will be better protected against a relapse
if they are switched to an AI. Finally, for patients currently completing adjuvant therapy
with tamoxifen, initiating extended adjuvant letrozole offers the only proven opportunity




Placenta, fibroblasts cell culture, malignant and nonmalignant breast tissues were used to
measure aromatase activity and to study the effects of aromatase inhibitors. All patients
had given their informed consent to participate in the study (approved by the Hospital
Trust Ethics Committee)
Placenta
Placenta was obtained from women immediately following delivery. It was washed,
chopped into small pieces and stored in aliquots of 500mg in liquid nitrogen. The
placenta was used as control system and the experiments were conducted in duplicates.
Culture of fibroblast cell lines from human breast tissue
Adipose tissue was obtained from patients undergoing mastectomy for the treatment of
breast cancer. The gross fat obtained from mastectomy specimens were collected and
transferred to the laboratory in an aseptic manner in sterile phosphate buffer saline in
ice. The tissue was processed immediately after collection.
Collection of breast tissue
Postmenopausal women with large (>3cm), oestrogen receptor rich (>20 fmol/mg
cystosol protein) primary breast cancers (stages T2, T3, NO, Nl) were studied. All
patients received primary endocrine therapy comprising aromatase inhibitors with either
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letrozole, anastrozole or exemestane. None had previously received treatment with
hormonal agents for breast cancer or were taking hormone preparations at the time of the
study. Tumour and adjacent nonmalignant tissues (when possible) were obtained by
surgical biopsy before commencing treatment and at the time of definitive surgery (3
months). All tissues were put on ice in the operating theatre and transported to the




2.1.1a Cell culture media
The fibroblast cell lines were cultured in Minimal Essential Medium (alpha MEM) and
supplemented with 15% v/v of heat inactivated foetal calf serum (FCS), Penicillin (100
pg/ml) and Streptomycin (100 pg/ml).
2.1.1b Culture of fibroblast cell lines
The cell lines were grown in monolayer culture in a humidified incubator maintaining an
atmosphere of 95% air and 5% CO2 at 37°C. All tissue culture procedures were carried
out in a laminar flow cabinet using aseptic techniques and using sterile, disposable
plastic pipettes and tips. To ensure a sterile environment, the laminar flow cabinet was
thoroughly cleaned with a solution of 70% ethanol before any operations were
conducted. In addition all cell lines were handled using disposable latex gloves.
2.1 2a Enzymatic dissociation of fibroblast cells
The fat was washed twice in 15 mis of Dulbecco 'A' phosphate buffered saline (PBS)
and chopped into small pieces using sterilised scissors and forceps. Aliquots of 2g were
then placed into universal containers and minced. A sterile filtered collagenase solution
(600 units/ml) in alpha MEM equivalent to 5ml per gram of tissue was mixed with the
tissue and the universal container was placed in a shaking incubator at 37°C. The tissue
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was incubated for 30 minutes with gentle agitation. The contents were allowed to settle
for 10 minutes and the liquid phase was aspirated from below the surface lipid layer and
centrifuged for 10 minutes at 3000 rpm. The supernatant was decanted and the resultant
pellet resuspended by inversion in 20 mis of Dulbecco 'A' PBS to wash out the
collagenase. The cells were again centrifuged at 3000 rpm for 10 minutes and washed in
Dulbecco 'A' PBS. These steps of centrifugation and washing were repeated twice,
prior to suspension of the pellet in alpha minimal essential medium supplemented with
15% heat inactivated foetal calf serum, Penicillin and Streptomycin.
2.1.2b Primary Cell Culture
The cells were resuspended in 2ml of growth medium per gram of original tissue and
plated out in a 6 well plate. Each well was used for 2 grams of tissue. The cultures were
incubated at 37°C for 48 hours in an atmosphere of 5% CO2 - 95% air at 37°C. After
48 hrs, cultures were washed twice with PBS and fresh media added. Media were
changed every 2-3 days until the cells grew to confluence (2-3 weeks).
2.1,2c Secondary Cell Culture
Continuous cell growth was maintained through regular subculture. After achieving 90%
confluence cells were harvested through trypsinisation, diluted 1:4 in medium and
seeded in 6 well dishes. The subculture process involved aspiration of spent medium
from cells followed by 2 washes with Dulbecco A phosphate buffered saline (PBS) and
a 3 minute incubation at 37°C in 2ml trypsin EDTA (0.2ml of 10 x trypsin in 1.8ml of
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Dulbecco A PBS). The cells were then detached through gentle agitation and 10ml of
appropriate media were added to the cell suspension. Following centrifugation at 2000
rpm for 5 minutes, resuspension of the pellet in 10ml of medium, repeated pipetting
ensured a single suspension. 2ml of this suspension were delivered into each well. The
cells were allowed to adhere over a 24-hour period before being supplemented with
fresh medium. There after the medium was changed every 48 hours. Beyond passage
one, the cells displayed a reduced growth rate and adherence to the plastic wells.
2.1 2d Long term storage of cells
The monolayers were washed twice in PBS and incubated with trypsin EDTA solution
(lmls) with gentle agitation until the cells had dispersed. The cells were then pelleted by
centrifugation at 2000 rpm for 10 minutes. The pellet was then resuspended in 1 ml of
freezing medium, which consisted of 5% dimethyl sulphoxide (DMSO) in FCS. The
cells were then mixed with the freezing medium by titration, before being transferred to
cryogenic ampoules and placed in the -70°C freezer overnight. The cells were then
transferred to the gas phase, liquid nitrogen store.
2.1 2e Recovery of cells
Frozen cells were recovered by thawing the vial at 37°C in the water bath and media
were added drop wise with gentle mixing for 10 seconds until twice the original volume
was added. The suspensions were transferred to 15 ml conical tubes, 10 ml of media
added with gentle mixing of the tube contents and centrifuged X 2 at 2000 rpm for 5
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minutes. The resultant pellet was resuspended in growth medium and transferred into 6
well plates.
2.1.2f Preparation of cell pellets
The cells were washed with phosphate buffer saline. Trypsin (1ml) was added to the
culture plate and the cells were allowed to detach from the plastic. The cells were then
transferred to a test tube and the culture plates were washed with PBS (X2). The tubes
were centrifuged for 10 minutes at 3000rpm. The pellets were resuspended in 0.5mls of
PBS and the cell count was carried using a haemocytometer.
2.1.2g Manual determination of cell numbers
Cells to be counted were incubated with 1ml of trypsin EDTA for 2 minutes at 37°C and
washed twice with Dulbecco 'A' phosphate buffered saline. The suspension was
transferred to a 10ml test tube centrifuged for at 3000 rpm 10 minutes. The pellets were
resuspended in 0.5ml of PBS and the cell numbers determined using both chambers of a
haemocytometer (five 1 mm squares in each chamber).
2.1.2h Aromatase assay
Aromatase activity was determined by 'tritium release assay' and the protocol used is an
adaptation of that described by Frieden et al. It is based on the measurement H water
after incubation with ip3H A4-androstenedione.
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The fibroblast cell cultures were allowed to grow to confluence. The culture medium
was removed and the cells washed twice in Dulbecco 'A' PBS. Two blanks were used as
a control, which consist of dishes containing media but no cells. To each 6 well plate, 4
ml of reaction mixture was added and the plates were incubated for 5 hours at 37°C in a
humidified atmosphere of 5% C02 - 95% air. The reaction was stopped by placing all
dishes in ice for 15 minutes. Media were aspirated (4mls) and added to ice cold
chloroform (5mls) in 10ml glass test tubes. Each test tube was shaken thoroughly (xlOO
times) and centrifuged at 2000 rpm for 5 minutes. Triplicate aliquots (10pl) of la-3H-
androst-4-ene-3, 17-dione were added to counting vials to measure the total counts and
calculate the specific activity of the precursor. Charcoal pellets were prepared by
centrifuging 1ml of charcoal suspension (2000rpm for 15 minutes) in 12 mm x 75mm
glass tubes and aspirating the supernatant. Duplicate aliquots (1.5ml) of aqueous phase
were removed and added to tubes containing charcoal pellets and vortexed. The tubes
were allowed to stand for 10 minutes with occasional mixing and then centrifuged at
3000 rpm for 15 minutes. Supernatant (1ml) from one duplicate was transferred into a
counting vial (A) containing NE260 liquid scintillant (10ml). Supernatant (1 ml) from
the other duplicate was transferred into a counting vial (B) and evaporated to dryness
before the addition of 10 ml of NE260. All vials were vortexed and their radioactivity
measured using Tri-Carb 11900 CA liquid scintillation analyser.
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2.2 EXVIVO STUDIES - BREAST TISSUE
2.2.a Preparation of particulate fraction
All the procedures were performed in liquid nitrogen unless stated otherwise. Tissue was
cut into small pieces and pulverised using a mikro dismembranator. The dry weight was
determined. The tissue was homogenised by hand in an all glass uniform homogeniser
with a 2ml of 0.1 M phosphate buffer. The homogenate was transferred to a 10ml
conical glass tube, washing out the homogeniser with a further 10ml buffer, vortex
mixed and centrifuged at 800g for 5 minutes (1900 rpm using a GPR centrifuge with
GH-3.7 rotor). The supernatant was decanted into thick wall polycarbonate tube and
centrifuged at 10,000g for 60 minutes (50,000 rpm using an L7 ultracentrifuge with 70
Ti rotor). The pellet (particulate fraction) was resuspended in 2.4 mis of buffer using a
soniprep 150 ultrasonic disintegrator in short bursts.
2.2.b Purification of androst-4-ene-3,17-dione
1 B-3H androst-4-ene-3, 17-dione, (100 pci/ml 3.61nmol/ml) was purified by thin layer
chromatography on silica gel using chloroform: acetone (185:15). It was dissolved in
ethanol to a concentration of lOOpCi/ml. Duplicate aliquots (lOpl) were transferred to
the incubation mixture, into 60x27mm glass counting vials containing 10ml NE260
liquid scintillator for measurement of the specific activity of the precursor.
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2.2 c Preparation of radioactivel ft 3H androst-4-ene-3,17-dione
Androst-4-ene-3, 17-dione 22ng/ml in buffer
Prepared from a lmg/ml ethanolic solution as follows:
1. Diluted 0.1 ml to 10 ml with buffer to give a lOpg/ml solution
2. Diluted 0.1 ml of solution (1) to 4.4 ml with buffer to give a 227ng/ml solution
2.2 d Aromatase assay for particulate fraction
To 1.1ml of cofactor/precursor mixture, prewarmed in a 50x12 mm flat bottom glass
tube, 0.5 ml of particulate fraction was added, vortex mixed and incubated at 37°C for 5
hours in a shaking water bath. A reagent blank was set up by substituting 0.5 ml of
buffer for the particulate fraction. The incubation was stopped by decanting the mixture
into
3 ml, of ice-cold chloroform in a 10 ml round bottom glass tube and shaking vigorously.
After centrifugation at 2000g for 3 minutes (3000 rpm using a GPR centrifuge with GH
3.7 rotor), the chloroform layer was discarded using a pasteur pipette and the aqueous
layer was re-extracted with a further 3 ml chloroform. Duplicate aliquots (0.8ml) of the
aqueous phase were transferred into 75x10mm round bottom glass tubes containing 1ml
of 5% charcoal suspension. Tubes were vortex mixed and incubated at 4°C for 10
minutes with occasional further mixing, then centrifuged at 2000g for 15 minutes
(3000rpm).
Supernatant (0.5 ml) from each tube in triplicate was transferred into a 60x27mm low
background glass counting vial (A) containing 10ml NE260 liquid scintillator. All vials
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were vortex mixed and their radioactivity measured using a Tri-carb 1900 CA liquid
scintillation analyser.
Radioactivity associated with 3H release into the aqueous phase was calculated as
follows:
Aqueous phase activity (dpm) = [(A-B) sample - (A-B) blank] x LI x 0J1 (dpm)
0.8 0.5
where A = mean ofAi, A2 and B = mean ofBi; B2
2.2. e Protein assay
Protein concentration was determined using a Bio-Rad protein assay kit which followed
the method of Bradford (1976). The protocol followed is detailed below:
lml of protein assay dye reagent in triplicate 12x75mm tubes, was added to 20pl of
buffer (blank), particulate fraction (sample) or BSA standards (0.1-0.8 mg/ml). Tubes
were vortex mixed, incubated for 5 mins at 20°C and 200pl of the reaction mixture
transferred to the wells of a micro titre plate. The absorbance of sample and standards
was measured at 600nm against the blank using a model 222550 EIA plate reader. The
protein concentration of the particulate fraction was determined from the standard curve
for BSA using an assay calculation program [Biosoft, Cambridge] and Macintosh IICS
[Apple computer Inc, Cupertino, California].
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Verification of assay
To determine the effects of aromatase inhibitors on aromatase activity in cultured
fibroblasts, experiments were conducted in duplicate cultures using blanks (plates with
media but no cells) as control, fibroblasts and with letrozole (lOOnm). Aromatase
activity was measured by tritium release assay as described before. The duplicate
samples were evaporated under a stream of nitrogen to eliminate any tritiated aqueous
products and aromatase activity was measured in paired samples before and after
evaporation.
Induction of aromatase activity in cell culture
Aromatase activity was induced by incubating the cell lines with dexamethasone (lpM)
in the presence of 15% FCS for 18 hours prior to the assay.
Study design I
Two different study methods were explored:
Cultures were preiucubated in the absence of aromatase inhibitors [18 hrs] and
assayed in its presence of various aromatase inhibitors - letrozole, anastrozole,
aminoglutethimide, fadrozole, formestane and exemestane.
• The sequence of preincubating cultures with dexamethasone (to induce
aromatase) and then adding inhibitors during the assay procedure parallels in situ
studies in patients whom assays are preformed in the presence of the drug.
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PREINCUBATION ASSAY INCUBATION
DEXAMETHASONE ^ 3H ANDROGENUtA tlHA Ul t
NO INHIBITOR INHIBITOR
Cultures were preincubated in the presence of aromatase inhibitors (18 hrs)
and assayed in its absence. This parallels the exvivo study where the tumour
is removed from the presence of the drug.
PREINCUBATION ASSAY INCUBATION
DEXAMETHASONE 3H ANDROGENUbA c I O OUI ,
INHIBITOR NO INHIBITOR
Study design II
Cyclic AMP was used for inducing aromatase activity. Cell cultures were incubated with
cyclic AMP in the absence of FCS for 72 hours prior to assay.
• Cultures were preincubated in the absence of aromatase inhibitors (72 hrs)
and assayed in its presence of various aromatase inhibitors - letrozole,
anastrozole, aminoglutethimide, fadrozole, formestane and exemestane. This
assay procedure parallels in situ studies in patients whom assays are







• Cultures were preincubated in the presence of various aromatase inhibitors
- letrozole, anastrozole, aminoglutethimide, fadrozole, formestane and
exemestane (72 hrs) and assayed in its absence. This parallels the exvivo
study where the tumour is removed from the presence of the drug.
CYCLIC AMP —HANDROGEN
C- LYLLlt AlVir * <^-.
AROMATASE INHIBITOR NO INHIBITOR
RESULTS
Results are expressed as mean and are the result of atleast three separate experiments.
SPSS version 14.0.2 (SPSS, Chicago, Illinois, USA) was used for all statistical analysis.
Data was analysed using the Mann Whitney U test. P<0.050 was considered statistically
significant.
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ISOLATION OF NUCLEIC ACID
2.3a Isolation of total RNA from primary cultured cells
Total RNA was extracted from cultured cells using a modification of the acid guanidium
phenol chloroform (AGPC) method of Chocczynski and Sacchi [1987]. In order to
minimise RNase contamination of the RNA preparation all solutions were prepared
using RNase free glassware, water, plasticware and chemicals. Wherever possible the
solutions were treated with 0.1% DEPC (diethyl pyrocarbonate) for 24 hours at room
temperature and subsequently autoclaved for 20 mins at 151b/sy on a liquid cycle.
2.3b Isolation of total RNA from snap frozen tissue
Breast tumour tissue obtained before and after treatment with letrozole was promptly
washed in Dulbecco 'A' PBS and snap frozen in liquid nitrogen. The frozen tissue was
stored at -70°C. The frozen tissue was disaggregated using a mikro dismembranator
fitted with a 7ml Teflon shaking flask and accompanying stainless steel grinding ball,
both of which were prechilled in liquid nitrogen. The dismembranator was operated on
full power for 20 seconds and the resulting tissue powder scraped into 5ml of solution
using a prechilled micro-spatula. The stainless steel grinding ball was also placed into
the aliquot of solution, since a significant amount of the powdered tissue adhered to the
ball. The RNA preparation was continued as outlined below.
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2.3c Quantitation
A 5|a.l of the RNA solution was diluted in nuclease free water (2.995ml) and the
concentration and the purity of the preparation determined spectrophotometrically. In
order to quantify the amount of RNA in the sample readings were taken at 260nm and
280nm. An OD26o of 1 corresponds to an RNA concentration of 40pg of RNA/ml. The
ratio between readings taken at 260nm and 280nm (OD260/ OD2go) provides an estimate
of the purity of the sample. A ratio of 2 corresponds to a pure sample and if the ratio was
less than 1.7 the sample was re-extracted with phenol chloroform.
2.3d Extraction of RNA
45pl of phenol: chloroform (1:1) was added to the RNA solution and the suspension
vortexed and spun at 13,000 rpm for 5 mins (4°C). The aqueous phase was transferred to
a fresh eppendorf tube and mixed with 45pl of chloroform: isoamylalcohol (49:1) prior
to a further centrifugation at 13,000 rpm for 5 mins (4°C). The aqueous phase was
removed and RNA precipitated by the addition of 3 volumes of ethanol and 3M sodium
acetate to 0.3M final concentration. The precipitated RNA was pelleted and resuspended
as previously described. The concentration of RNA solution could then be reassessed
spectophotometrically as before.
2.3e RNA check gel
The 2% agarose gel was prepared by melting 1 g of agarose NA in 75 ml of IX TBE
using a microwave oven. The molten agarose was cooled to approximately 40°C before
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adding lpl of lOmg/ml ethidium bromide. The agarose was then poured into a level tray
containing a comb ofwell dimension 5.5 x 1.5 mm 16 well comb. The gel was run in
800 ml of 0.5 X TBE in midi-gel apparatus.
5pl of sample and lpl of loading buffer (6XM) could be loaded per well alongside
Lambda DNA restricted by EcoRI and Hind III. Electrophoresis was carried out at 100
volts for 45 minutes. Then the gel was examined and photographed under ultra violet
transillumination. The RNA sample was considered good if 8S and 24S bands were the
only clear visible major bands on electrophoresis. Only RNA samples that were good
both by spectrophotometry and by electrophoresis have been taken for reverse
transcription (RT).
2.3f Reverse transcription of total RNA
The protocol for first strand synthesis of cDNA from samples of total RNA is a
modification of that described in the Promega protocol. A volume of total RNA solution
corresponding to 1.5pg total RNA was aliquoted into a 500)4.1 test tube. The tube was
then heated to 85°C for 5 minutes and cooled on ice for 3 minutes. It was pulsed in a
microcentrifuge and the RNA mix was added to the solution. The tube was vortexed,
pulsed in a microcentrifuge and then incubated at 42°C for 60 minutes. Then the reverse
transcription mixture was heated to 90°C for 5 minutes and followed by a 5 minutes
incubation on ice. Potency of reverse transcription (RT) was verified by PCR with
primers to GAPDH gene.
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2.3g Aromatase gene
Expression of the coding part of aromatase mRNA was verified examining the region
across exons 2 and 3 (fig 3). The four most common variants of the untranslated and
alternatively spliced first exon were also studied (1.1, 1.4, 1.3 and Pll variants). In all
instances, a nested design of PCR was used; after a first round of PCR, 1/10 of PCR
products were taken for the second PCR with nested primers. Primers sequences and
cycling conditions are in table 7 and 8. PCR products were detected following
electrophoresis in 2% agarose gel and staining with ethidium bromide.
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Fig 3: DESIGN OF NESTED PCR
Variants of 1 st axon Coding part
r
1 L1 I——I u\-— I.3 [■ P.IJ | II exon III exon ..Etc.
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UJ1" round of RCRs u Nested Primers
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CTG GAG GGC TGA ACA CTG GG Harada et al (1993)
1.4 (lb) GAC CAA CTG GAG CCT GAC A
1.3 (lc) CCT TGT TTT GAC TTG TAA CCA
P.1I (Id) AAC AGG AGC TAT AGA TGA AC
II for 1st round GTC AAG GAA CAC AAG ATG GT
II nested ATC GTG CCT GAA GCC ATG CC Based on the
Sequences of II and
III exons published
in the Gene Bank
III nested TTG TAG TAG TTG CAG GCA CT
III for 1 st round ATA ATG AGT GTT TCC TCT CC
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Table -8: PCR conditions
Step PCR-mix Cycling
1st round of PCR 2 mM MgC12, 0.2 mM dNTP,
1 xPCR buffer and
Taq 25 mU/pl (Promega)
0.5 pM 1 st round primers
Total volume of 25 pi
Initial denaturation: 95°C
3 min; 40 cycles: 95° C
30s, 50°C 45s, 72°C 30s
Final elongation: 72°C
3 min
2nd round of PCR 2 mM MgC12, 0.2 mM dNTP,
1 xPCR buffer and
Taq 25 mU/pl (Promega)
0.5 pM 2nd round primers,
2.5pl of 1st round
PCR products
Total volume of 25 pi
Initial denaturation: 95°C
3 min; 35 cycles: 95° C




2.3h Agarose gel electrophoresis of PCR products
The PCR products were analysed by electrophoresis in 2% agarose gels containing IX
trisborate EDTA buffer (TBE).
Preparation of agarose gel
The 2% agarose gel was prepared by melting lg of agarose in 75 ml of IX TBE using a
microwave oven. The molten agarose was cooled to approximately 40°C before adding
lpl of lOmg/ml ethidium bromide. The agarose was then poured into a level tray
containing a comb of well dimension 5.5 x 1.5 mm 16 well comb.
Electrophoresis of samples in agarose gel
The gel was run in 800 ml of 0.5 X TBE in midi-gel apparatus. Bluescript and lambda
DNA were used as molecular weight markers. 18pl of each PCR reaction with 2pl of
DNA loading buffer could be loaded per well alongside. Electrophoresis was performed
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RESULTS
1. VALIDATION EXPERIMENTS
1.1 Validation of aromatase assay
Aromatase activity was measured by tritium release assay method. The determination of
aromatase activity was based on the measurement of (3H) water after incubation with
(ip3H) A 4 androstenedione. Mammary fibroblasts were used as test system and the
radioactivity in the aqueous phase was measured after charcoal extraction as described
before. Supernatant (1ml) from one tube was transferred into a background glass
counting vial (A) containing liquid scintillator and the supernatant from the other tube
was transferred into a counting vial (B). The second aliquot (B) was evaporated to
dryness under a continuous stream of nitrogen to eliminate any tritiated aqueous
products. All vials were vortex mixed and their radioactivity measured. The results are
shown in table -9.
Blank incubations are included in each experiment to assess background radioactivity.
The blanks, which contained only media but no cells, demonstrated a very low
radioactivity confirming that the background activity was very low. The fibroblasts
(control) displayed significant aromatase activity as high as 9267 dpm. This activity was
profoundly inhibited by the aromatase inhibitor letrozole (lOOnm) by almost 97%
demonstrating that letrozole is a potent aromatase inhibitor.
Evaporation of duplicate aliquots (tube B) - blank, control and with letrozole contained
only very low levels of radioactivity. The low counts measured following evaporation
confirms that 3H released into water was only measured and the aqueous phase was not
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contaminated by tritiated steroids. This experiment confirmed the validity of the
methodology used.
Tritium release assay quantifies the release of tritium from the ip position of the
substrate into the aqueous phase of the reaction mixture. Although the tritium atoms are
located in both a (20%) and P (80%) positions of the substrate, only the tritium atom in
the P position is incorporated into water during the aromatisation reaction. Thus, the
conversion rate can be determined by the isolation and quantification of the tritiated
water.
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Table-9: Validation of aromatase assay
The table represents the mean dpm (of atleast three experiments) before and after
evaporation.
Sample Before Evaporation After Evaporation A-B
A B
Blanks 77 55 22
Control 9267 458.7 8808
With letrozole 96 10.5 84.5
Blanks - contains no cells
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1.2 Effect of letrozole on aromatase activity in placenta
The potency of aromatase inhibitor letrozole (lOOnm) to inhibit aromatase activity was
tested using the placental system. Placenta was obtained and processed as previously
described. Aromatase activity was determined by tritium release assay.
The results are shown in table 10. 97% of aromatase activity was inhibited when
placental microsomes were incubated in the presence of letrozole. Significant aromatase
activity was observed with placenta. Letrozole consistently inhibited aromatase activity
in all the experiments carried out (atleast three). This has again demonstrated that the
new generation aromatase inhibitors such as letrozole are potent inhibitors of aromatase
activity.
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Table -10: Effect of letrozole on aromatase activity in placenta
Represents the dpm of three experiments conducted separately.
Expt No Blanks Placenta with letrozole % Inhibition
1. 81 12538 367 97
2. 75 11268 397 97
3. 71 12641 348 97
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1.3 Letrozole in assay phase
Fibroblasts were preincubated with dexamethasone (lpM) for 18 hours and 15% FCS
and letrozole (lOOnm) was added during the assay phase.
Interestingly the fibroblasts demonstrated significant aromatase activity. 97% of
aromatase activity was markedly inhibited by letrozole as seen in table-11. Letrozole
has thus consistently inhibited aromatase activity by 97% irrespective of using placental
microsomes or fibroblasts.
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Table-11: Aromatase activity with letrozole (100nm) in the assay
phase
Experiment No Sample DPM % of Inhibition
1. Control 12639 97
Letrozole 279
2. Control 9267 97
Letrozole 209
3. Control 11308 97
Letrozole 265
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1.4 Invitro test system for measuring aromatase inhibition
Cultured mammary fibroblasts, placenta and breast cancer homogenates are useful to
assess the ability of aromatase inhibition by aromatase inhibitors. The inhibitory effects
IC50 (50% inhibitory concentration) of aminoglutethimide, letrozole, anastrozole,
exemestane and formestane are summarised in table - 12 and 13 a & b.
Aminoglutethimide, letrozole, anastrozole, exemestane and formestane inhibited
aromatase activity in a dose related manner in each system tested; but the newer drugs
were magnitudes of order more potent than aminoglutethimide. Thus, micromolar
concentrations were required for aminoglutethimide while only nanomolar
concentrations were needed with letrozole, anastrozole, exemestane and formestane. The
newer type II inhibitors (letrozole, anastrozole) were more potent than type I inhibitors
(exemestane and formestane). Letrozole and exemestane are more potent in whole cell
cultures than in disrupted cell preparations. Amongst the type II inhibitors letrozole is
the most potent and exemestane is more potent than the other type 1 agent formestane.
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Table 12: Relative invitro potency of aromatase inhibitors as
determined using mammary fibroblast cultures as a test system
Mammary fibroblast cultures








Table 13 a: Relative invitro potency of aromatase inhibitors as
determined using placental microsomes as a test system
Placental Microsomes








Table 13 b: Relative invitro potency of aromatase inhibitors as
determined using breast cancer homogenates as a test system
Breast cancer homogenates









In this chapter, the methodology and the different types of test system used are
discussed.
The tritium release assay was used to measure aromatase activity in this study. Tritium
release assay was originally described by Thompson and Siiteri and modified by
Ackerman et al. It is based on the measuring the amount of 3H-water released upon
enzymatic conversion of radiolabeled androstenedione during aromatisation of
androstenedione or testosterone to oestrone. However, the assay requires the use of
radioactive materials and specialised equipment for radiometric measurement [Stresser
DM], Tritiated water assay quantifies the release of tritium from the 1[3 position of the
substrate into the aqueous phase of the reaction mixture. Aromatase activity is quantified
by the stereo specific loss of 1P 3H of the substrate into the aqueous phase of the reaction
mixture during aromatisation.
Tritiated substrates in which the radiolabel is present at both ip and 2 P positions are
commonly available and these lead to higher blank values owing to the ability of the
hydrogen at the 2 position to exchange albeit at a low rate with water [Siiteri PK, 1982].
IP 3H labelled substrates are utilised in this study to increase the specificity of the assay
and the background counts, especially when tissue samples are used in which enzyme
activity is so low. Blank incubations are included in each experiment to assess
background radioactivity. Only low levels of radioactivity were measured in the blanks
(background) in the experiments conducted. The background activity was assessed by
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using blanks (using media only) and the experiments were always performed in
duplicates, thus eliminating experimental bias in the methodology.
The methodology was verified by the low counts measured (following evaporation of
3 3
H20) in the validity experiments, which confirms that H released into water was only
measured and the aqueous phase was not contaminated by tritiated steroids.
There are different types of methods by which the biochemical efficacy of an aromatase
inhibitor may be assessed: invitro measurements, evaluation in animal models and
invivo assessment of endocrine efficacy in humans [James VHT, 1989]. The latter two
models were beyond the scope of this thesis.
An invitro model system was used in this study to test the potency of aromatase
inhibitors and test systems such as placenta, breast cancer homogenate, adipose tissue
and cultured fibroblasts were used in this study. The reason for using different test
systems including its advantages and disadvantages are addressed.
There are numerous test systems, which can be used to assess the ability of different
agents to inhibit aromatase activity. These screens include placental microsomes,
particulate tumour fraction and whole cell system. The most widely used test system for
aromatase inhibition is placental microsomes; although universally employed, they do
not reflect the low levels of aromatase activity seen in peripheral tissues [Stresser DM].
In addition, if antiaromatase agents are to be used in postmenopausal breast cancer
patients, it seems appropriate to screen these drugs against peripheral tissues, which are
the primary sites of oestrogen biosynthesis in postmenopausal women. About 70% of
breast cancers, when incubated as particulate fraction (invitro) display aromatase activity
[Miller WR, 2000] and these can be used as a screen. Therefore, it is more appropriate to
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screen aromatase inhibitors against peripheral tissues. Finally, while disrupted cell
preparations are useful test systems, they do not account for other factors such as cellular
drug uptake; therefore it is advisable to include whole cell system such as cultured
fibroblasts in any screen. Thus whole cell system such as placenta, breast cancer
homogenate and cultured fibroblasts were used in this study to determine the effects of
aromatase inhibitors.
The reason for using fibroblast cell culture from mammary adipose tissue is discussed.
Aromatase activity mainly occurs in stromal cells that surround adipocyctes and these
stromal cells grow in cell culture as fibroblasts [Price T]. Adipose tissue is the major site
of oestrogen biosynthesis in postmenopausal women, with the local production of
oestrogen in breast adipose tissue implicated in the development of breast cancer [Rubin
GL], This is based on the following evidence: (i) fat is able to aromatise androgens (ii) fat is a
major component of body mass [Forbes GB] (iii) fat is the main reservoir for steroids
[Deslypere JP] and (iv) degree of obesity relates to the level of circulating oestrogens and
incidence of oestrogen-dependent conditions [MacDonald PC]. The large mass in the body
fat is expected to be the main contributors to total peripheral oestrogen formation mainly
in postmenopausal women [Forbes GB]. Microsomal fractions or cultured fibroblasts
(derived from mammary adipose tissue) yields small quantities of oestrogen if incubated
with androgen precursors and this would release picromolar quantities of oestrogen
which would be sufficient to mediate oestrogen mediated events if this potential was
realised in situ (although it has low levels of conversion). Therefore mammary fibroblast
cell culture model system was more appropriate to be used in this study.
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A variety of tissue preparations have been used to measure adipose tissue aromatase
activity (invitro). These include tissue slices, minces, cell suspension or culture,
homogenates and various sub cellular fractions. The method described by Nimod and
Ryan utilized the soluble extract of tissue homogenates and has subsequently been used
successfully by a number of groups. In this study fibroblast, cell culture prepared from
breast adipose tissue was mainly used.
It should be noted that all the tissues were processed similarly and no variation in
materials or methods were introduced. All experiments were conducted in primary cell
cultures without passaging, as both basal and induced aromatase activity were maximal
in primary and early passage cultures and aromatase activity markedly decreased with
increasing passage [Miller WR, 1993]. These results whilst not definitive could be
consistent with local secretion of factors by tumours, which are capable of transiently
influencing aromatase activity in adipose tissue.
Before embarking upon studies investigating the effects of aromatase inhibitors on
aromatase activity, a series of control experiments were undertaken. The consistency in
reproducibility of the methodology was initially ascertained by conducting several
preliminary experiments using cultured fibroblasts and placenta. Adipose tissue was
used in the majority of the experiments. In some of the preliminary experiments placenta
was used since they exhibit higher aromatase activity than adipose tissue and therefore
require shorter incubation times. Significant aromatase activity could be demonstrated in
both fibroblasts and placenta. The effect of aromatase inhibitors such as letrozole was
tested using placenta and fibroblasts culture. 97% of aromatase activity was inhibited by
letrozole demonstrating its remarkable potency.
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Aromatase inhibitors also exhibited different potency in the different test systems. The
sensitivity to individual inhibitors was similar to that previously reported in placental
microsomes [di Salle R; Plourde PV, 1994]. In breast cancer homogenates, the two type
II inhibitors (letrozole, anastrozole) were more potent than the type I drugs (exemestane,
formestane) [Miller WR, 1997], It was also observed that letrozole and exemestane
seemed to have greater potency in cultured fibroblasts. This could relate to the
differences between disrupted and whole-cell preparations or between malignant and
nonmalignant tissues. Interestingly, letrozole seems to have increased potency in whole
cell systems and it has been postulated that the drug may accumulate to a greater extent
in such systems [Bhatnagar AS, 1999].
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2. EFFECTS OF AROMATASE INHIBITORS ON
AROMATASE IN CULTURED FIBROBLASTS [in the
presence of Dexamethasone]
2.1 Incubation of fibroblast culture with aromatase inhibitors
Fibroblast cultures were incubated in the presence of dexamethasone for 18 hours and
then assayed for aromatase activity in the presence of various inhibitors -
aminoglutethimide, letrozole, anastrozole, exemestane and formestane. The results are
shown in fig - 3.
All the drugs produced a dose response curve. Aromatase activity was markedly
suppressed at all concentrations studied with both types (I and II) of inhibitors.
The highest inhibitory effect was seen with lOOpM of aminoglutethimide, lOnm of
letrozole while anastrozole, exemestane and formestane produced maximum inhibitory
effect at lOOnm concentration (p<0.001). Thus all the drugs apart from
aminoglutethimide required nanomolar concentrations to produce inhibitory effect,
while aminoglutethimide required micromolar concentration. Letrozole was more potent
than other type II inhibitors (p<0.001) and exemestane was more potent than formestane
(p=0.039).
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Fig 3: incubation of fibroblasts cultures with aromatase
inhibitors
Effect on aromatase activity expressed as percentage [%] of control cultures without
inhibitors and are mean of at least three separate experiments. The columns represent the
means and the bars the standard errors of the means.
100.0
1 10 100 1 10 100 0.1 1 10 1 10 100 1 10 100
fiM nM
AMINOGLUTETHIMIDE ANASTROZOLE LETROZOLE EXEMESTANE FORMESTANE
CONCENTRATION OF AROMATASE INHIBITORS
120
2.2 Preincubation of fibroblasts culture with letrozole
Cultures were preincubated with letrozole (l-1000nm) for 18 hours and then assayed for
aromatase by incubating with ip3H A 4 androstenedione for 5 hours in the absence of
letrozole. The determination of aromatase activity was based on tritium release assay as
previously described. The results are shown in fig 4a and 4b.
Preincubation with letrozole produced enhanced activity at lower concentrations
(2-20 nm) and this was statistically significant (p<0.005). Inhibition of aromatase
activity could be demonstrated at higher concentrations (100 -1000 nm) of letrozole
(p<0.0005). Interestingly drug doses between 2 and 20nm consistently produced an
increase in aromatase activity. The maximum inductive effect of about 127% was
produced with letrozole at a concentration of 5nm.
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Fig 4a: Preincubation of fibroblasts with letrozole
Effect on aromatase activity expressed as percentage [%] of control cultures without
inhibitors and are mean of at least three separate experiments. The columns represent the
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Cultures were preincubated with letrozole (lOOnm) in the absence of dexamethasone.
Tritium release assay was carried out as described before.
Fig 4b shows the effects of preincubation with letrozole (in the absence of
dexamethasone).
Letrozole produced five-fold increase in basal levels (which were low).






2.3 Preincubation of fibroblasts culture with anastrozole,
aminoglutethimide and fadrozole
Cultures were preincubated with anastrozole (0.1-1000nm), fadrozole (l-100nm) and
aminoglutethimide (lpm -10pm) and then assayed for aromatase activity in the absence
of inhibitors as previously described.
Pre-incubation produced enhanced aromatase activity at all concentrations studied with
all the three inhibitors - anastrozole, fadrozole and aminoglutethimide. The results are
shown in figure 5.
Anastrozole produced enhancement of aromatase activity at all concentrations (0.1 -
1000 nm) studied rather than the expected inhibitory effect (p<0.0005). Interestingly,
inductive effect could be demonstrated even at O.lnm (p=0.004). Inductive effect
remained almost stable between 1 - lOOnm and demonstrated a gradual decline at
1000 nm.
Fadrozole induced aromatase activity at all doses studied with maximum effect seen at
lOnm (p=0.008). However with an increase in the concentration (lOOnm), a gradual
decline in the inductive effect was noted (p < 0.05).
Aminoglutethimide also consistently induced aromatase activity at all concentrations
studied (p=0.058). Increase in aromatase activity was seen as concentrations were
increased from lOOnm to 10pm (120 to 190%). Thus the magnitude of inductive effect
increased with increase in the concentrations studied (p=0.095).
Preincubation of cultured fibroblasts with type II inhibitors and assaying for aromatase
activity in the absence of inhibitors, have demonstrated a variable paradoxical response.
This has been contradictory to the effects of aromatase inhibitors invivo situation.
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However of all the type II inhibitors letrozole alone has been able to retain part of its
inhibitory effect at certain concentrations while the other drugs - anastrozole, fadrozole
and aminoglutethimide have all failed to realise their full inhibitory potential. This may
have important clinical implication, which will be discussed later.
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Fig 5: Preincubation of fibroblasts with aromatase inhibitors -
anastrozole, fadrozole and aminoglutethimide
Values are presented as a % of control cultures and are mean of three separate
experiments. The columns represent the means and the bars represent the standard errors
of the means.
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2.4 Preincubation with type I aromatase inhibitor - formestane
Cultures were preincubated with formestane (l-1000nm) and then assayed for aromatase
activity in the absence of the inhibitor. The determination of aromatase activity was
based on tritium release assay as previously described. The results are shown in fig - 6.
Preincubation with the nonsteroidal inhibitor formestane, markedly inhibited aromatase
activity at all concentrations (lnm -1000 nm) studied. The inhibitory effect produced by
formestane was statistically significant at all concentrations studied (p<0.0005).
However, marked inhibitory effect was noticed with an increase in concentration from 1
to lOOnm with 5nm producing maximum inhibitory effect (p=0.001).
Thus formestane demonstrated its inhibitory effect on aromatase activity on
preincubation with dexamethasone.
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Fig 6: Preincubation of fibroblasts with formestane
Values are presented as a % of control cultures and are mean of three separate
experiments. The columns represent the means and the bars represent the standard errors
of the means
DISCUSSION
Both type I and type II aromatase inhibitors studied markedly suppressed aromatase
activity when assayed i n their presence. All the aromatase inhibitors - steroidal
(exemestane, formestane) and non steroidal (letrozole, anastrozole,
aminoglutethimide and fadrozole) drugs studied produced a dose response with
greatest effect observed with the highest concentration studied.
Pre-incubation with type II inhibitors paradoxically enhanced aromatase activity
rather than producing the expected inhibitory effect. On the contrary, type I
inhibitors markedly and consistently inhibited aromatase activity in all circumstances.
Interestingly the inhibitory effect seen with type I inhibitors was greater when
pre-incubated with these inhibitors than when the drugs were added during the assay
phase itself.
To explore the effects further, fibroblasts cell cultures were preincubated with
cyclic AMP and similar experiments were conducted. The results are discussed in the
next chapter.
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3. Effects of aromatase inhibitors on cultured
fibroblasts [in the presence of Cyclic AMP]
3.1 Preincubation of cultured fibroblasts with letrozole and
anastrozole
Cultured fibroblasts were preincubated with letrozole and anastrozole for 72 hours in the
presence of cyclic AMP and then assayed for aromatase activity in the absence of
inhibitors. The results are as shown in fig 7.
Pre-incubation with letrozole and anastrozole resulted in enhanced aromatase activity at
all concentrations studied (l-100nm). Letrozole produced inductive effect between doses
of l-100nm (p<0.0005) with maximum inductive effect of 150% seen with lOnm
(p=0.002). It must also be noted with letrozole, concentrations above lOnm produce a
gradual decline in inductive effect and at a concentration of 1000 nm inhibitory effect
was seen (p=0.041).
The aromatase inhibitor anastrozole produced greater inductive effect when compared
with letrozole at all concentrations studied. The inductive effect appears to increase with
the increase in concentration of anastrozole studied. Anastrozole produced maximum
inductive effect of greater than 200% at lOOnm (p=0.012). The inductive effect on
aromatase activity produced by anastrozole was seen at all concentrations studied (1-
1000 nm) and this effect was significant (p<0.0005).
Letrozole produced inductive effect at concentrations of 1-1 Onm with both
dexamethasone (as seen previously) and cyclic AMP and this effect was statistically
significant (p=0.02). At lOOnm significant inhibitory effect was observed with letrozole
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in the presence of dexamethasone while inductive effect was seen with cyclic AMP
(p=0.02). Letrozole produced marked inhibitory effect at lOOOnm in the presence of both
dexamethasone and cyclic AMP but the inhibitory effect produced with dexamethasone
was highly significant (P<0.0005).
Letrozole produced inhibitory effect between 100 - lOOOnm in the presence of
dexamethasone while a 10-fold increase in concentration is required to produce similar
effect in the presence of cyclic AMP. It was also observed that letrozole produced
almost a 50% greater inhibitory effect at the same concentration of lOOOnm in the
presence of dexamethasone (as demonstrated before).
Anastrozole produced inductive effect at all concentrations studied both in the presence
of dexamethasone (as seen previously) and cyclic AMP. The inductive effect seen with
cyclic AMP was markedly greater than with dexamethasone between concentrations of
5-1000 nm (p<0.005). Interestingly at lnm almost similar inductive effect was produced
by anastrozole irrespective of the co-inducer used (P=0.65). Thus anastrozole produced
inductive effect on preincubation in the presence of both dexamethasone and cyclic
AMP.
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Fig 7: Effect on aromatase activity on preincubation of cultured
fibroblasts with letrozole and anastrozole
Expressed as percentage of control systems without inhibitors. The columns represent
the means and the bars represent the standard error of the means.














3.2 Preincubation with fadrozole and aminoglutethimide
Fibroblasts were pre-incubated with varying concentration of aminoglutethimide (pm)
and fadrozole (nm) and assay was carried out as previously described. The results are
shown in fig 8.
Both fadrozole and aminoglutethimide produced an increase in aromatase activity at all
concentrations studied.
Fadrozole produced a dose response curve. Maximum inductive effect of 179% was seen
at lOnm with fadrozole (p=0.005). However significant inductive effect was observed
with fadrozole in the presence of cyclic AMP (P<0.005) than in the presence of
dexamethasone (as described before).
Aminoglutethimide produced induction of aromatase activity between doses of 1 to
100 pm concentration and this statistically significant (p=0.01). The maximum inductive
effect of 150% was seen at a concentration of 10pm (p=0.002). Aminoglutethimide
required larger doses (micromolar) concentrations to produce its effects.
The inductive effect produced by aminoglutethimide was markedly greater in the
presence of cyclic AMP than in the presence of dexamethasone (p=0.005) at all
concentrations studied (l-100nm). However aminoglutethimide failed to produce the
expected inhibitory effect on preincubation irrespective of the co-inducer used.
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Fig 8: Effect on aromatase activity on preincubation of with
fadrazole and aminoglutethimide
Expressed as percentage of control systems without inhibitors. The columns represent
the means
and the bars represent the standard error of the means.







3.3 Preincubation with type I aromatase inhibitors
The fibroblasts were preincubated with varying concentrations of exemestane and
formestane and then assayed for aromatase activity in the absence of the aromatase
inhibitors. The results are as seen in fig 9.
Aromatase activity was markedly inhibited at all concentrations studied with both
exemestane and formestane (l-1000nm). The bell shaped curves were observed with
type I inhibitors. Exemestane produced greater inhibitory effect in comparison with
formestane (p<0.05) at all concentrations studied (1- lOOOnm). This effect may
demonstrate the potent effect of exemestane observed in the clinical setting. Maximum
inhibitory effect was observed with lOnm of exemestane and lOOnm of formestane.
Interestingly, exemestane produced greater inhibitory effect in the presence of
dexamethasone (as described before) than in the presence of cyclic AMP (p<0.0005) at
all concentrations studied (1-lOOnm).
Similarly formestane also produced significant inhibitory effect on preincubation with
dexamethasone (as described before) than cyclic AMP (p=0.002). The effect observed at
lOOnm of formestane was statistically significant on preincubation in the presence of
both the co-inducers (p<0.0005).
Thus both the type I aromatase inhibitors exemestane and formestane expressed
inhibition of aromatase activity in the presence of cyclic AMP.
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Fig 9: Preincubation with type I aromatase inhibitors in the
presence of Cyclic AMP
Effect on aromatase activity expressed as % of control systems without inhibitors. The
columns represent the means and the bars represent the standard error of the means of
three separate experiments.
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3.4 Incubation of fibroblasts in the presence of aromatase
inhibitors
Fibroblast cultures were preincubated with cyclic AMP for 72 hours and then assayed in
the presence of various inhibitors including letrozole, anastrozole, aminoglutethimide,
fadrozole, formestane and exemestane. The results are shown in fig 10.
Both type I and type II drugs produced inhibitory effects when assayed for aromatase
activity in the presence of aromatase inhibitors. Marked inhibition of aromatase activity
was observed at all concentrations with all the aromatase inhibitors studied. However the
magnitude of inhibitory effect produced with both type of inhibitors were greater in the
presence of dexamethasone (as described before) than in the presence of cyclic AMP
and this was statistically significant (p<0.0005).
It must also be noted that the inhibitory effect produced by letrozole was significantly
greater than that produced by anastrozole (p<0.01). Aminoglutethimide required larger
concentration to produce its effect in comparison to other drugs (p=0.006).
Exemestane and formestane almost produced similar inhibitory effects (p<0.0005).
Maximum inhibitory effect was seen at lOnm with both exemestane and formestane
(p<0.0005).
Thus all the aromatase inhibitors demonstrated their full inhibitory potential when
incubated in the presence of inhibitors irrespective of the co-inducers used.
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Fig 10: Effect on aromatase activity on incubation with various
aromatase inhibitors
Expressed as percentage of control systems. The columns represent the means and the
bars represent the standard error of the means.
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DISCUSSION
Aromatase activity was markedly inhibited by both steroidal inhibitors - exemestane
and formestane and nonsteroidal aromatase inhibitors - letrozole, anastrozole,
fadrozole and aminoglutethimide when assayed in their presence.
Thus similar inhibitory effect was observed with both type I and type II inhibitors
irrespective of the inducers used in the study. However the magnitude of inhibition
was greater in the presence of dexamethasone than in the presence of cyclic AMP.
This may have implication in the clinical setting, which shall be addressed in the
discussion chapter.
However the type II aromatase inhibitors failed to realise their full inhibitory effect
and produced induction of aromatase activity on preincubation. Letrozole alone
produced partial inhibitory effects only at certain concentration (lOOOnm).
Anastrozole produced a greater induction of aromatase activity in the presence of
cyclic AMP than in the presence of dexamethasone. The older generation of
aromatase inhibitor aminoglutethimide continued to exhibit similar effects but
required larger doses in comparison to newer group of drugs.
The paradoxical inductive effect on preincubation was consistently observed
irrespective of the co-inducers used with type II inhibitors. This has clearly
demonstrated that both the co-inducers - dexamethasone and cyclic AMP has
probably no influence on the mechanism causing such paradoxical effects.
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Interestingly with type I aromatase inhibitors marked inhibition of aromatase activity
was observed on preincubation in the presence of both the co-inducers. Thus the type
I inhibitors never failed to exert the expected inhibitory effect in all the experimental
setting studied. This may have implication in the sequence of use of aromatase
inhibitors, which shall be addressed later in the discussion chapter.
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4. Preincubation of fibroblast culture with androstenedione
Fibroblast cultures were preincubated with androstenedione (10 pi: lpci, substrate) in
the presence of aromatase inhibitors (letrozole and formestane) and assayed in the
absence of inhibitors. The results are shown in table - 14.
It was observed that letrozole produced a paradoxical induction of aromatase activity at
lOnm. However it continued to produce inhibitory effect at certain concentrations - lnm
and lOOnm. The response produced by letrozole in the presence of the substrate is
similar to the effect produced in the presence of inducers (as described earlier).
On the contrary the type I inhibitor formestane continued to demonstrate marked
inhibitory effect even in the presence of androstenedione at all concentrations studied.
Formestane demonstrated maximum inhibitory effect at lOnm. The magnitude of
inhibitory effect produced by formestane is similar to the response obtained in the
presence of inducers - dexamethasone and cyclic AMP (as described earlier). This has
demonstrated that the type I inhibitors consistently inhibit aromatase activity in all
circumstances.
Thus the addition of substrate did not influence the paradoxical stimulatory effect
observed invitro with letrozole at certain concentrations (lOnm) (p=0.038) and the
inhibitory effect observed with formestane (p< 0.05) at all concentrations. This may
have implications when the aromatase inhibitors are used in the clinical setting and shall
be addressed later in the discussion chapter.
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Fig 11: Preincubation of fibroblasts culture with
androstenedione
Values are represented as % of control cultures in the absence of inhibitors. The columns
represent the means and the bars represent the standard error of the means of three
separate experiments.
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5. Effect of aromatase inhibitors on aromatase activity with time
Cells were preincubated in the presence of dexamethasone and aromatase activity was
determined at 6, 24 and 48 hours after addition of aromatase inhibitors to the culture
media and activity was determined in the presence of aromatase inhibitors - letrozole
and exemestane. The results are shown in fig 12a and 12b.
Letrozole produced inhibition of aromatase activity at all concentrations studied. The
maximum inhibitory effect was seen at lnm. Letrozole continued to exert inhibitory
effect when incubated between 6 to 48 hours. It is observed that letrozole produced a
similar response as seen previously irrespective the duration of incubation.
Exemestane also produced inhibition of aromatase activity at all concentrations studied.
The maximum inhibitory effect was seen at lOnm. Exemestane when incubated between
6 to 48 hours produced inhibition of aromatase activity. It was also noted that
exemestane produced a consistent inhibitory effect irrespective of the duration of
incubation.
Thus the consistent inhibitory effect observed in the presence of both letrozole and
exemestane might have important implication when used in treatment of breast cancer,
which shall be discussed later.
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Fig 12a: Time course of fibroblast cells treated with letrozole
100
0.1 1 10 0.1 1 10 0.1 1 10
6 hours 24 hours 48 hours
CONCENTRATION OF LETROZOLE [nM|
144






1 10 100 10 100 1 10 100
6 hours 24 hours 48 hours
CONCENTRATION OF EXEMESTANE [nM]
145
DISCUSSION
The results from incubation of culture of breast adipose tissue fibroblasts confirm the
remarkable efficacy of the newly developed aromatase inhibitors. This is most readily
seen with aromatase activity being effectively inhibited in the invitro study.
Both steroidal and nonsteroidal aromatase inhibitors inhibited aromatase activity in
dose-related fashion, with concentrations of aminoglutethimide required at micro molar
range, while others including anastrozole, letrozole, exemestane and formestane were
able to inhibit at nanomolar concentrations. It confirms the potency of the newer
generation of aromatase inhibitors with the newer inhibitors at least 100-fold more
potent than aminoglutethimide.
Dexamethasone and cyclic AMP were used to induce aromatase activity and the reasons
for using, these inducers will be discussed.
Isolated stromal cells from breast cancer tissue contains aromatase enzyme, which can
be stimulated to nearly four orders of magnitude by dexamethasone, phorbol esters and
cyclic AMP [Simpson ER, 1983], Dexamethasone was the most effective steroid in
stimulating aromatase activity and this effect was blocked by actinomycin or
cyclohexamide [Simpson ER, 1983]. In this study, preincubation of fibroblast cultures
with various aromatase inhibitors in the absence of dexamethasone illustrated a five fold
increase in basal levels of aromatase (which were low). The stimulatory effect of
dexamethasone was apparent after a preincubation period of 4 hours and was maximal
after 24 hours with no further increase in activity thereafter [Simpson ER, 1981], In this
study preincubation was carried out for 18 hours as this duration has been previously
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confirmed to produce optimal stimulatory effect [Miller WR, 1993]. Inclusion of
dexamethasone for 18 hours in the culture media markedly induced aromatase activity
with the effects being dose related between concentrations 10"7and 10"8. The stimulatory
effects of dexamethasone were noted only in the presence of foetal calf serum (FCS) in
the culture medium [Simpson ER, 1983]. Activation of aromatase activity by foetal calf
serum in the presence of glucocorticoids is not only confined to adipose tissue but also
has been reported with skin fibroblasts and hepatocytes [Lanoux MJ]. Various reasons
have been postulated to be responsible for the inductive effect of glucocorticoids.
Glucocorticoids may increase aromatase activity by binding to specific receptor, which
induces synthesis of specific proteins the cytochrome P450. It is also known to activate
sequences and bind transcription factors of the STAT family. This may induce
transcription ofmRNA, which results in synthesis of new protein cytochrome P450.
In this study cyclic AMP was also used to potentiate aromatase activity. Fibroblast cell
cultures were preincubated with cyclic AMP for 72 hours and in the absence of foetal
calf serum. It has been previously demonstrated that cyclic AMP stimulated aromatase
activity after 48 hours and the presence of foetal calf serum, inhibited this stimulatory
effect by 70% [Mendelson CR 1986]. Hence all the experiments were conducted in the
absence of foetal calf serum. The inhibitory effect of foetal calf serum may be due to the
presence of certain factors that inhibits aromatase activity by acting on one or more
complex components of the enzyme complex that are increased by cyclic AMP. The fact
that serum inhibited the stimulatory effect of aromatase activity by cyclic AMP and the
time course of induction were markedly different for dexamethasone and cyclic AMP
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and are suggestive of different molecular events mediating aromatase induction with
both these agents [Simpson ER, 1983].
The strength of the fibroblast cell culture model used in this study, is that it simulated
both invitro and invivo conditions. Cultures ofmammary fibroblasts were preincubated
with aromatase inhibitors (to simulate patient treatment) and then assayed in the absence
of drugs as were the breast tissues from treated patients (mimic exvivo studies).
Additional cultures were set up using the design of incubating the cultures in the absence
of aromatase inhibitors but assaying for aromatase activity in the presence of aromatase
inhibitors (mimics the invivo studies). The study model adopted has the advantage that
invivo conditions could be simulated using the invitro setting.
Interestingly, all the drugs, both type I and type II inhibitors - exemestane, formestane
and letrozole, anastrozole, fadrazole and aminoglutethimide demonstrated significant
inhibitory effects on incubation (pO.OOl). Letrozole was more potent than other type II
inhibitors (p<0.001) and exemestane was more potent than formestane (p=0.039). This
inhibitory effect demonstrates the potency of the newer generation of aromatase
inhibitors. The inhibitory effect on aromatase activity was greater with 100pm of
aminoglutethimide, lOnm of letrozole while other inhibitors - anastrozole, fadrazole,
exemestane and formestane produced greater inhibitory effect at lOOnm concentration.
This demonstrates that small doses may be required for treatment (invivo) with both type
I and II inhibitors, except with aminoglutethimide which may require larger doses.
Aminoglutethimide also lacks the specificity which may be due to its interference with
other cytochrome P450 systems [Santen RJ, 1981]. The newer generation drugs such as
letrozole and anastrozole have relatively minimal effects on other cytochrome P450
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containing enzymes including those involved in glucorticoids synthesis [Trunet PF;
Masamura S, 1995]. This would mean no corticoid replacement is required when using
the newer generation of aromatase inhibitors.
In the preincubation setting letrozole produced a bell shaped dose response curve with
inductive effect at lower concentrations of 2-20nm (p<0.005) and inhibition at higher
doses lOO-lOOOnm (p<0.0005). This response pattern was similar to that observed by
Miller et al [1999]. In contrast when assays were performed in the presence of letrozole
consistent inhibitory effect was seen. This experimental setting is similar to ex-vivo
setting and may have important clinical implications which will be addressed later.
Interestingly the inhibitory effect seen with letrozole at lOOnm is less than that seen with
the same concentration when present in the assay phase.
In comparison to letrozole, anastrozole on preincubation produced persistent enhanced
activity at all concentrations studied (p<0.0005). It reached a plateau effect with lnm
and this remained persistent at lOOnm. However when assays were performed in the
presence of anastrozole consistent inhibitory effect was produced and the inhibitory
potential was less than that of letrozole (p<0.001). Fadrozole on preincubation displayed
consistent enhancement of aromatase activity similar to other drugs in the same group
(p=0.008). The effects produced by fadrozole could not be compared to other studies as
no similar experiments were conducted in breast fibroblasts. However Harada et al
[1998b] observed similar paradoxical effects in JEG3 choriocarcinoma cell culture lines.
Such effects may reflect the selective affinity of type II agents for the cytochrome P450
in aromatase. Aminoglutethimide also produced inductive effect in the preincubative
setting (p=0.058) and inhibitory effect on incubation but requiring micro molar
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concentrations. This is similar to the response observed previously [Miller WR, 1987].
This may have clinical implication in the dosage of drugs used as small dosage of new
aromatase inhibitors would be sufficient to achieve oestrogen suppression while large
doses of aminoglutethimide may be needed to be obtain the same suppressive effect.
Enhanced aromatase activity following exposure to aminoglutethimide has also been
reported in other culture systems [Miller WR, 2000].
Interestingly when type I drugs were studied, both exemestane and formestane
(p<0.0005) produced consistent inhibitory effect at all concentrations studied on
preincubation. The type I agents produced lesser inhibitory effect in the inductive phase
than when the drug was measured in the assay itself. The persistent inhibitory effect seen
with type I drugs may reflect the irreversible binding of the drug, which may be totally
independent of the amount of aromatase produced [Brodie AMH, 1986].
Letrozole was more potent than other type II inhibitors with lOnm producing greater
inhibitory effect (p<0.001). This has clearly demonstrated the superior potency of
letrozole than the other type II drugs. Dixon et al have observed similar potent effects of
letrozole in the clinical setting. They also observed that letrozole alone was able to retain
some of its inhibitory potential at certain concentrations. This may have important
implication in the clinical sequence of the use of aromatase inhibitors. Probably potent
drugs such as letrozole (at certain concentrations) must be commenced initially and with
development of drug resistance type I drugs could be used.
When preincubated with type II inhibitors, a paradoxical increase in aromatase activity
was observed and when incubated in the presence of inhibitors (either type I or type II),
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all the inhibitors markedly and consistently inhibited aromatase activity. This is
contradictory to the normal inhibitory potential of aromatase inhibitors both in the
clinical and invivo situations. Similar paradoxical results have also been reported in
culture of JEG3 and HepG2 cells in which type II inhibitors such as fadrozole and
vorozole enhanced aromatase activity [Harada N, 1998b]. Thus the persistent
paradoxical effect produced in different cell culture models may have important
therapeutic implications.
Co-agents like glucocorticoids are well known to induce aromatase activity. Therefore it
was necessary to prove that the paradoxical inductive effect of aromatase inhibitors was
not a feature of the inducers. Primary culture studies were preincubated with dibutyryl
cyclic AMP to induce aromatase activity and experiments were conducted in similar
settings. The results of this study are not comparable as no similar experiments have
been conducted to date.
Incubation which simulated patient treatment produced marked inhibition of aromatase
activity with type I inhibitors, while type II inhibitors produced a paradoxical increase in
aromatase activity. When assayed in the presence of inhibitors, both steroidal and
nonsteroidal aromatase inhibitors, markedly inhibited aromatase activity. The aromatase
inhibitor anastrozole produced greater inductive effect when compared with letrozole at
all concentrations studied (p<0.0005). Letrozole alone demonstrated inhibitory effect at
higher concentrations in comparison to other drugs in the same group (p=0.041). This
may illustrate the superior potency of letrozole which alone is able to retain its inhibitory
effect at certain concentrations.
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Interestingly, on preincubation and incubation with type I inhibitors aromatase activity
was inhibited at all concentrations studied (1-lOOOnm). Exemestane produced greater
inhibitory effect in comparison with formestane (p<0.05) and appears to be more potent
than formestane and this may be ascertained from the results of the new clinical trials.
The paradoxical inductive effect on aromatase activity observed with type II drugs on
preincubation was demonstrated both with dexamethasone and dibutyryl cyclic AMP.
This has clearly demonstrated that paradoxical inductive effect observed in certain
circumstances with type II agents is not a feature of the inducers. Though the two
inducers dexamethasone and cyclic AMP mediate induction of aromatase activity by
different molecular events, the effects produced by the steroidal and non steroidal
aromatase inhibitors is consistent proving that the effects displayed by them is not
influenced by the inducers used.
The inductive effects of aromatase inhibitors observed under certain conditions in cell
culture model may have important clinical implications in the use of these drugs. Thus
the type II drugs may be associated with hormonal escape phenomenon with the long
term use and the type I inhibitors may be indicated in such situations.
Various reasons for the paradoxical effect exhibited by type II drugs can be postulated. It
can be a reflection of the different mechanism of action of the two groups of drugs or it
can be due to alteration at a molecular level. The lack of full inhibition and the enhanced
activity of type II inhibitors may reflect the reversible nature of these inhibitors and its
ability to induce aromatase mRNA/stabilize aromatase protein.
The ability to induce aromatase mRNA/stabilisation of aromatase protein has been
reported by Harada et al [1998b] in JEG-3 cells (invitro) and in mice (invivo) and by
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Chen et al [1999], These effects have been attributed to stabilisation of the enzyme
protein by protection from proteolytic digestion. Additionally, such inhibitors might
stabilise the aromatase enzyme by preventing the destructive peroxidation associated
with hydroxylation.
The substrate androstenedione is known to protect the steroidal inhibitors from
inactivation and it would be of importance to determine its effect invitro. The steroidal
compounds are analogues of the substrate androstenedione and compete with the
substrate for the enzyme-binding site. In addition they may be suicide inhibitors, which
bind covalently to the enzyme-binding site in an energy dependent manner. This
mechanism has been demonstrated invitro by increasing the duration of preincubation
with the inhibitor prior to measurement of aromatase activity [Brodie AMH, 1981].
Fibroblast cultures were preincubated with the substrate (androstenedione) in the
presence of aromatase inhibitors (letrozole and formestane) and assayed in the absence
of inhibitors. The physiological concentration of androstenedione had no influence on
the inhibition. Addition of substrate did not influence the paradoxical stimulatory effect
observed with letrozole and the inhibitory effect of formestane (invitro). Harada et al
[1999] believed that aromatase inhibitors and substrates bind competitively to same
binding sites within the aromatase molecule to form conformationally tight complexes,
which would be resistant to proteolytic degradation. The pharmacodynamics of steroidal
inhibitor is determined partly by the continued presence of the inhibitor and partly by the
synthesis of new enzyme. Thus the use of this type of inhibitor may result in substantial
intracellular build up of the drug, which would need to be addressed in the clinical
setting.
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The influence of variation in time on the effects of aromatase inhibitors was also studied.
The fibroblasts were treated with letrozole and exemestane (l-1000nm) over 6-48
hours and assayed in its absence. Both consistently inhibited aromatase activity with
time having no influence on its effects. However Harada et al [1998b] observed a time
dependent increase in aromatase protein using JEG cells with the non steroidal
agents - fadrozole, vorozole and pentrozole and mRNA levels in the cells remain
unchanged during the inhibitor treatment. It was therefore suggested that aromatase
inhibitors increased aromatase protein through stabilisation and reduced protein
turnover.
Thus the inductive effects of aromatase inhibitors observed under certain conditions
(invitro setting) may have important clinical implication. Long term use of type II
aromatase inhibitors may be associated with hormonal escape phenomenon which may
necessitate the use type I inhibitors in such situation.
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6. Exvivo studies
6.1 Treatment with letrozole
Aromatase activity was measured (invitro) in nine paired samples ofmalignant and
non-malignant tissues obtained before and after treatment with letrozole 2.5mg/day for 3
months. Particulate fractions were prepared and aromatase activity was determined as
described previously. The results are summarised in figure 13 and 14.
All patients had measurable aromatase activity in pretreated tumour samples varying
between 0.5 to 3.38 fmol/mg protein/hour. Eight patients had decreased aromatase
activity and only one patient demonstrated paradoxical increase in activity following
treatment with letrozole. The aromatase activity in responding tumours was almost
negligible following treatment. The changes following treatment with letrozole was
statistically significant (p=0.017) with a mean difference of 3.52 between pre and post
treated tumour samples. This demonstrates the potency of letrozole in reducing
aromatase activity in tumour tissues. Only one tumour demonstrated paradoxical
induction of aromatase activity. Aromatase activity increased from 1.2 fmol/mg
protein/hour in pretreated sample to 1.5 fmol/mg protein/hour in post-treated tissue and
this change was not statistically significant (p=0.46). One patient had paradoxical
increase in aromatase activity in tumour tissue also demonstrated similar effect in the
nonmalignant tissue following treatment although the aromatase activity in the
nonmalignant tissue was higher than the tumour itself.
In nonmalignant breast tissue measurable aromatase activity was demonstrated in all the
pretreated tissue samples. Nonmalignant tissues had a variable amount of aromatase
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activity ranging between 0.3 - 47.3 fmol/mgprotein/hour. It was interesting to note that
one sample of non malignant tissue had initially very high measurable aromatase activity
(47.3 fmol/mgprotein/hour) which decreased following treatment. Significant decrease
in aromatase activity was observed in five patients and paradoxical increase in activity
was observed in four patients following treatment. The changes following treatment with
letrozole in non malignant tissues was statistically insignificant (p=0.36) with a mean
difference of 4.15 between pre and post treated tumour samples. The paradoxical
increase in activity was mostly observed in specimens, which had initially low
aromatase activity. The paradoxical increase in aromatase activity was however
statistically insignificant (p=l). Thus the non malignant tissues have demonstrated
variable response following treatment with letrozole.
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Fig 13: Aromatase activity in malignant breast tissues before




Fig 14: Aromatase activity in nonmalignant breast tissues




6.2 Treatment with anastrozole
Aromatase activity was measured in malignant and nonmalignant tissues (invitro) in
patients before and after treatment with anastrozole (lmg/day) for 3 months. Particulate
fraction of tumours obtained from two patients and nonmalignant tissues from five
patients were prepared and aromatase activity was determined as described before. The
results are shown in Table 15 and Fig 15.
Both the tumour samples had significant aromatase activity in the pretreated tissues and
higher aromatase activity was expressed in comparison to nonmalignant tissues.
Following treatment both the tumours studied, displayed a significant decrease in
aromatase activity (p<0.05).
The nonmalignant tissues had demonstrated significant aromatase activity in pretreated
tissue samples in all but one, which had almost no measurable activity. Four had
decrease in aromatase activity following treatment (p=0.01). The mean difference
between pre and post treatment sample was 2.50. Paradoxical increase in activity was
observed following treatment in one sample (p<l). The nonmalignant tissues that
demonstrated a paradoxical induction in aromatase activity had initially no measurable
activity.
Thus the malignant and nonmalignant tissues studied displayed the expected inhibition
in aromatase activity following treatment though the numbers studied were small.
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Table -15: Aromatase activity invitro in paired samples of breast








Fig 15: Effects of 3 months of treatment with anastrozole on





6.1 Treatment with exemestane
Six postmenopausal women were treated with exemestane (25 mg) for 3 months.
Particulate fractions of malignant and non malignant tissues were prepared. Aromatase
activity was determined. The results are shown in fig 16.
Aromatase activity varied between 0.6 - 7.9 fmol/mg protein/hour in the pretreated
tissues samples. Similar to other aromatase inhibitors pretreated tumours had measurable
aromatase activity. Four patients had a decrease in activity and two patients had a
paradoxical increase in activity following treatment. The changes following treatment
with exemestane in malignant tissues was significant (p<.05). The mean difference
between pre and post treated tumour samples was 1.44. The two samples which
demonstrated paradoxical increase in aromatase activity following treatment had also
initially low aromatase activity. The paradoxical increase in aromatase activity in
malignant tissue samples was statistically insignificant (P<1).
Thus most malignant tissues treated with exemestane demonstrated a decrease in
aromatase activity following treatment.
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Fig 16: Effects of 3 months of treatment with exemestane on





Treatment with aromatase inhibitors
Aromatase activity was well demonstrable in all the tumour samples studied before
treatment. Following treatment decrease in aromatase activity was seen in most of them.
This could be consistent with the observation that tumour tissues have high aromatase
activity and significant suppression occurs with the use of third generation aromatase
inhibitors. The changes following treatment letrozole, anastrozole and exemestane were
statistically significant between pre and post treated tumour samples (p=0.017, p=0.01,
p<0.05). This demonstrates the potency of the third generation aromatase inhibitors in
reducing aromatase activity in tumour tissues. The decrease in aromatase activity
following treatment occurred in majority of the tumours samples treated; one of nine
treated with letrozole, two of two treated with anastrozole, four out six treated with
exemestane. It is interesting to note the mean difference between pre and post treated
tumour samples treated with letrozole was greater (3.52) in comparison with exemestane
(1.44).
Paradoxical increase in activity could only be seen with one letrozole and two
exemestane treated tumours (statistically insignificant). The paradoxical increase in
aromatase activity observed in one letrozole treated tumour had produced a similar
response in the nonmalignant tissue also. The paradoxical increase in aromatase activity
was seen in tumour tissues, which had initially low aromatase activity before treatment.
In contrast, both the anastrozole treated tumours showed the expected inhibition of
aromatase activity following treatment.
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Nonmalignant breast tissues demonstrated variable aromatase activity. Paradoxical
increase in activity was observed in four patients following treatment with letrozole and
one treated with anastrozole. The changes following treatment in non malignant tissues
was statistically significant with anastrozole (p=0.01) and insignificant with letrozole
(p=0.36). On the contrary, most of the nonmalignant tissues demonstrating paradoxical
increase in aromatase activity had initially low activity in comparison to its tumour
counterparts. Decrease in aromatase activity was observed in five patients treated with
letrozole (p=l) and four patients treated with anastrozole (p<l), although was not
statistically significant. The paradoxical increase in activity was mostly observed in
specimens, which had initially low aromatase activity. Thus the non malignant tissues
have demonstrated variable response following treatment.
The reason for paradoxical increase in aromatase activity may be that, invitro estimates
of treated specimens may under estimate the decrease of inhibition produced invivo: this
makes the use of protocols that accurately measure of in situ activity essential when
assessing the putative efficacy of individual inhibitors. Although observation in
experimental test systems is informative, they may not necessarily reflect events
occurring within the body. Other possible causes includes that invitro assays may
underestimate the potency of type II inhibitors. Even though aromatase activity may be
blocked by the drugs in situ, the reversible nature of the association of type II drugs may
mean that aromatase activity is released from its inhibition. This would not be the case
for irreversible type I inhibitors which have also demonstrated failure of total inhibition
of aromatase activity in certain tumours. Thus failure of suppression of aromatase
activity has been demonstrated in certain malignant and nonmalignant tissues following
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primary treatment with letrozole, anastrozole and exemestane. The reasons for such
paradoxical mechanism are discussed in detail in the following chapter.
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DISCUSSION
Postmenopausal patients with large operable oestrogen receptor (ER) positive primary
breast cancers were treated with aromatase inhibitors - letrozole, anastrozole and
exemestane. Experiments were undertaken using paired specimens of both malignant
and nonmalignant breast tissues obtained before and after treatment. The effects of
aromatase inhibitors were assessed, by comparing aromatase activity before and
following treatment.
Although different methods can be used to measure aromatase activity, biochemical
assay was used in this study. The bias in variability in the amount of tissue used was
eliminated by measuring the protein content and results were expressed as fmol/mg
protein/hour. The study sample consisted of a group of 16 postmenopausal patients.
Aromatase activity varied in pre and post treated malignant and nonmalignant tissues
studied. Possible explanations for the variation will be addressed.
Aromatase activity was demonstrated in all the tumour tissues studied. This finding was
similar to the observation made in other studies with measurable aromatase activity both
in normal and malignant breast tissues [Perel E, 1982; Reed MJ, Lu Q]. Aromatase
activity detected (0.3 - 3.72 pmol /g protein /hour) in pretreated tumour tissues was
similar to the observation made by Lipton et al. In this study higher aromatase activity
was demonstrated in malignant tissues while the activity was variable in nonmalignant
tissues. This finding was similar to that of James et al, who demonstrated higher
aromatase activity in breast tumours (invitro). Previous studies have shown a significant
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correlation between aromatase activity and tumour bearing quadrants [Miller WR, 1987]
but this was not addressed as this was beyond the scope of this thesis.
Results of this study showed marked decrease in aromatase activity following treatment
in most of the tumour tissues while variable response were observed in nonmalignant
tissues. The majority of tumours treated with aromatase inhibitors have showed a
consistent inhibitory effect although paradoxical increase in activity was observed in
three patients. Marked decrease in activity following treatment was observed both with
letrozole (p=0.017) and anastrozole (p<0.05) in all but in one patient. This correlates
with the findings of Dixon et al where marked suppression of aromatase activity was
noted in letrozole treated patients (invivo). The exemestane treated patients also
demonstrated a decrease in activity following treatment except for two patients (p< .05).
Thus the third generation aromatase inhibitors have demonstrated their potency in
reducing aromatase activity following treatment in most of the tumour samples studied.
In nonmalignant breast tissues the degree of decrease with treatment was less marked
and paradoxical increases in activity were seen in cases in which aromatase activity was
initially low. Although there was a paradoxical increase in aromatase activity following
treatment it was noticed to be statistically insignificant, although the numbers treated
were small. Interestingly all these patients had a clinical response, which may reflect the
low sensitivity and specificity of the invitro assays itself.
Possible explanations for the variation in aromatase activity before and after treatment
are addressed.
A comparison was made assessing aromatase activity before and after treatment in a
retrospective study of patients demonstrating a significant reduction of aromatase in
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responding tumours and a significant increase in non-responding tumours. These
changes were observed when the clinical behaviour of the tumours was already known.
Interestingly all the tumours had a clinical response but for one. This may reflect the fact
that invitro estimation may not be a direct reflection of invivo activity. The timing of
obtaining specimen may be important as these were all taken at the end of 3 months,
which was an arbitrary period of treatment. It must also be noted that the study was
conducted in specimens stored in liquid nitrogen.
Although aromatase inhibitors are used to treat breast cancer, treatment has found to
increase the level of aromatase in the breast tissue of some patients as observed in this
study. Changes in aromatase activity following treatment have been previously studied
invitro to other aromatase inhibitors mainly aminoglutethimide. Paradoxical increase in
aromatase activity in tumours from patients treated with aminoglutethimide has been
initially observed by Miller et al [1987]; this activity was still shown to be sensitive to
aminoglutethimide, by demonstrating inhibition after invitro incubation with the drug.
The different types of assay, the problems in measurement of aromatase activity are
addressed.
Bezwoda et al have demonstrated that tumour aromatisation in breast cancer tissue was a
useful measurement in predicting response to therapy [1987], In this study aromatase
activity during neoadjuvant therapy has been useful in predicting response to treatment
in malignant tissues while variable effect has been observed in nonmalignant tissues.
Aromatase activity during neoadjuvant therapy would be a useful predictor of response
to treatment if reliable method of assessment were available. The present accepted 'gold
standard' method of estimation of aromatase activity is biochemical assay, which may
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not reflect the insitu activity [Shenton KC]. The vitro assays performed require fresh or
frozen tissue and are more cumbersome. They may also not accurately reflect the invivo
activity. It must be noted that parallel studies using product isolation assay were not
performed in this study. It may be possible that some tumours may release 3H from
lbeta androstenedione into aqueous phase without being able to detect radioactively
labelled oestrogen by product formation. However the use of product isolation assay
may also display the phenotype with low / no aromatase activity despite the amount of
mRNA transcripts.
Assessment of invivo activity has been carried by Reed and Dixon et al. It requires
administration of radioactive material (invivo) and assessment is carried out in the
presence of the administered drug [Santen RJ, 1982]. The invivo technique is invasive,
involves use of radioactively labeled infusions and an extra procedure in patient
management and could also be influenced by paracrine and local factors.
Immunohistochemistry techniques can be performed in paraffin embedded material. It
requires reliable antibodies and reproducible scoring systems. Immunohistochemical
assays are controversial as the exact localisation of aromatase activity is yet to be
determined. Attempts have been made to develop reliable immunohistochemistry
techniques and a multicentre collaborative group has been established to generate and
validate new aromatase monoclonal antibodies [Sasano H, 2003], Reverse transcriptase
polymerase chain reaction can demonstrate the presence of aromatase RNA but it
requires amplification, quantitation and has cumbersome handling techniques.
Another indirect method of assessment is by measuring circulating serum oestradiol. All
of the current third-generation aromatase inhibitors (exemestane, anastrozole, letrozole)
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reduce the amount of circulating serum oestradiol to such a low level, that it can barely
be measured by commonly used assays. Furthermore, it is unclear whether the
differences in the serum levels are important in predicting or controlling response to
antiaromatase agents in breast cancer patients. However, serum oestrogen levels were
not measured as it was beyond the aim of this thesis. As oestrogen levels in the
circulation do not necessarily reflect those in the breast and because local aromatase
activity may be affected by antiaromatase agents, it is essential to determine the effects
of aromatase inhibitors on the endocrinology within the breast.
Aromatisation is considered to play an important role in development of breast
carcinoma and hence methods to detect aromatase must be highly sensitive and specific.
The role of intratumoural aromatase is becoming more important as the use of aromatase
inhibitors continue to increase in clinical setting [Brueggemeier RW] and it would be a
predictive marker to determine the response to treatment. Therefore in future,
development of a reliable technique for the assessment of intratumoural aromatase is
highly desirable in order to optimise the treatment modalities.
The reasons for the variable result seen in this study with malignant and nonmalignant
tissues may be related to methodology. Invitro studies yield results, in which inhibition
is incomplete or activity may be increased, other endocrinological data on circulating
oestrogens or whole-body perfusion studies suggest that inhibition of peripheral
aromatase is almost total [Geisler J, 1998], Invivo assays have demonstrated a decrease
in activity following treatment with aromatase inhibitors [Miller WR, 2001]. Thus
invitro assays performed from inhibitor treated patients may not accurately reflect the
degree of inhibition produced invivo. Exvivo studies of tissue aromatase indicated that
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such measurements consistently underestimate the inhibitory potential of reversible non¬
steroidal agents. Although aromatase activity may be blocked by non-steroidal agents in
situ, invitro assays are performed without the addition of inhibitors so aromatase activity
can be released from its inhibition due to the reversible nature of type II drugs (but not
type I). It could also be due to the fact that tumour aromatase activity may be influenced
by systemic and local factors. Invitro measurement of tumour aromatase activity may
probably not reflect activity invivo due to potentiating effects of growth factors,
cytokines and proteins.
The various mechanisms, which may produce paradoxical response following treatment,
are addressed.
Paradoxically breast cancers from patients treated with aminoglutethimide display
elevated levels of aromatase; comparisons of sequential tumour samples taken before
and following treatment show that aromatase may be induced as much as 25 fold [Miller
WR, 1988], Addition of the same drug to cultures of fibroblast cell lines also produced a
profound increase in aromatase activity. These effects would be consistent with the
drugs ability to induce cytochrome P450 hydroxylase [Santen RJ, 1981]. Thus elevated
aromatase could potentially reduce the drug efficacy and under these circumstances
individuals might be beneficially treated with type I aromatase inhibitor.
The increase in aromatase activity in non-responding tumours may be a reflection of the
growth of unresponsive tumour. There is also a possible concern that aromatase
inhibitors can lead to stimulation of tumour growth in this subgroup of patients. It may
be that the cells may represent resistant clones, which were more in non-responding
tumours although the number in this study is small.
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The different mechanisms that may account for drug resistance have also been
discussed. General endocrine resistance emerges when the tumour is originally hormone
independent or becomes so especially with oestrogen receptor (ER) negative tumours
and such cancers are unlikely to respond to aromatase inhibitors. Cellular heterogeneity
with regard to hormone receptors and sensitivity has been documented [Hamon JT]
although clinical observations are not totally compatible with differential clonal
destruction. Thus if successful treatment with aromatase inhibitors were associated with
selective destruction of oestrogen receptor positive cells and relapse associated with
emergence of negative clones, oestrogen receptor content should fall. On the contrary,
sequential analysis of tumours from patients treated with aminoglutethimide have shown
that in majority oestrogen receptor (ER) levels following response are similar to before
treatment. However all samples used in this study were oestrogen rich tissues. Oestrogen
receptor status following treatment was not measured as this was beyond the aim of this
thesis.
Experience with chemotherapeutic drugs suggests either the presence of efflux pumps or
metabolic activity which reduces the effective levels of drug within the target cell
[Juranka PF], Clear evidence for such allied phenomena in aromatase inhibitors
resistance is lacking. It is possible that in individual patients, hormone escape could
contribute to tumour regrowth. If this is true more effective measures to suppress
oestrogen levels should be beneficial.
Exvivo studies show that aromatase in a subset of tumour appears resistant to type I
inhibitor formestane [Reed MJ]. Interestingly resistance can also be demonstrated
invitro. Tumour homogenates were incubated with increasing concentration of 4
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hydroxy androstenedione and a type II inhibitor (aminoglutethimide). Certain tumours
showed classic sensitivity to both type of inhibitors while others displayed resistance to
4-hydroxy androstenedione while remaining sensitive to type II inhibitor. Similar
differential resistance/sensitivity has been shown in site mutagenesis studies of
aromatase enzyme [Kadohama N] but the particular causative mutations have not been
shown to be present in clinical specimens [Sourdaine MG].
Acquired resistance after successful treatment with hormonal therapy may also result
from emergence of hormone resistant clones of tumour cells, which may have been
present from the initiation of therapy. Genetic alterations may be responsible for failure
to respond and molecular analysis of the gene in these tumours may provide supportive
evidence. This was not carried out as it was beyond the scope of our study but would
provide a valuable insight for investigation in future. Structure function studies have
been performed in which site mutation, have been introduced into cDNA encoding for
aromatase [Kadohama N]. One point mutation has shown to decrease sensitivity to 4
hydroxystenedione without changing itself. This phenotype has some relevance to breast
cancer as a subset of tumours appear to have aromatase activity which is insensitive the
inhibitory effects of 4 hydroxyandrostenedione while maintaining sensitivity to
aminoglutethimide [Miller WR, 1997]. Sourdaine et al failed to provide such evidence
and suggested that it may be due to other modifications.
Thus in this study aromatase activity during neoadjuvant therapy has been useful in
predicting response to treatment in malignant tissues while variable effect has been
observed in nonmalignant tissues.
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7. Breast adipose tissue on treatment with letrozole -
polymerase chain reaction [PCR]
The object of the present study was to determine the distribution of various exon-
specific transcripts in breast adipose tissues obtained before and following treatment
with letrozole (2.5 mg) for 3 months, as this would enable to understand the nature of
the factors regulating aromatase expression following treatment. To achieve this, we
employed competitive RT-PCR, utilising an internal standard for each exon-specific
transcript of the CYP19 gene, as well as for the coding region, to evaluate total CYP19
gene transcripts.
Aromatase gene expression was studied in 6 samples of breast adipose tissue obtained
before and following treatment with letrozole (2.5 mg] for 3 months. Total RNA was
isolated using the Guanidine-Thiocyanate method as described before and purity
checked by spectrophotometry and electrophoresis. Reverse transcription (RT) was
performed with oligo-dT primers using a Promega kit in accordance with manufacturer's
recommendation. Efficiency of reverse transcription (RT) was verified by polymerase
chain reaction (PCR) with primers to GADPH gene. In all instances, a nested design of
PCR was used. Expression of coding part of aromatase mRNA was verified examining
the regions across exons II and III. The four most common variants of the untranslated
and alternatively spliced first exon were also studied - 1.1,1.3, 1.4 and PII variants. The
results are shown in table - 17.
Using primers on the coding region of aromatase, no product was detected after the first
round of PCR (40 cycles) but following a second round of PCR (with nested primers)
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products were observed in all the 6 samples studied before and following treatment with
letrozole. The major band was of expected size (393bp) (fig 17).
In terms of RT-PCR for transcripts of the non-coding exon I, one or more product was
found in all the 6 samples studied before and after treatment. The coding part of
aromatase gene was expressed in all the samples studied. PII, 1.3 and 1.4 variants of the
1st exon were detected in most cases before and following treatment with letrozole.
1.3 and P.II variants were detected in all the pre and post treated samples studied. The 1.1
variant was seen only in post treated sample 2. The 1.4 variant was observed in all the
samples except in post treated sample 3. This meant that there could be possible
induction of exon I variant 1.1 and 1.4 following treatment with letrozole in samples 2
and 3. To confirm this, the nested PCR was repeated using samples 2 and 3 and the
results are shown in table - 18.
The induction of exon I variant 1.1 and 1.4 could not be reproduced using samples 2 and
3. Thus in patients 2 and 3, treatment with letrozole apparently induced expression of a
previously unused variant of the 1st exon although this result was not reproducible. This
discrepancy could be caused by the low levels of aromatase in adipose tissue and this
challenges the current methodology of using nested PCR for detection of mRNA. Data
on expression of the coding part of aromatase gene (exons II and III) also confirms the
presence of aromatase mRNA in human adipose tissue. The minor non-specific products
and the lack of consistency of expression in some samples probably reflect the difficulty in
selective amplification of extremely low abundant template from total RNA samples from the
tissue. Low abundance of the specific products and appearance of non-specific minor PCR
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products have also been reported for extragonadal aromatase expression in other peripheral
tissues [Harada N 1990, Koos RD 1993].
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Table-17: mRNA Expression [RT- nested PCR] of aromatase in
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Table -18: mRNA Expression [RT= nested PCR] of aromatase in
adipose tissue before and following treatment with letrozole
[experiment repeated to assess reproducibility]
Patients'
code
Sample PII 1.3 1.4 1.1 Coding
part (Il-III
exons)


























Fig 17: Nested PCR - demonstrating samples 1 and 6 before
and following treatment with letrozole
Cuff I.3 I.4
I I I
• l Aand 6A- breast adipose tissues before treatment
• lBand6B- breast adipose tissues after treatment.
• Specific products are visible - the major bands for exons PII, 1.3, 1.4 and C in the
samples shown. No product - seen in the negative control (W sample).
• In all other samples signals seen - positive controls (H lines).
GAPDH- gene -positive control: H - product for GAPDH gene (451 bp, positive
control): T - aromatase- positive tumour (another positive control).
• Expected PCR products size: PII - 393 bp, 1.3 - 390 bp, 1.4 - 383 bp, I.I - 425 bp,
C - 305 bp and H - 451 bp.
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Treatment of breast adipose tissue with letrozole - using PCR
The aromatase gene consists of 10 exons. Several alternative regions located in the 5'
area of the gene are used as the exon I in different tissues. This provides mechanism for
tissue-specific regulation of aromatase transcription because different variants of the 1st
exon are controlled by different promoters. Exon 1.4 has promoter containing a
glucocorticoid-responsive element but 1.3 and P.II variants are controlled by cAMP
dependent mechanisms. At the same time, the start of translation is located in the second
exon [HaradaN, 1990b]. This means that the alternative splicing of the exon I affects the
gene regulation only; whereas the coding part of the mRNA and protein structure does
not depend on the exon I selection. Thus whilst there is a single protein for aromatase,
multiple variants of RNA transcripts exist, differing according to the nature of
untranslated exon 1 .
Use of Polymerase Chain Reaction (PCR) technology has allowed for determination of
expression of P-450AROM in samples of breast adipose tissue before and following
treatment with letrozole. In terms of the exon I usage in adipose tissue, this study
suggests that the aromatase mRNA may by derived from different promoters. Such
features are similar to those reported for aromatase gene activity in other peripheral
tissues [Harada N, 1993a]. In the present work the activity of I.I ("placental" or la)
variant, 1.4 ("adipose" or lb), 1.3 and P.II ("ovarian" or Ic and Id) variants of the exon I
were studied. The pattern of the exon I usage, found in the present study for adipose
tissue, is similar to the pattern reported for adipose tissue by others: 1.4, 1.3 and P.II
with prevalence of 1.4 exon [A garwal V, 1 997], In some cases (patients 2 and 3)
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treatment with letrozole apparently induced activity of previously un-used variants of the
1st exon, although this result was not reproducible.
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DISCUSSION
CYP 19 gene and aromatase activity is subject to complex hormonal regulation, which is
mediated in part by alternative use of tissue specific promoters of the CYP 19 gene
[Mahendroo M], The human gene is revealed to contain multiple variants of exon 1,
which are tissue specifically, selected [Means GD, 1989]. Each exon 1 is flanked with a
unique promoter region, which may explain tissue-specific transcription. P450 is
stimulated upstream of untranslated exons 1.4 and are regulated in a positive fashion by
glucorticoids and growth factors present in serum [Zhao Y, 1996]. In contrast,
transcripts containing exon 1.4 are absent when cells are maintained in the presence of
cyclic AMP derivatives and when fibroblasts are placed in culture, the proportions of
these exon specific transcripts depend on the stimulatory factors present in the culture
medium [Bulun SE, 1994a], Thus when aromatase activity is stimulated by members of
class I cytokines such as interleukin 6 in the presence of glucorticoids, the transcripts
present are derived from promoter 1.4 and when activity is stimulated by dibutyryl
cAMP the transcripts present are those specific for PII and 1.3 [Agarwal VR, 1996],
Activity of aromatase P450 arom is aberrantly increased in adipose fibroblasts
surrounding breast carcinomas, giving rise to proliferation of malignant cells [Zhou J,
2001], Attempts were made in this project to study the exon specific transcripts and the
changes in fibroblast cell lines following treatment with aromatase inhibitors in the
presence and absence of glucorticoids and dibutyryl cAMP. However, the experiments
failed to detect any changes due to very low level of mRNA in the fibroblast cells.
Hence, development of new techniques in the future to isolate low levels of aromatase
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activity in mammary fibroblasts cell cultures would be useful. This would lead to better
understanding of molecular changes underlying the changes in aromatase activity in cell
culture models, which could be translated into clinical practice.
Aromatase mRNA in normal breast tissues is mainly transcribed from exon lb (1.4) of
the gene. However, in breast cancer tissues, it is often transcribed from exon lc/ld
(I.3/PII). Such a switching from exon lb to exon lc/ld has often been found
concomitantly with elevated levels of aromatase mRNA [Harada N, 1999]. Regulation
of aromatase in breast adipose tissue becomes abnormal during carcinogenesis due to
switching of exons I and promoters, resulting in overproduction of oestrogens under
control of a new promoter [Harada N, 1995].
To explore this effect aromatase messenger ribonucleic acid (mRNA) and the type of
multiple exons 1 of the human aromatase gene transcribed in breast adipose tissues
before and after treatment with letrozole (2.5mg) were studied. The four most common
variants of the untranslated (I.l/a placental, I.4/b adipose and PII/ lc/d ovarian variants)
and alternatively spliced first exons were analysed. No product was detected after the
first round of PCR but following a second round of PCR (with nested primers), products
were observed. Analysis of P450 arom transcripts in samples of breast adipose tissue has
previously revealed that in addition to exon 1.4 specific transcripts, promoter II specific
as well as exon 1.3 specific transcripts are present, albeit in low copy number
[Mahendroo M], Thus, no products were detected after the first round of PCR and this
may due to the low quantities of mRNA transcripts and aromatase activity. However,
despite the low level of P450 arom mRNA and aromatase activity, it is possible, that
local biosynthesis in breast cancers may be of physiological and clinical significance.
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Therefore, development of new techniques for the quantification of such low aromatase
activity would be highly desirable in future.
Following nested PCR for transcripts of the non-coding exon I, one or more product was
found in all the samples studied before and after treatment. The coding part of aromatase
gene was expressed in all the samples studied. Therefore, this study demonstrates the
presence ofmRNA transcripts for aromatase in human adipose tissue.
It is known that 1.4 promoter contains a glucocorticoid-responsive element but 1.3 and
P II variants are controlled by cAMP-dependent mechanism. Exons 1.3 and PII are the
two major exons present in aromatase mRNA isolated from breast tumours as detected
by performing RT-PCR analyses [Zhou C, 1995; Bulun SE, 2003]. Results, suggests that
promoters 1.3 and II are the major promoters directing aromatase activity in breast
cancer and surrounding stromal cells and fibroblasts [Chen S, 1999], PII, 1.3 and 1.4
variants of the 1st exon were detected in most cases before and following treatment with
letrozole in this study. Two patients (2 and 3) demonstrated possible induction of the
new exons after treatment with letrozole although it was not reproducible. These
findings, suggests that there is a may be a switch in the regulatory mechanism of
aromatase activity from normal breast tissue to cancerous tissue.
Therefore, this study demonstrates the presence of mRNA transcripts for aromatase in
human adipose tissue. Level of aromatase mRNA in adipose tissue is low. Neither
conventional ("end-point") nor nested PCR can be used for quantitative measurement of
aromatase transcripts in this tissue.
Although aromatase activity and level ofmRNA activity are low, such small activity can
be meaningful, because low activity may be compensated by bulk of the tissue in the
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body. Switching of tissue-specific exons 1 though not totally reproducible in this study,
may affect strict regulation, leading to abnormal activity of the aromatase, which could
account for paradoxical effects/resistance in long-term use of aromatase inhibitors
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CONCLUSION
This thesis has successfully examined the effects of different aromatase inhibitors on
aromatase activity and assessed the activity of aromatase in response to endocrine
therapy. It has confirmed that the aromatase inhibitors are potent and effective in
inhibiting aromatase activity. Indeed, it is one of the fewer studies to report the effects of
different aromatase inhibitors using the cell culture model invitro.
The effects of antiaromatase drugs on aromatase in fibroblast cell culture model would
be useful in defining the role of aromatase inhibitors when translated into clinical
practice. The steroidal aromatase inhibitors have produced persistent inhibitory effect in
all circumstances (both on preincubation and incubation) while paradoxical stimulatory
effects have been observed with type II inhibitors in certain circumstances (on
preincubation). The relevance of this type of response would be useful in determining
the sequence of use of aromatase inhibitors in the clinical setting. Interestingly at least at
one concentration, all the type II inhibitors produced a paradoxical increase in aromatase
activity. This induction of aromatase activity can result from enhanced transcription of the
aromatase gene and or stabilisation of the aromatase protein. It may be postulated that
increased levels of aromatase protein following chronic treatment with type II inhibitors
could lead to break-through of oestrogen synthesis and renewed tumour growth. It also
indicates the possibility that long-term use of type II inhibitors can result in hormonal
escape and drug resistance. Hence, it would be useful to use type II inhibitors such as
anastrozole or letrozole followed by type I inhibitors in sequence. However, this effect
when translated into clinical practice can only be determined after significant clinical
187
follow up of patients treated on long-term aromatase inhibitors. The results also suggest
that the type II agents - letrozole, anastrozole, fadrazole and aminoglutethimide are
reversible, where as type I agents - exemestane and formestane are irreversible.
An accurate measurement of aromatase activity allows better understanding of the
response to endocrine therapy at a cellular level. The changes in aromatase activity
revealed interesting trends with almost total suppression of aromatase activity following
treatment in tumour tissues and a variable effect in nonmalignant tissues. Surprisingly so
far, no positive correlation has been linked to recurrence or survival. Nevertheless, the
significant positive correlations between the degree of response and treatment activity
are potentially important in understanding the mode of action of aromatase inhibitors
and should be examined further.
The examination of changes in aromatase activity before and after treatment in
nonmalignant tissues has raised the possibility of alteration of activity following
treatment. However, the relatively few patients receiving primary endocrine therapy has
made it difficult to draw any useful conclusion from this section of work. Because of the
potential implication of this finding, further work with the aromatase activity needs to be
undertaken. Selection for endocrine therapy requires the identification of markers that
accurately predict response/resistance. Molecular profiling may offer the opportunity to
distinguish between clinically responsive and non-responsive tumors and may provide
important information about the heterogeneity of endocrine resistance in the future.
Intratumoral aromatase is an important therapeutic target for the treatment of post¬
menopausal oestrogen-dependent breast cancers. Therefore, reliable methods should be
developed for routine application for the detection of intratumoral aromatase.
188
Biochemical assays used in determining aromatase inhibitors are cumbersome and need
large amount of tissue. Development of appropriate antibodies to detect and assess
aromatase would avoid this problem in future. Hence, further work would be required of
estimating aromatase activity through other methods. The potential promise of
developing new techniques to assess aromatase at the molecular level would be
rewarding. The limiting factors include quality, quantity and the low RNA activity in
these tissues.
The new generation of aromatase inhibitors, are potent and specific inhibitors of
aromatase peripherally and within the breast. The inhibitors differ with regard to
structure and mode of interaction with the aromatase enzyme and this may account for
their effects. The work done in this thesis has demonstrated unusual effects of aromatase
inhibitors, which has to be confirmed from the long-term use of aromatase inhibitors and
from clinical trials.
The aromatase inhibitors have emerged as an effective and safe alternative to tamoxifen
in the adjuvant setting. Given the proven efficacy of AIs in recent clinical trials, the
remaining questions include definitive sequencing strategy, timing, and duration of use.
Ongoing trials include head-to-head comparisons between the AIs in early-stage breast
cancer; the results of these trials should further optimise the use of AIs. New studies in
both the preclinical and clinical settings will explore the role of the steroidal aromatase
inhibitors such as exemestane in comparison to the nonsteroidal aromatase inhibitors
such as letrozole and anastrozole and may prove of considerable interest. Results from
trials comparing steroidal and nonsteroidal AIs will determine whether meaningful
clinical differences in efficacy or adverse events exist between the classes ofAI. Studies
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concerning lack of cross-resistance and optimum sequencing will also provide useful
data over the next few years.
Thus the new generation of aromatase inhibitors, provide not only new approaches to
treatment but also help in instigating the contribution of aromatase to tumour induction
and proliferation. This study has demonstrated the effects of aromatase inhibitors on
aromatase in response and resistance to therapy. It forms the basis for more detailed
work in future to optimise the use of currently available aromatase inhibitors in the
hormonal treatment of breast cancer.
190
BIBLIOGRAPHY
1. Ackerman GE, Smith ME, Mendelson CR, MacDonald PC, Simpson ER.
Aromatization of androstenedione by human adipose tissue stromal cells in
monolayer culture. J Clin Endocrinol Metab 1981; 53:412-417.
2. Agarwal VR, Bulun SE, Leitch M, Rohrich R, Simpson ER. Use of alternative
promoters to express the aromatase cytochrome P 450 gene in breast adipose
tissue of cancer free and breast cancer patients. J Clin Endocrinol Metab 1996;
81:3843-3849.
3. Agarwal VR, Ashanullah CI, Simpson ER, Bulun SE. Alternatively spliced
transcripts of the aromatase cytochrome P450 (CYP19) gene in adipose tissue of
women. J Clin Endocrinol Metab 1997; 82:70-74.
4. Anderson EDC, Forrest APM, Levack PA, Chetty U, Hawkins RA. Response to
endocrine manipulation and oestrogen receptor concentration in large operable
breast cancer. Br J Cancer 1989; 60:223-226.
5. Antonio C W, Nancy ED .Use of serms for the adjuvant therapy of early-stage
breast cancer. Annals of the New York academy of Sciences 2001; 949:80-88
6. Arpino G, Green SJ, Allred DC, Lew D, Martino S, Osborne CK, Elledge RM:
HER-2 amplification, HER-1 expression, and tamoxifen response in oestrogen
receptor-positive metastatic breast cancer: a southwest oncology group study.
Clin Cancer Res 2004; 10(17): 5670-5676.
7. Arteaga CL, Tandon AK, Von Hoff DD, Osborne CK. Transforming growth
factor beta: potential autocrine growth inhibitor of oestrogen receptor-negative
human breast cancer cells. Cancer Res 1988; 48: 3898-3904.
8. Allred DC, Harvey JM, Berardo M & Clark GM. Prognostic and predictive
factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11:
155-168.
9. Blarney RW. Guidelines on endocrine therapy of breast cancer, EUSOMA. Eur J
Cancer 2002; 38:615-634.
191
10. ATAC Trialists' Group. Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M,
Forbes JF et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in
Combination) trial after completion of 5 years' adjuvant treatment for breast
cancer. Lancet 2005; 365: 60-62.
11. Bajetta E, Zilembo N, Dowsett M, Guillevin L, Di Leo A, Celio L et al. Double-
blind, randomised, multicentre endocrine trial comparing two letrozole doses, in
postmenopausal breast cancer patients. Eur J Cancer 1999; 35:208-213.
12. Bajetta E, Zilembo N, Barni S, Noberasco C, Martinetti A, Ferrari L et al. A
multicentre, randomized, pharmacokinetic, endocrine and clinical study to
evaluate formestane in breast cancer patients at first relapse: endocrine and
clinical results. Ann Oncol 1997; 8:649-654.
13. Baniahmad A, Tsai M. Mechanisms of transcriptional activation by steroid
hormone receptors. J Cell Biochem 1993; 51:151-156.
14. Baird DT, Uno A, Melby JC. Adrenal secretion of androgens and oestrogens.
J Endocrinol 1969; 45:135-136.
15. Bardou VJ, Arpino G, Elledge RM, Osborne CK, Clark GM. Progesterone
receptor status significantly improves outcome prediction over oestrogen
receptor status alone for adjuvant endocrine therapy in 2 large breast cancer
databases. J Clin Oncol 2003; 21:1973-1979
16. Beatson G. On the treatment of inoperable cases of carcinoma of the mammary:
suggestions for a new method of treatment with illustrative cases. Lancet 1896;
2:162-165.
17. Beatson G. The treatment of cancer of the breast by oophorectomy and hyoid
extract. BMJ 1901;2:1145-1148.
18. Beex L, Rose C, Mouridsen H, Jassem J, Nooij M, Estape J, Paridaens R, Piccart
M, Gorlia T, Lardenoije S, Baila L. Continuous versus intermittent tamoxifen
versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first
line endocrine treatment in advanced breast cancer: an EORTC phase III study.
Eur J Cancer 2006; 42( 18):3178-85.
192
19. Beral V, Hermon C, Reeves G, Peto R. Sudden fall in breast cancer death rates in
England and Wales. Lancet 1995; 345: 1642-1643.
20. Bezwoda WR, Mansoor N, Dansey R. Correlation of breast tumour aromatase
activity and response to aromatase inhibition with aminoglutethimide 1987, 44:
345-349.
21. Bezwoda WR, Esser JD, Dansey. The value of oestrogen and progesterone
receptor determination in advanced breast cancer. Cancer 1991; 68: 867-872.
22. Bhatnagar AS, Hausler A, Schieweck K, Eang M, Bowman R. Highly selective
inhibition of oestrogen biosynthesis by CGS20267. A new nonsteroidal
aromatase inhibitor. J Steroid Biochem Mol Biol 1998; 37:1021-1027.
23. Bhatnagar AS, Miller WR. Pharmacology of inhibitors of oestrogen biosynthesis.
In: Oestrogens and antioestrogens II: Pharmacology and clinical applications of
Oestrogens and antioestrogens Oertel M & Schillinger E (eds), Springer-Verlag,
Berlin, 1999:223-230.
24. Bhatnagar AS, Brodie AMH, Long BJ, Evans DB, Miller WR. Intracellular
aromatase and its relevance to the pharmacological efficacy of aromatase
inhibitors. J Steroid Biochem Mol Biol 2001; 76:199-202.
25. Black LJ, Sato M, Rowley ER, Magee DE, Bekele A, Williams DC et al.
Raloxifene (EY139481 HCI) prevents bone loss and reduces serum cholesterol
without causing uterine hypertrophy in ovariectomised rats. J Clin Invest 1994;
93:63-69.
26. Block GE, Vial AB, Pullen FW. Oestrogen excretion following operative and
irradiation castration in cases ofmammary cancer; a preliminary report. Surgery
1958;43:415-422.
27. Bloom HJ, Richardson WW, Harries E J. Natural history of untreated breast
cancer (1805-1933). Comparison of untreated and treated cases according to
histological grade ofmalignancy. BMJ 1962; 5299: 213-221.
28. Botha JL, Bray F, Sankila R, Parkin DM. Breast cancer incidence and mortality
trends in 16 European countries. Eur J Cancer 2003; 39:1718-1729.
29. Boyd S. An oophorectomy in cancer of the breast. BMJ 1900; 2:1161-1167.
193
30. Brinton LA, Schairer C, Hoover RN, Fraumeni JF. Menstrual factors and risk of
breast cancer. Cancer Invest 1988; 6: 245-254.
31. Brinton LA, Baling JR, Liff JM, Malone KE, Stanford JL. Oral contraceptives
and breast cancer risk among younger women. J Natl Cancer Inst 1995; 87: 827-
835.
32. Brodie AMH, Garnett WM, Hendrickson JR, Tsai-Morris CH, Marcotte PA,
Robinson CH. Inactivation of aromatase in vitro by 4-hydroxy-4-androstene-
3,17-dione and 4-acetoxy-4-androstene-3,17-dione and sustained effects in vivo.
Steroids 1981; 38: 693-702.
33. Brodie AMH, Santen RJ. Aromatase in breast cancer and the role of
aminoglutethimide and other aromatase inhibitors. Crit Rev Oncol Hematol
1986; 5: 361-339.
34. Brodie AMH. Aromatase inhibitors in the treatment of breast cancer. J Steroid
Biochem Mol Biol 1994; 49: 421- 428.
35. Brueggemeier RW. Aromatase, aromatase inhibitors, and breast cancer. Am J
Ther 2001; 8:333-344.
36. Buzdar AU, Hortobagyi G. Update on endocrine therapy for breast cancer. Clin
Cancer Res 1998; 4:527-534
37. Buzdar AU, Jonat W, Howell A, Jones SE, Blomqvist CP, Vogel CL, Eiermann
W, Wolter JM, Steinberg M, Webster A, Lee D. Anastrozole versus megestrol
acetate in the treatment of postmenopausal women with advanced breast
carcinoma: results of a survival update based on a combined analysis of data
from two mature phase III trials. Arimidex Study Group. Cancer 1998;
83(6): 1142-52.
38. Bulbrook RD. Hormones and breast cancer. The Breast 1992; 1:9-13.
39. Bulun SE, Simpson ER. Competitive reverse transcription-polymerase chain
reaction analysis indicates that levels of aromatase cytochrome P450 transcripts
in adipose tissue of buttocks, thighs, and abdomen of women increase with
advancing age. Clin Endocrinol Metab. 1994a; 78:428-432.
194
40. Bulun SE, Simpson ER 1994 Breast cancer and the expression of aromatase in
breast adipose tissue. Trends Endocrinol Metab 1994b; 5:113-120.
41. Bulun SE, Zeitoun K, Takayama K, Noble L, Michael D, Simpson E et al.
Oestrogen production in endometriosis and use of aromatase inhibitors to treat
endometriosis. Endocr Relat Cancer 1999a; 6: 293-301.
42. Bulun SE, Zeitoun K, Sasano H, Simpson ER. Aromatase in aging women.
Semin Reprod Endocrinol 1999b; 17:349-58.
43. Bulun SE, Zeiton KM, Takayama K, Sasano H, Simpson ER. Aromatase in
endometriosis: biological and clinical application. In: Aromatase inhibition and
breast cancer, Miller WR, Santen RJ (eds), Marcel Dekker, New York, 2001;
279-298.
44. Bulun SE, Sebastian S, Takayama K, Suzuki T, Sasano H, Shozu M. The human
CYP19 (aromatase P450) gene: update on physiologic roles and genomic
organization of promoters. J Steroid Biochem Mol Biol 2003; 86:219-224.
45. Bulun SE, Simpson ER. Aromatase expression in women's cancers. Adv Exp
Med Biol 2008; 630:112-32.
46. Bundred N, Campbell I, Coleman R, et al. Zoledronic acid in the prevention of
cancer treatment-induced bone loss in postmenopausal women receiving
letrozole as adjuvant therapy for early breast cancer (ZO-FAST study). Eur J
Cancer Suppl 2006; 4:48.
47. Buzdar AU, Smith R, Vogel C, Bonomi P, Keller AM, Favis G et al. Fadrazole
versus megestrol acetate treatment of postmenopausal patients with metastatic
breast carcinoma; results of two randomised double blind controlled multi-
institutional trials. Cancer 1996a; 77:2503- 2513.
48. Buzdar AU, Jonat W, and Howell A et al. Anastrozole, a potent and selective
aromatase inhibitor, versus megestrol acetate in postmenopausal women with
advanced breast cancer; results of overview analysis of two phase III trials. J
Clin Oncol 1996b; 14: 2000-2011.
49. Buzdar AU. Anastrazole (Arimidex)-an aromatase inhibitor for the adjuvant
setting? Br J Cancer 2001a; 85:6-10.
195
50. Buzdar AU. The use of endocrine therapy. Endocrine therapy in the treatment of
metastatic breast cancer. Semin Oncol 2001b; 28: 291-304
51. Buzdar AU, Robertson JFR, Eiermann W, Nabholtz JM. An overview of the
pharmacology and pharmacokinetics of the newer generation aromatase
inhibitors anastrozole, letrozole and exemestane. Cancer 2002; 95: 2006-2016.
52. Cash AJ, Brough MNP, Cohen, and. Satoh PS. Aminoglutethimide as an
inhibitor of adrenal steroidogenesis. Mechanism of action and therapeutic trial. J
Clin Endocrinol Metab 1967; 27: 1239-1268.
53. Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham
S et al. Molecular origin of cancer: catechol oestrogen-3, 4-quinones as
endogenous tumour initiators. Proc Natl Acad Sci USA 1997; 94:10937-10942.
54. Chappel SC, Resko JA, Norman RL, Spies HG. Studies on rhesus monkeys on
the site where oestrogen inhibits gonadotropins: delivery of 17beta-oestradiol to
the hypothalamus and pituitary gland. J Clin Endocrinol Metab 1981; 52:1-8.
55. Chen S, Besman MJ, Sparkes RS et al. Human aromatase: cDNA cloning
southern blot analysis, and assignment of the gene to chromosome 15. DNA Mol
Biol 1988; 7: 27-38.
56. Chen S, Zhou D, Okubo T, Kao YC, Yang C. Breast tumour aromatase;
functional role and transcriptional regulation. Endocr Relat Cancer 1999; 6:149-
156.
57. Chen S, Zhou D, Okubo T, Kao YC, Eng ET, Grube B et al. Prevention and
treatment of breast cancer by suppressing aromatase activity and expression. Ann
N Y Acad Sci 2002; 963: 229-230.
58. Cheung KL, Willsher PC, Pinder SE, et al. Predictors of response to second-line
endocrine therapy for breast cancer. Breast Cancer Res Treat 1997; 45:219-224.
59. Chia S, Gradishar W. Fulvestrant: expanding the endocrine treatment options for
patients with hormone receptor-positive advanced breast cancer. Breast 2008; 17
Suppl 3:S 16-21.
196
60. Clarke MJ. Ovarian ablation in breast cancer, 1896 to 1998: milestones along
hierarchy of evidence from case report to Cochrane review. BMJ 1998;
317:1246-1248.
61. Clarke R, Brunner N, Katz D, Glanz P, Dickson RB, Lippman ME, Kern FG.
The effects of a constitutive expression of transforming growth factor-alpha on
the growth of MCF-7 human breast cancer cells in vitro and in vivo. Mol
Endocrinol. 1989;3:372-380.
62. Cleland WH, Mendelson CR, Simpson ER. Effects of aging and obesity on
aromatase activity of human adipose cells. J Clin Endocrinol Metab 1985;
60:174-177.
63. Cocconi G, De Lisi V, Boni C, Mori P, Malacarne P, Amadori D et al.
Chemotherapy versus combination of chemotherapy and endocrine therapy in
advanced breast cancer. Cancer 1983; 51:581-588.
64. Cole MP, Jones CTA, Todd IDH. A new anti-oestrogenic agent in late breast
cancer. An early clinical appraisal of ICI46474. Br J Cancer 1971; 25: 270-74.
65. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and
hormonal contraceptives: collaborative re-analysis of individual data on 53,297
women with breast cancer and 100,239 women without breast cancer from 54
epidemiological studies. Lancet 1996; 347:1713-1727.
66. Collaborative Group on Hormonal Factors in Breast Cancer. Breast cancer and
hormone replacement therapy: collaborative re-analysis of data from 51
epidemiological studies of 52,705 women with breast cancer and 108,411
women without breast cancer. Lancet 1997; 350:1047-1059.
67. Coombes RC, Goss PE, Dowsett M, Hutchinson G, Cunningham D, Jarman M et
al. 4-Hydroxyandrostenedione treatment for postmenopausal patients with
advanced breast cancer. Steroids 1987; 50:245-252.
68. Coombes RC, Hughes SW, Dowsett M. 4-Hydroxystenedione: a new treatment
for postmenopausal patients with breast cancer. Eur J Cancer 1992; 2A: 1941-
1945.
197
69. Coombes RC, Haynes BP, Dowsett M, Quigley M, English J, Judson IR et al.
Idoxifene: report of a phase I study in patients with metastatic breast cancer.
Cancer Res 1995; 55: 1070-1074.
70. Coombes RC, Hall E, Gibson LJ, Paridaens R, Jassem J, Delozier T, et al.
Intergroup Exemestane Study. Phase III study of letrozole versus tamoxifen as
first-line therapy of advanced breast cancer in postmenopausal women: analysis
of survival and update of efficacy from the International Letrozole Breast Cancer
Group. N Engl J Med 2004; 350:1081-1092.
71. Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA et al.
Raloxifene reduces the risk of breast cancer and may decrease the risk of
endometrial cancer in post-menopausal women: two-year findings from the
Multiple Outcomes of Raloxifene Evaluation (MORE) trial. JAMA. 1999;
281:2189-2197.
72. Daniel CW, Silberstein GB. Development of the mammary gland. In: The
Mammary gland, Neville MC, Daniel CW (eds). Plenum, New York, 1987:3.
73. Dao TL, Sinha DK, Nemoto T, Patel J. Effect of oestrogen and progesterone on
cellular replication of human breast tumours. Cancer Res 1982; 42: 359-362.
74. Darbre PD, Daly RJ. Effects of oestrogen on human breast cancer cells
in culture. Proc R Soc (Edin) 1989; 95B:119-132.
75. deConinck EC, McPherson LA, Weigel RJ. Transcriptional regulation of
oestrogen receptor in breast carcinomas. Mol Cell Biol 1995; 15:2191-2196.
76. De Bortoli M, Dati C. Hormonal regulation of type I receptor tyrosine kinase
expression in the mammary gland. J Mammary Gland Biol Neoplasia. 1997;
2(2): 175-85.
77. DeCourmellers F. La radiotherapie indirecte, ou dirigee par les correlations
organiques. Archives d' Electricite Medicale 1922; 32:264.
78. Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ et al.
Effects of raloxifene on bone mineral density, serum cholesterol concentrations,
and uterine endometrium in postmenopausal women. N Engl J Med. 1997;
337:1641-1647.
198
79. den Tonkelaar I, Seidell JC, Collette HJ, de Waard F. A prospective study on
obesity and subcutaneous fat patterning in relation to breast cancer in
postmenopausal women participating in the DOM project. Br J Cancer 1994; 69:
352-357.
80. Deslypere JP, Verdonck L, Vermeulen A. Fat tissue: a steroid reservoir and site
of steroid metabolism, J Clin Endocrinol Metab 1985; 61:564-570
81. Dickson RB, Lippman ME. Control of human breast cancer by oestrogen, growth
82. factors and oncogenes. In: Breast Cancer: Cellular and Molecular Biology,
Lippman ME, Dickson R (eds), Kluwer, Boston, 1988:119-166.
83. di Salle R, Omati G, Giudici D, Lassus M, Evans TRJ, Coombes RC.
Exemestane, a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol
1992; 43: 137-143.
84. Dixon JM, Love CDB, Renshaw L, Bellamy C, Cameron DA, Miller WR.
Lessons from the use of aromatase inhibitors in the neoadjuvant setting. Endocr
Relat Cancer 1999; 6: 227-230.
85. Dlugi AM, Miller JD, Knittle J. Lupron depot (leuprolide acetate for depot
86. suspension) in the treatment of endometriosis: A randomised, placebo-controlled,
double-blind study. Lupron Study Group. Fertil Steril 1990; 54: 419-427.
87. Dombernowsky P, Smith I, Falkson G, Leonard R, Panasci L, Bellmunt J et al.
Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-
blind randomised trial showing a dose effect and improved efficacy and
tolerability compared with megestrol acetate. J Clin Oncol 1998; 16: 453-461.
88. Dowsett M, Stein RC, Mehta A, Coombes RC. Potency and selectivity of the
non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer
patients. Clin Endocrinol 1990; 32:623-624.
89. Dowsett M, Coombes RC. Second generation aromatase inhibitor-4-hydroxy-
androstenedione. Breast Cancer Res Treat 1994; 30:81-87.
90. Dowsett M. Biological background to aromatase inhibition. The breast 1996;
5:1-6.
199
91. Duffy MJ. Predictive Markers in Breast and Other Cancers: A Review. Clinical
Chemistry 2005;51:494-503
92. Earp HS, Dawson TL, Li X, Yu H. Heterodimerisation and functional interaction
between EGF receptor family members: A new signalling paradigm with
implication for breast cancer research. Breast Cancer Res Treat 1995; 35:115-
132.
93. Early breast cancer trialist's collaborative group (EBCTCG). Systematic
treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133
randomised trials involving 31,000 recurrences and 24,000 deaths among
750,000 women. Lancet 1992; 339:1-71.
94. Early breast cancer trialist's collaborative group (EBCTCG). Ovarian ablation in
early breast cancer: overview of the randomised trials. Lancet 1996; 348:1189 -
1196.
95. Early breast cancer trialist's collaborative group (EBCTCG): Tamoxifen for
early breast cancer. An overview of the randomised trials. Lancet 1998;
351:1451-1467.
96. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of
chemotherapy and hormonal therapy for early breast cancer on recurrence and
15-year survival: an overview of the randomised trials. Lancet 2005; 365:1687-
1717.
97. Edwards DP, Chamness GC, McGuire WE. Oestrogen and progesterone receptor
proteins in breast cancer. Biochem Biophys Acta 1979; 560:457-486.
98. Eiermann W, Paepke S, Appfelstaedt J. Letrozole neoadjuvant breast cancer
study group. Preoperative treatment of postmenopausal breast cancer patients
with letrozole. A randomised double blind multicentre study. Ann Oncol 2001;
12:1527-1532.
99. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of
postmenopausal breast cancer patients with letrozole: a randomised double-blind
multicenter study. Ann Oncol 2001; 12:1527-32.
200
100. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant
endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, oestrogen
receptor-positive primary breast cancer: evidence from a phase III randomized
trial. J Clin Oncol 2001; 19:3808-16.
101. Ellis MJ, Coop A, Singh B, et al: Letrozole inhibits tumor proliferation more
effectively than tamoxifen independent of HER1/2 expression status. Cancer Res
2003; 63:6523-6531
102. Ellis MJ, Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence
of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:
2817-2826
103. Emons G, Grundker C, Hanf V. Are oestrogens carcinogens? Zentralbl Gynakol
2002; 124:559-565.
104. Ellis MJ. Neoadjuvant Endocrine Therapy for Breast Cancer: More Questions
than answers. J Clin Oncol 2005; 22: 4842-4844
105. Eppenberger URS, Leavano S, Schoumacher F, Evans D, Muller H, Eppenberger
S. Molecular Epidemiology of aromatase expression in 1182 primary breast
cancers. In: Aromatase Inhibition and Breast Cancer. Miller WR & Santen RJ,
Marcel Dekker, New York, 2001:199-212.
106. Evans TR, Di Salle E, Ornati G, Lassus M, Benedetti MS, Pianezzola E et al.
Phase I endocrine study of exemestane (FCE 24304), a new aromatase inhibitor,
in postmenopausal women. Cancer Res 1992; 52:5933-5939.
107. Falkson CI, Falkson HC.A randomised study of CGS 16949A (fadrozole) versus
tamoxifen in previously untreated postmenopausal patients with metastatic breast
cancer. Ann Oncol 1996; 7:465-469.
108. Fentiman IS. The causes of breast cancer. In: Detection and treatment of early
breast cancer, Lippincott, Philadelphia, 1990:11-30.
109. Filicori M, Flamigni C. GnRH agonists and antagonists. Current clinical status
Drugs 1988; 35:63-82.
110. Fernandez PL, Jares P, Rey MJ, Campo E, Cardesa A. Cell cycle regulators and
their abnormalities in breast cancer. Mol Pathol 1998; 51:305-309.
201
111. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J et al. A
randomised clinical trial evaluating tamoxifen in the treatment of patients with
node negative breast cancer who have oestrogen positive tumours. N Engl J Med
1989; 320:479 -484.
112. Fendrick JL, Raafat AM, Haslam SZ. Mammary gland growth and development
from the postnatal period to postmenopause: ovarian steroid receptor ontogeny
and regulation in the mouse. J Mammary Gland Biol Neoplasia. 1998; 3(l):7-22.
113. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N et al.
Five versus more than five years of tamoxifen therapy for breast cancer patients
with negative lymph nodes and oestrogen receptor-positive tumours. J Natl
Cancer Inst 1996; 88:1529-1542.
114. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J et al.
Tamoxifen for prevention of breast cancer: Report of the National Surgical
Adjuvant Breast and Bowel Project P-l study. J Natl Cancer Inst 1998; 90:1371-
1388.
115. Fisher B, Dignam J, Bryant J, Wolmark N. Five versus more than five years of
tamoxifen for lymph node-negative breast cancer. Updated findings from the
National Surgical Adjuvant Breast and Bowel Project B-14 randomised trial. J
Natl Cancer Inst 2001; 93: 684-690.
116. Fisher B. Highlights from recent National Surgical Adjuvant Breast and Bowel
Project studies in the treatment and prevention of breast cancer. CA Cancer J
Clin 1999; 49(3): 159-177
117. Fishman J. Biochemical mechanism of aromatisation. Cancer Res 1982;
42:3277s -3280s.
118. Flemming J, Madarnas Y, Franek JA. Fulvestrant for systemic therapy of locally
advanced or metastatic breast cancer in postmenopausal women: a systematic
review. Breast Cancer Res Treat 2008; 6.
119. Fisher B, Dignam J, Bryant J, et al. Five versus more than five years of
tamoxifen therapy for breast cancer patients with negative lymph nodes and
oestrogen receptor-positive tumors. JNatlCancer Inst 1996; 88:1529^12.
202
120. Forbes GB. Human body composition, Springer-Verlag, New York, 1987:350.
121. Freiss G, Prebois C, Vignon F. William L. McGuire Memorial Symposium.
Control of breast cancer cell growth by steroids and growth factors: interactions
and mechanisms. Breast Cancer Res Treat 1993; 27:57-68.
122. Frieden EH, Patkin JK, Mills M. Effects of follicle stimulating hormone (FSH)
upon steroid aromatization in vitro. Proc Soc Exp Biol Med 1968; 129:606-609.
123. Foster PA. Steroid metabolism in breast cancer. Minerva Endocrinol 2008;
33(l):27-37.
124. Geisler J, King N, Anker G, Ornati G, Di Salle E, Lonning PE, Dowsett M. In
vivo inhibition of aromatisation by exemestane, a novel irreversible aromatase
inhibitor, in postmenopausal breast cancer patients. Clin Cancer Res 1998;
4:2089-2093.
125. Gallego MI, Binart N, Robinson GW, Okagaki R, Coschigano KT, Perry J,
Kopchick JJ, Oka T, Kelly PA, Hennighausen L. Prolactin, growth hormone, and
epidermal growth factor activate Stat5 in different compartments of mammary
tissue and exert different and overlapping developmental effects. Dev Biol. 2001;
229(1): 163-75.
126. Geisler J, King N, Dowsett M, Ottestad L, S, Walton P et al. Influence of
anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo
aromatisation and plasma oestrogen levels in postmenopausal women with breast
cancer. Br J Cancer 1996; 74:1286-1291.
127. Gershanovich M, Chaudri HA, Campos D, Lurie H, Bonaventura A, Jeffrey M et
al. Letrozole, a new oral aromatase inhibitor: randomised trial comparing 2.5 mg
daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with
advanced breast cancer. Letrozole International Trial Group (AR/BC3). Ann
Oncol 1998; 9:639-645.
128. Goldhirsch A, Gelber RD. Endocrine therapies of breast cancer. Semin Oncol
1996; 23:494-505.
129. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ et al. A
randomised trial of letrozole in postmenopausal women after five years of
203
tamoxifen therapy for early-stage breast cancer. N Engl J Med. 2003; 349:1793-
1802.
130. Gower DB, Cooke GM. Regulation of steroid-transforming enzymes by
endogenous steroids. J Steroid Biochem 1983; 19:1527-1556.
131. Gradishar WJ, Jordan VC. Endocrine therapy of breast cancer. In: The Breast:
Comprehensive Management of Benign and Malignant Disease. Bland KI,
Copeland EM (eds), WB Saunders, Philadelphia, 2000:1350-1372
132. Grady D, Cauley JA, Geiger MJ, Kornitzer M, Mosca L, Collins P, Wenger NK,
Song J, Mershon J, Barrett-Connor E; Raloxifene Use for The Heart Trial
Investigators. Reduced incidence of invasive breast cancer with raloxifene
among women at increased coronary risk. J Natl Cancer Inst. 2008; 100(12):854-
61.
133. Green S, Chambon P. The oestrogen receptor: from perception to mechanism. In:
Nuclear hormone receptors, Parker MG (eds), Academic, London, 1991:15.
134. Griffiths CT, Hall TC, Saba Z, Barlow JJ, Nevinny HB. Preliminary trial of
aminoglutethimide in breast cancer. Cancer 1973; 32:31-37.
135. Grodin JM, Siiteri PK, MacDonald PC. Source of oestrogen production in
postmenopausal women. J Clin Endocrinol Metab 1973;36:207-214
136. Hamon JT, Allegra JC. Loss of hormonal responsiveness in cancer. In:
Endocrine management of cancer: Biological basis, Stoll BA (eds), Karger,
Basel, 1988:61-71.
137. Hansen RK, Bissell MJ: Tissue architecture and breast cancer: the role of
extracellular matrix and steroid hormones. Endocr Relat Cancer 2000; 7:95-113
138. Harada N, Yamada K, Saito K, Kibe N, Dohmae S, Takagi Y. Structural
characterisation of the human oestrogen synthetase (aromatase) gene. Biochem
Biophys Res Commun 1990a; 166:365-372.
139. Harada N. Aromatase and intracrinology of oestrogen in hormone-dependent
tumours. Oncology 1990b; 57:7-16.
140. Harada N, Utsumi T, Takagi Y. Tissue specific expression of the human
aromatase cytochrome P 450 gene by alternative use of multiple exons 1 and
204
promoters, and switching of tissue-specific exons 1 in carcinogenesis. Proc Natl
AcadSciUS A 1993;90:11312-11316.
141. Harada N, Utsumi T, Takagi Y. Molecular and epidemiological analyses of
abnormal expression of aromatase in breast cancer. Pharmacogenetics 1995; 5: S
59-64.
142. Harada N, Honda S. Molecular analysis of aberrant expression of aromatase in
breast cancer tissues. Breast Cancer Res Treat 1998a; 49: 315-321.
143. Harada N and Hatano O. Inhibitors of aromatase prevent degradation of the
enzyme in cultured human tumour cells. Br J Cancer 1998b; 77:567-572.
144. Harada N, Honda SI, Hatano O. Aromatase inhibitors and enzyme stability.
Endocr Relat Cancer 1999; 6:211-218.
145. Harvey JM, Clark GM, Osborne CK, Allred DC. Oestrogen receptor status by
immunohistochemistry is superior to the ligand-binding assay for predicting
response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17:
1474-1481
146. Harris IK, Hawkins RA, White C, Bundred NJ. Prognostic significance of
oestrogen and progesterone receptor activities in breast cancer. Br J Surg 1987;
74: 1009-1013.
147. Haslam SZ, Woodward TL. Reciprocal regulation of extracellular matrix
proteins and ovarian steroid activity in the mammary gland. Breast Cancer Res.
2001; 3(6):365-72.
148. Hayes DF, Van Zyl JA, Hacking. Randomised comparison of tamoxifen and two
separate doses of toremifene in postmenopausal patients with metastatic breast
cancer. J Clin Oncol 1995; 113:2556-2566.
149. Hemsell DL, Grodin JM, Brenner PF, Siiteri PK, MacDonald PC. Plasma
precursors of oestrogen. II. Correlation of the extent of conversion of plasma
androstenedione to estrone with age. J Clin Endocrinol Metab 1974; 38:476-479.
150. Henderson BE, Pike MC, and Casagrande JT. Breast cancer and the oestrogen
window hypothesis. Lancet 1981; 2:363-364.
205
151. Henderson BE, Pike MC, Ross RK. Epidemiology and risk factors. In: Breast
cancer: diagnosis and management. Bonadonna G (eds), John Wiley, New York,
1984:1-17.
152. Henderson BE, Ross RK, Judd HL. Do regular ovulatory cycles increase breast
cancer risk? Cancer 1985; 56:1206-1208.
153. Henderson BE, Ross RK, Berstein L. Oestrogen as a cause of human cancer: The
Richard and Hinduja Rosenthal foundation award lecture. Cancer Res 1988;
48:246-253.
154. Henderson BE, Ross RK, Pike MC. Hormonal chemoprevention of cancer in
women. Science 1993; 259:633-638.
155. Horowitz KB, McGuire WL, Pearson OH, and SegaloffA. Predicting response to
endocrine therapy in human breast cancer: a hypothesis. Science 1975; 189:726-
727.
156. Hovey RC, Trott JF, Vonderhaar BK. Establishing a framework for the
functional mammary gland: from endocrinology to morphology. J Mammary
Gland Biol Neoplasia 2002; 7:17-38.
157. Houghton J On behalf of the ATAC Trialists' Group. Initial adjuvant therapy
with ANA (S) reduced rates of early breast cancer recurrent and adverse events
compared with TAM (T) data reported on behalf of the ATAC (arimidex, TAM,
alone or in combination) Trialists' group. Ann Oncol 2006; 17(Suppl. 9)
158. Howell A, Howell SJ, Clarke R, Anderson E.Where do selective estrogen
receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast
cancer treatment algorithms? J Steroid Biochem Mol Biol. 2001; 79(l-5):227-37.
159. Huober J, Thurlimann B. Adjuvant endocrine therapy in breast cancer. Ther
Umsch 2008; 65(4): 193-200
160. Huggins C, Bergenstal DM. Inhibition of human mammary and prostatic cancers
by adrenalectomy. Cancer Res 1952; 12:134-141.
161. Hulka BS, Liu ET, Lininger RA. Steroid hormones and risk of breast cancer.
Cancer 1994; 74:1111-1124.
206
162. Hunter DJ, Spiegelman D, Adami HO, Beeson L et al. Cohort studies of fat
intake and the risk of breast cancer. N Engl J Med 1996; 334:356-361.
163. Ingle JN, Krook JE, Green SJ, Kubista TP, Everson LK, Ahmann DL et al.
Randomised trial of bilateral oophorectomy versus tamoxifen in premenopausal
women with metastatic breast cancer. J Clin Oncol 1986; 4: 178-185.
164. Iveson TJ, Ahem J, Smith IE. Response to third-line endocrine treatment for
advanced breast cancer. Eur J Cancer 1993; 4: 572-574.
165. James VHT, McNril JM, Yamoamoto T, Honjo H, Okada H. Aromatase activity
in normal breast and breast tumour tissues: in vivo and in vitro studies. Steroids
1987; 50: 269-279.
166. Jakesz R, Jonat W, Gnant M, et al. Switching of postmenopausal women with
endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant
tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005;
366:455-62.
167. Jakesz R, Gnant M, Greil R, et al. The benefits of sequencing adjuvant tamoxifen
and anastrozole in postmenopausal women with hormone responsive early breast
cancer: 5 year-analysis of the ABCSG trial. Breast Cancer Res Treat Rep 2005;
94 (Suppl, 1):S10. Abstract 13
168. Jemal A, Thomas A, Murray T, Thun M. Cancer statistics, 2002. Cancer J Clin
2002; 52:23-47.
169. Jensen EV, DeSombre ER, Jungblut PW. In: Oestrogen receptors in hormone
responsive tissues and tumours. Wissler RW, Dao TL, Wood S Jr (eds),
University ofChicago Press, Chicago, 1967:15-30.
170. Johanessen DC, Lonning PE. Aromatase inhibitiors in malignant diseases of
aging. Drugs aging 1992; 2:530-545.
171. Jonat W, Kaufmann M, Blarney RW, Howell A, Collins JP, Coates A, et al. A
randomised study to compare the effect of the luteinising hormone releasing
hormone (LHRH) analogue goserelin with or without tamoxifen in pre and
perimenopausal patients with advanced breast cancer. Eur J Cancer 1995;
31A:137-142.
207
172. Jonat W. Overview of luteinizing hormone-releasing hormone agonists in early
breast cancer-benefits of reversible ovarian ablation. Breast Cancer Res Treat.
2002; 75 (l):S23-6.
173. Jordan VC. A therapeutic withdrawal can make a strategic advance. Ann Oncol
1992; 3:587-588.
174. Jordan VC, Gradishar WJ. Molecular mechanisms and future uses of
antioestrogens. Mol Aspects Med 1997; 18:167-247.
175. Juranka PF, Zastawny RL, Ling V.P-glycoprotein: multidrug-resistance and a
superfamily of membrane-associated transport proteins. FASEB J 1989; 3:2583-
2592.
176. Kadohama N, Yarborough C, Zhou D, Chen S, Osawa Y. Kinetic properties of
aromatase mutants Pro308Phe, Asp309Asn, and Asp309Ala and their
interactions with aromatase inhibitors. J Steroid Biochem Mol Biol 1992;
43:693-701.
177. Kaplowitz PB.Aromatase inhibitors as therapy for pubertal gynaecomastia. In:
Aromatase inhibition and breast cancer, Miller WR, Santen RJ (eds), Marcel
Dekker, New York 2001: 279-298.
178. Kaufman RJ. Advanced breast cancer - additive hormonal therapy. Cancer 1981;
47: 2398-2403.
179. Kaufmann M, Bajetta E, Dirix I et al. Survival advantage of exemestane over
megestrol acetate (MA) in postmenopausal women with advanced breast cancer
refractory to tamoxifen (TAM): results of a phase III randomised double-blind
study. Proc Am Soc Clin Oncol 1999; 18:109.
180. Kaufmann M, Bajetta E, Dirix LY, Fein LE, Jones SE, Cervek J et al.
Exemestane improves survival compared with megestrol acetate in
postmenopausal patients with advanced breast cancer who have failed on
tamoxifen, results of a double-blind randomised phase III trial. Eur J Cancer
2000; 36:S86-87.
181. Keen JC, Dixon JM, Miller EP, Cameron DA, Chetty U, Hanby A, Bellamy C &
Miller WR. Expression of Ki-Sl and BCL-2 and the response to primary
208
tamoxifen therapy in elderly patients with breast cancer. Breast Cancer Research
and Treatment 1997; 44 123-133.
182. .Kelloff GJ, Lubet RA, Fay JR, Steele VE, Boone CW, Crowell JA et al.
Farnesyl protein transferase inhibitors as potential cancer chemopreventives.
Cancer Epidemiol Biomarkers Prev 1997; 6:267-282.
183. Kern FG, McLeskey SW, Zhang L: Transfected MCF-7 cells as a model for
breast cancer progression. Breast Cancer Res Treat 1994; 31:153.
184. King RJ, Wang DY, Daly RJ, Darbre PD. Approaches to studying the role of
growth factors in the progression of breast tumours from the steroid sensitive to
insensitive state. J Steroid Biochem. 1989; 34:133-138.
185. Killinger DW, Perel E, Daniilescu D, Kharlip L, Lindsay WR. The relationship
between aromatase activity and body fat distribution. Steroids 1987; 50:61-72.
186. Klein KO, Demers LM, Santner SJ, Baron J, Cutler GBJM, Santen RJ. Use of
ultrasensitive recombinant cell bioassay to measure oestrogen levels in women
with breast cancer receiving the aromatase inhibitor, letrozole. J Clin Endocrinol
Metab 1995; 80:2658-2660.
187. Kleeberg UR, Dowsett M, Carrion RP, Dodwell DJ, Vorobiof DA, Aparicio LA
et al. A randomised comparison of oestrogen suppression with anastrozole and
formestane in postmenopausal patients with advanced breast cancer. Oncology
1997; 54:19-22.
188. Kvinnsland S, Anker G, Dirix L. Antitumour efficacy of exemestane a novel
irreversible oral aromatase inhibitor postmenopausal patients with metastatic
breast cancer failing tamoxifen. Breast Cancer Res 1997; 46:217.
189. Larionov AA, Vasyliev DA, Mason JI, Howie AF, Berstein LM, Miller WR.
Aromatase in skeletal muscle. J Steroid Biochem Mol Biol. 2003; 84:485-492.
190. Labrie F, Belanger A, Simard J, van Luu-The, Labrie C. Dehydroepiandrosterone
and peripheral androgen and oestrogen formation: intracrinology. Ann N Y Acad
Sci. 1995;774:16-28.
191. LeClercq G, Heuson JC. Therapeutic significance of sex steroid hormone
receptors in the treatment of breast cancer. Eur J Cancer 1977; 13:1205-1215.
209
192. Lee AV, Hilsenbeck SG, Yee D. IGF system components as prognostic markers
in breast cancer. Breast Cancer Res Treat 1998; 47: 295-302.
193. Lippert TH, Seeger H, Mueck AO. Metabolism of endogenous oestrogens In:
Oestrogens and antioestrogens: handbook of experimental pharmacology. Oettel
M, Schillonger E (eds), Springer Verlag, Berlin, 1998:243-71.
194. Lippman ME, Bolan G. Oestrogen responsive breast cancer in long-term tissue
culture. Nature 1975; 256:592- 593.
195. Lippman ME, Dickson RB, Gelmann EP, Rosen N, Knabbe C, Bates S et al.
Growth regulation of human breast carcinoma occurs through regulated growth
factor secretion. J Cell Biochem 1987; 35:1-16.
196. Lipsett M. Steroid hormones. In: Reproductive Endocrinology: Physiology,
Pathophysiology and Clinical Management, Yen SSC, Jaffe RB (eds), WB
Saunders, Philadelphia, 1986:140-153
197. Lipton A, Santner SJ, Santen RJ, Harvey HA, Feil PD, White-Hershey D et al.
Aromatase activity in primary and metastatic human breast cancer. Cancer 1987;
59:779-782.
198. Litherland S, Jackson I.M. Antioestrogens in the management of hormone-
dependent cancer. Cancer Treat Rev 1988; 15: 183-194
199. Longcope C, Pratt JH, Schneider SH, Fineberg SE. Aromatisation of androgens
by muscle and adipose tissue in vivo. J Clin Endocrinol Metab 1978; 46:146-
152.
200. Lonning PE. Pharmacology of new aromatase inhibitors. The Breast 1996; 5:
202-208.
201. Lonning PE, Helle SI, Johannessen DC, Ekse D, Adlercreeutz H. Influence of
plasma oestrogen levels on the length of the disease free-interval in
postmenopausal women with breast cancer. Breast Cancer Res Treat 1996;
39:335-341.
202. Lonning PE, Paridaens R, Thurlimann B, Piscitelli G, di Salle E. Exemestane
experience in breast cancer treatment. J Steroid Biochem Mol Biol 1997; 61:151.
210
203. Lonning PE, Geisler J, Dowsett M. Pharmacological and clinical profile of
anastrozole. Breast Cancer Res Treat 1998; 49:S53-57.
204. Lonning PE. Adjuvant endocrine treatment of early breast cancer. Hematol
Oncol Clin North Am. 2007; 21 (2):223-38.
205. Love RR, Newcomb PA., Wiebe DA., Surawicz TS, Jordan VC, Carbone PP,
DeMets D L. Effects of tamoxifen therapy on lipid and lipoprotein levels in
postmenopausal patients with node negative breast cancer. J Natl Cancer Inst
1990;82:1327-1332
206. Lu Q, Nakamura J, Savinov A, Yue W, Weisz J, Dabbs DJ et al. Expression of
aromatase protein and messenger ribonucleic acid in tumour epithelial cells and
evidence of functional significance of locally produced oestrogen in human
breast cancers. Endocrinology 1996; 137:3061-3068.
207. Luft R, Olivencrona H. Experience with hypophysectomy in man. J Neurosurg
1953; 10:301-316.
208. Lundgren S, Gundersen S, Klepp R, Lonning PE, Lund E, Kvinnsland S.
Megestrol acetate versus aminoglutethimide for metastatic breast cancer. Breast
Cancer Res Treat 1989; 14:201-206.
209. Macaulay VM, Nicholls JE, Gledhill J, Rowlands MG, Dowsett M, Ashworth A.
Biological effects of stable over expression of aromatase in human hormone-
dependent breast cancer cells. Br J Cancer 1994; 69:77-83.
210. McArdle CS, Crawford D, Dykes EH, Caiman KC, Hole D, Russell AR et al.
Adjuvant radiotherapy and chemotherapy in breast cancer. Br J Surg 1986;
73:264-266.
211. MacDonald PC, Edman CD, Hemsell DL, Porter JC, Siiteri PK. Effect of obesity
on conversion of plasma androstenedione to oestrone in postmenopausal women
with and without endometrial cancer. Am J Obstet Gynecol 1978; 130:448-455.
212. MacDonald PC, Madden JD, Brenner PF, Wilson JD, Siiteri PK. Origin of
oestrogen in normal men and in women with testicular feminisation. J Clin
Endocrinol Metab 1979; 49:905-916.
211
213. Mahendroo M, Mendelson CR, Simpson ER. Tissue specific and hormonally
controlled alternative promoters regulate aromatase cytochrome P450 gene
expression in human adipose tissue. J Biol Chem 1993; 268:19463-19470.
214. Mahendroo MS, Mendelson CR, Simpson ER. Tissue-specific and hormonally
controlled alternative promoters regulate aromatase cytochrome P450 gene
expression in human adipose tissue. J Biol Chem 1993; 268:19463-19470.
215. Manders P, Beex LV, Tjan-Heijnen VC, Span PN, Sweep CG. Vascular
endothelial growth factor is associated with the efficacy of endocrine therapy in
patients with advanced breast carcinoma. Cancer 2003; 98(10):2125-2132.
216. Manders P, Tjan-Heijnen VC, Span PN, Grebenchtchikov N, Geurts-Moespot
AJ, van Tienoven DT, Beex LV, Sweep FC: The complex between urokinase-
type plasminogen activator (uPA) and its type-1 inhibitor (PAI-I) independently
predicts response to first-line endocrine therapy in advanced breast cancer.
Thromb Haemost 2004; 91(3):514-521.
217. Masamura S, Adlercreutz H, Harvey H, Lipton A, Demers LM, Santen RJ,
Santner SJ. Aromatase inhibitor development for treatment of breast cancer.
Breast Cancer Res Treat 1995; 33:19-26.
218. Matsumoto K. Hormones and growth of cancer. Nippon Naibunpi Gakkai Zasshi.
1992; 68:577-583.
219. McGuire WL, Carbone PP, Sears ME, Escher GC. Oestrogen receptors in human
breast cancer: an overview. In: Oestrogen receptors human breast cancers, Raven
Press, New York, 1975.
220. McGuire WL, Chamness GC, Fuqua SA. Oestrogen receptor variants in clinical
breast cancer. Mol Endocrinol 1991; 5:1571-1577.
221. McGuire WL. Steroid hormone receptors in breast cancer treatment strategy. Rec
Prog Hormone Res 1980;36:135-156
222. Mclnerney EM, Tsai MJ, O'Malley BW, Katzenellenbogen BS. Analysis of
oestrogen receptor transcriptional enhancement by a nuclear hormone receptor
coactivator. ProcNatl Acad Sci USA 1996; 93:10069-10073.
212
223. Means GD, Mahendroo MS, Corbin CJ, Mathis JM, Powell FE, Mendelson CR
et al. Structural analysis of the gene encoding human aromatase cytochrome P-
450, the enzyme responsible for oestrogen biosynthesis. J Biol Chem. 1989;
264:19385-19391.
224. Means GD, Mahendroo MS, Corbin CJ, Mathis JM, Powell FE, Mendelson CR,
Simpson ER. Structural analysis of the gene encoding human aromatase
cytochrome P-450, the enzyme responsible for estrogen biosynthesis. J Biol.
Chem. 1989;264:19385-19391.
225. Mendelson CR, Corbm CJ, Smith ME, smith J, Simpson ER. Growth factors
suppress and phorbol esters potentiate the action of dibutyryl adenosine 3', 5'-
monophosphate to stimulate aromatase activity of human adipose stromal cells.
Endocrinol 1986; 118:968- 973.
226. Mendelson CR, Evans CT, Simpson ER. Regulation of aromatase in oestrogen-
producing cells. J Steroid Biochem 1987; 27:753-737.
227. Miller AA, Becher R, Schmidt CG. Plasma concentrations of
medroxyprogesterone acetate and megestrol acetate during long-term follow-up
in patients treated for metastatic breast cancer. J Cancer Res Clin Oncol 1988;
114:186-190.
228. Miller WR, Flawkins RA, Forrest AP. Significance of aromatase activity in
human breast cancer. Cancer Res 1982; 42:3365s-3368s.
229. Miller WR, Dixon JM, Scott WN, Forrest APM. Classification of human breast
cysts according to electrolyte and androgen conjugate composition. Clin Oncol
1983; 9: 227 -232.
230. Miller WR. Steroid metabolism in breast cancer. Rev Endocr Rel Cancer 1986;
23: 23-30.
231. Miller WR, O'Neill J. The importance of local synthesis of oestrogen within the
breast. Steroids 1987; 50:537-48.
232. Miller WR. Endocrine treatment for breast cancers: Biological rationale and
current progress. J Steroid Biochem Mol Biol 1990; 37:467-480.
213
233. Miller WR. Aromatase activity in breast tissue. J Steroid Biochem Mol Biol.
1991; 39:783-790.
234. Miller WR, Anderson TJ, Hawkins RA, Keen J, Dixon JM. Neoadjuvant endocrine
235. treatment; the Edinburgh experience. In: Howell A, Dowsett M, eds. European
School of Oncology Update Vol 4- Primary Medical Therapy for Breast Cancer.
Amsterdam: Elsevier, 1991:89-99.
236. Miller WR, Mullen P. Factors influencing aromatase activity in the breast. J
Steroid Biochem Molec Biol 1993; 44:597-604.
237. Miller WR. Steroid hormones and cancer: basic biology and endocrinology. Eur
J Surg Oncol 1996; 22:627- 637.
238. Miller WR, Mullen P, Sourdaine P, Watson C, Dixon JM, Telford J. Regulation
of aromatase activity within the breast. J Steroid Biochem Mol Biol. 1997;
61:193-202.
239. Miller WR. Biology of aromatase inhibitors: pharmacology/endocrinology
within the breast. Endocr Relat Cancer 1999; 6:187-195.
240. Miller WR, Dixon JM. Antiaromatase agents: preclinical data and neoadjuvant
therapy. Clin Breast Cancer 2000; FS9-S14.
241. Miller WR, Anderson TJ, Evans DB, Krause A, Hampton G, Dixon JM. An
integrated view of aromatase and its inhibition. J Steroid Biochem Mol Biol
2003; 86: 413-421.
242. Miller WR, Jackson J. The therapeutic potential of aromatase inhibitors. Expert
Opin Investig Drugs. 2003; 12:337- 351.
243. Mosselman S, Polman J, Dijkema R. ER beta: identification and characterization
of a novel human oestrogen receptor. FEBS Lett. 1996; 392:49-53.
244. Naftolin F, Ryan KJ, Petro Z. Aromatisation of androstenedione. J Clin
Endocrinol Metab 1970; 33:368-370.
245. Nash JD, Ozols RF, Smyth JF, Hamilton TC. Oestrogen and antioestrogen
effects on the growth of human epithelial ovarian cancer in vitro. Obstet Gynecol
1989; 73: 1009-1016.
214
246. National Statistics, Cancer trends in England and Wales 1950 - 1999. SMPS
No.66, The Stationery Office.
247. National Statistics, Mortality statistics: cause, England and Wales 2000 (2001),
General Register Office for Scotland, Annual Report for Scotland 2000 (2001),
General Register Office for Northern Ireland, Annual Report 2000 (2001).
248. Nevassaari K, Heikkinen M, Taskinen P. Tamoxifen and thrombosis. Lancet
1978; 2:946-947.
249. Noel A, Hajitou A, Hoir C L et al. Inhibition of stromal matrix metalloproteases:
effects on breast-tumour promotion by fibroblasts. Int J Cancer 1998; 76:267-
273.
250. Nolvadex Adjuvant Trial Organization: Controlled trial of tamoxifen as adjuvant
agent in management of early breast cancer: Interim analysis at 4 years by
NATO. Lancet 1983; 1:257-261.
251. Nuttall ME, Bradbeer IN, Stroup GB, Nadeau DP, Hoffman SJ, Zhao H et al.
Idoxifene: a novel selective oestrogen receptor modulator prevents bone loss,
lowers cholesterol levels in ovariectomized rats and decreases uterine weight in
intact rats. Endocrinology 1998; 139:5224-5234.
252. O'Neill JS, Elton RA, Miller WR. Aromatase activity in adipose tissue from
breast quadrants: a link with tumour site. BMJ 1988; 296:741-743.
253. O'Regan RM, Cisneros A, England GM, MacGregor JI, Muenzner HD, Assikis
VJ, et al. Effects of the antioestrogens tamoxifen, toremifene and IC 182,780 on
endometrial cancer growth. J Natl Cancer Inst 1998; 90:1552-1558.
254. Osborne CK and Arteaga CL. Autocrine and paracrine growth regulation of
breast cancer: clinical implications. Breast Cancer Res Treat 1990; 15:3-11.
255. Osborne CK. Tamoxifen in the treatment of breast cancer. N Engl J Med 1998;
339:1609-1618.
256. Olivotto I.A., Bajdik CD, Ravdin PM., et al: Population-based validation of the
prognostic model adjuvant for early breast cancer. J Clin Oncol 2005; 23(12):
2716-2725.
215
257. Ovarian ablation or suppression in premenopausal early breast cancer: results
from the international adjuvant breast cancer ovarian ablation or suppression
randomized trial. Adjuvant Breast Cancer Trials Collaborative Group. J Natl
Cancer Inst 2007; 99(7):516
258. Parazzini F, Braga C, La Vecchia C, Negri E, Acerboni S, Franceschi S.
Hysterectomy, oophorectomy in premenopause, and risk of breast cancer. Obstet
Gynecol 1997; 90:453-6.
259. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of
tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004; 351:2817-
2826
260. Perel E, Wilkins D, Killinger DW. The conversion of androstenedione, to
oestrone, oestradiol, and testosterone in breast tissue. J Steroid Biochem 1980;
13: 89-94.
261. Perel E, Blackstein ME, Killinger DW. Aromatase in human breast carcinoma.
Cancer Res 1982; 42:3369a-3372a.
262. Perez CR, Alberola CV, Calabressi F, Michael RT, Santos R, Delozier T et al.
Comparison of the selective aromatase inhibitor formestane with tamoxifen as
first line hormonal therapy in post menopausal women with advanced breast
cancer. Ann Oncol 1994; 5:S 19-24.
263. Peto R, Boreham J, Clarke M, Davies C, Beral V. UK and USA breast cancer
deaths down 25% in year 2000 at ages 20-69 years. Lancet 2000; 355: 1822.
264. Romond EH., Perez EA., Bryant J et al. Trastuzumab plus adjuvant
chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005;
353 (16): 1673-1684.
265. Peto R., Boreham J, Clark M., et al: UK and USA breast cancer deaths down
25% in year 2000 at ages 20-69 years. Lancet 2000; 355 (9217): 1822.
266. Pedchenko VK, Imagawa W: Estrogen treatment in vivo increases keratinocyte
growth factor expression in the mammary gland. J Endocrinol 2000; 165:39-49
267. Plourde PV, Dyroff M, Dukes M. Arimidex: a potent and selective fourth
generation aromatase inhibitor. Breast Cancer Res Treat 1994; 30:103-111.
216
268. Plourde PV, Dyroff M, Dowsett M, Demers L, Yates R, Webster. Arimidex: a
new oral once-a-day aromatase inhibitor. J Steroid Biochem Mol Biol 1995;
53:175-179.
269. Poortman J, Thijssen JHH, Schwarz F. Androgen production and conversion to
oestrogens in normal postmenopausal women and in selected breast cancer
patients. J Clin Endocrinol Metab 1973; 37:101.
270. Price T, Aitken J, Head J, Mahendroo MS, Means GD, Simpson ER.
Determination of aromatase cytochrome P450 messenger RNA in human breast
tissues by competitive polymerase chain reaction amplification. J Clin
Endocrinol Metab 1992; 74:1247-1252.
271. Pritchard KI. The use of endocrine therapy. Hematol Oncol Clin North Am 1989;
3:765-805.
272. Pritchard KI. Endocrine therapy of advanced disease: analysis and implications
of the existing data. Clin Cancer Res 2003; 9:460S-467S
273. Purohit A, Ghilchik MW, Duncan L, Wang DY, Singh A, Walker MM et al.
Aromatase activity and interleukin-6 production by normal and malignant breast
tissues. J Clin Endocr Metab 1995; 80:3052-3058.
274. Read LD, Katzenellenbogen BS. Characterisation and regulation of oestrogen
and progesterone receptors in breast cancer. Cancer Treat Res. 1992; 61:277-299.
275. Ravdin PM, Green S, Dorr TM et al. Prognostic significance of progesterone
receptor levels in oestrogen receptor-positive patients with metastatic breast
cancer treated with tamoxifen: results of a prospective Southwestern Oncology
Group study. J Clin Oncol 1992;10:1284-1291
276. Reed MJ, Owen AM, Lai LC, Coldham NG, Chilchick MW, Shaikh N A et al. In
situ oestrogen synthesis in normal breast and breast tumour tissues: effect of
treatment with 4-hydroxyandrostenedione. Int J Cancer 1989; 44:233- 237.
277. RelfM, LeJeune S, Scott PA et al. Expression of the angiogenic factors: vascular
endothelial cell growth factor, acidic and basic fibroblast growth factor, tumour
growth factor beta-1, platelet-derived endothelial cell growth factor, placental
217
growth factor and pleiotrophin in human primary breast cancer and its relation to
angiogenesis. Cancer Res 1997; 57:963-969
278. Richards JS, Hickey GJ, Chen SA, Shively JE, Hall PF, Gaddy-Kurten D et al.
Hormonal regulation of oestradiol biosynthesis, aromatase activity, and
aromatase mRNA in rat ovarian follicles and corpora lutea. Steroids 1987;
50:393-409.
279. Ring A, Dowsett M. Mechanisms of tamoxifen resistance. Endocr Relat Cancer
2004; 11:643-58.
280. Rose C, Mouridsen H. Preferred sequence of endocrine therapies in advanced
breast cancer. In: Endocrine-dependent breast cancer: Critical assessment of
recent advances, Santen R, Juhos E (eds), Hans Huber, Bern, 1988: 81.
281. Robertson JF, Blarney RW. The use of gonadotrophin-releasing hormone
(GnRH) agonists in early and advanced breast cancer in pre- and perimenopausal
women. Eur J Cancer 2003; 39(7):861-9.
282. Robertson J. Selective oestrogen receptor modulators/new antioestrogens: a
clinical perspective. Cancer Treatment Reviews, 2004; 8: 695 - 706
283. Rubin GL, Zhao Y, Kalus AM, Simpson ER. Peroxisome proliferator-activated
receptor gamma ligands inhibit oestrogen biosynthesis in human breast adipose
tissue: possible implications for breast cancer therapy. Cancer Res 2000;
60:1604-1608.
284. Rudali G, Apion F, Muel B. Mammary cancer produced in mice with oestriol.
Eur J Cancer 1975; 11:39-41.
285. Russo J, Ao X, Grill C, Russo IH. Pattern of distribution of cells positive for
oestrogen receptor alpha and progesterone receptor in relation to proliferating
cells in the mammary gland. Breast Cancer Res Treat 1999; 53(3):217-27.
286. Russo J, Russo IH. The role of estrogen in the initiation of breast cancer. J
Steroid Biochem Mol Biol 2006; 102(1-5): 89-96
287. Santen RJ, Samojilik E, Wells SA. Resistance of the ovary to blockade of
aromatisation with aminoglutethimide. J Clin Endocrinol Metab 1980; 51:473-
477.
218
288. Santen RJ, Worgul TJ, Samojlik E, Interrante A, Boucher AE, Lipton A, et al. A
randomised trial comparing surgical adrenalectomy with aminoglutethimide plus
hydrocortisone in women with advanced breast cancer. N Engl J Med 1981; 305:
545-551.
289. Santen RJ, Worgul TJ, Lipton A, Harvey H, Boucher A, Samojlik E, et al.
Aminoglutethimide as treatment of postmenopausal women with advanced breast
carcinoma: correlation of clinical and hormonal responses. Ann Intern Med
1982; 96:94-101.
290. Santen RJ, Martel J, Hoagland M, Naftolin F, Roa L, Harada N et al. Stromal
spindle cells contain aromatase in human breast tumours. J Clin Endocrinol
Metab 1994; 79:627-632.
291. Santen RJ, Martel J, Hoagland M, Naftolin F, Roa L, Harada N et al.
Demonstration of aromatase activity and its regulation in breast tumour and
benign breast fibroblasts. Breast Cancer Res Treat 1998; 49:S93-S99.
292. Santen RJ, Yue W, Naftolin F, Mor G, Berstein L. The potential of aromatase
inhibitors in breast cancer prevention. Endocr Rel Cancer 1999; 6:235- 243.
293. Sasano H, Murakami H. Immunolocalisation of aromatase in human breast
disorders using different antibodies. Breast Cancer Res Treat 1998a; 49:S79-84.
294. Sasano H, Takashashi K, Satoh F, Nagura H, Harada N. Aromatase in the human
central nervous system. Clin Endocrinol 1998b; 48:325-329.
295. Sasano H, Harada N. Intratumoral Aromatase in human Breast, endometrial and
ovarian malignancies. Endocr Rev 1998c; 19:593-607.
296. Sasano H, Edwards DP, Anderson TJ, Silverberg SG, Evans DB, Santen RJ et al.
Validation of new aromatase monoclonal antibodies for immunohistochemistry:
progress report. J Steroid Biochem Mol Biol. 2003; 86:239-244.
297. Sasco AJ, Kaaks R, Little RE. Breast cancer: occurrence, risk factors and
hormone metabolism. Expert Rev Anticancer Ther 2003; 3:546-562.
298. Schmitt FC. Multistep progression from an oestrogen dependent growth towards
an autonomous growth in breast carcinogenesis. Europ J Cancer 1995; 12:2049-
2052.
219
299. Sengupta S, Jordan VC. Selective oestrogen modulators as an anticancer tool:
mechanisms of efficiency and resistance. Adv Exp Med Biol 2008; 630:206-19.
300. Shaw HS, Ellis MJ. Letrozole in the treatment of breast cancer. Expert Opin
Pharmacotherapy 2002; 3:607-617.
301. Shenton KC, Dowsett M, Lu Q, Brodie AMH, Sasano H, Sacks NP, Rowlands
MG. Comparison of biochemical aromatase activity with aromatase
immunohistochemistry in human breast carcinomas. Breast Cancer Res Treat
1998; 49:S 101-107.
302. Shibuya K, Mathers CD, Boschi-Pinto C, Lopez AD, Murray CJ. Global and
regional estimates of cancer mortality and incidence by site: II. Results for the
global burden of disease 2000. BMC Cancer 2002; 2:37.
303. Silva MC, Rowlands MG, Dowsett M, Gusterson B, McKinna JA, Fryatt I et al
Intratumoral aromatase as a prognostic factor in human breast carcinoma. Cancer
Res 1989;49:2588-2591.
304. Simpson ER, Ackerman GE, Smith ME, Mendelson CR. Oestrogen formation in
stromal cells of adipose tissue of women: induction by glucocorticoids. Proc Natl
Acad Sci 1981; 78:5690-5694.
305. Simpson ER, Cleland WH, Mendelson CR. Aromatisation of androgens by
human adipose tissue in vitro. J Steroid Biochem. 1983; 19( 1 B):707-713.
306. Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Corbin CJ, Mendelson
CR. Tissue-specific promoters regulate aromatase cytochrome P450 expression.
Clin Chem 1993;39:317-324.
307. Simpson ER, Zhao Y, Agarwal VR, Michael MD, Bulun SE, Hinshelwood MM,
et al. Aromatase expression in health and disease. Recent Prog Horm Res 1997;
52: 185-213.
308. Simpson ER, Zhao Y, Agarwal VR, Michael MD, Bulun SE, Hinshelwood MM,
Graham-Lorence S, Sun T, Fisher CR, Qin K, Mendelson CR. Aromatase
expression in health and disease. Recent Prog Horm. Res 1997; 52:185-213.
220
309. Siiteri PK, Macdonald PC. Role of extraglandular oestrone metabolism in human
endocrinology. In: Handbook of physiology, Greep RO, Astwood EB (eds),
American Physiological society, Washington DC, 1973:615- 630.
310. Siiteri PK. Review of studies on oestrogen biosynthesis in the human.
Cancer Res 1982 42:3269-3273
311. Smith I, Dowsett M. Comparison of anastrozole vs tamoxifen alone and in
combination as neoadjuvant treatment of estrogen receptor positive (ERC)
operable breast cancer in postmenopausal women: the IMPACT trial. Breast
Cancer Res Treat 2003; 82 (Suppl 1):S6
312. Sourdaine P, Parker MG, Telford J, Miller WR. Analysis of the aromatase
cytochrome P450 gene in human breast cancers. J Mol Endocrinol. 1994; 3:331-
337.
313. Sorlie T, Tibshirani R, Parker J, et al: Repeated observation of breast tumor
subtypes in independent gene expression data sets. Proc Natl Acad Sci USA
2003; 100:8418-8423
314. Speirs V, Carder PJ, Lane S, Dodwell D, Lansdown MRJ, Hanby AM. Oestrogen
receptor B: what it means for patients with breast cancer. Lancet Oncol 2004;
5:174-181.
315. Stoll BA. Progestin therapy of breast cancer: comparison of agents. BMJ 1967;
2:338-341.
316. Surmacz E, Guvakova MA, Nolan MK, et al. Type 1 insulin-like growth factor
receptor function in breast cancer. Breast Cancer Res Treat 1998; 47:255-267.
317. Sutherland RL, Thrall OWJ, Watts CKW, Musgrave E. Oestrogen and progestin
regulation of cell cycle progression. J Mamm Gland Bio Neoplasia 1998; 3:63-
72.
318. Tabar L, Vitak B, Chen HH, Yen MF, Duffy SW, Smith RA et al. Beyond
randomised controlled trials: organized mammographic screening substantially
reduces breast carcinoma mortality. Cancer. 2001; 91:1724-1731.
319. Tan SH, WolffAC. The role of ovarian ablation in the adjuvant therapy of breast
cancer.Curr Oncol Rep 2008; 10(l):27-37.
221
320. Theodor HL, Harald S, Alfred OM. The impact of endogenous oestradiol
metabolites on carcinogenesis. Steroids 2000; 65: 357-369.
321. Thompson EA Jr, Siiteri PK. The involvement of human placental microsomal
cytochrome P-450 in aromatization. J Biol Chem. 1974; 249:5373-5378.
322. Thomssen C, Schmitt M, Goretzki L, Oppelt P, Pache L, Dettmar P et al.
Prognostic value of the cysteine proteases cathepsin B and cathepsin L in human
breast cancer. Clin Cancer Res 1995; 1:741- 746.
323. Thorsen T, Tangen M, Stoa KF. Concentration of endogenous oestradiol as
related to oestradiol receptor sites in breast tumour cytosol. Eur J Cancer Clin
Oncol 1982; 18:333-337.
324. Thurlimann B, Keshaviah A, Coates AS, et al. Breast International Group (BIG)
1-98 Collaborative Group. A comparison of letrozole and tamoxifen in
Postmenopausal women with early breast cancer. N Engl J Med 2005; 353:2747-
57.
325. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, Banerjee S, Koenig KL, Shore
RE, et al. A prospective study of endogenous oestrogens and breast cancer in
postmenopausal women. J Natl Cancer Inst. 1995; 87:190-197.
326. Travis RC, Key TJ. Oestrogen exposure and breast cancer risk. Breast Cancer
Res 2003; 5:239-247.
327. Trichopoulas D, MacMahon B, Cole P. Menopause and breast cancer risk. J Natl
Cancer Inst 1972; 48:605-613.
328. Trunet PF, Vreeland F, Royce C, Chaudri HA, Cooper J, Bhatnagar AS. Clinical
use of aromatase inhibitors in the treatment of advanced breast cancer. J Steroid
Biochem Mol Biol. 1997; 61:241-245.
329. Tzukerman M, Esty A, Santiso-Mere D. Human oestrogen receptor
transactivational capacity is determined by both cellular and promoter context
and mediated by functionally distinct intramolecular regions. Mol Endocrinol
1994; 8:21-30.
330. Ulrich P. Testosterone (Male Hormone) et son role possible dans le traitement
de certains cancers du sein. Internat. Union Cancer. 1939: 4:377.
222
331. Utsumi T, Harada N, Maruta M, Takagi Y. Presence of alternatively spliced
transcripts of aromatase gene in breast cancer. J Clin Endocrinol Metab 1996; 81:
2344-2349.
332. Van Leeuwen FE, Benraadt J, Coebergh JW, Kiemeney LA, Gimbrere CH, Otter
R et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer.
Lancet 1994; 343:448- 452.
333. Varela RM, Thomas GH. Oestrogen synthesis and oestradiol binding by human
mammary tumours. Cancer Res 1978; 38:2429- 2433.
334. Veronesi U, Pizzocaro G, Rossi A. Oophorectomy for advanced carcinoma of the
breast. Surg Gynaecol Obstet 1975; 141:569 -570.
335. Veronesi U, Saccozzi R, Del Vecchio M, Banfi A, Clemente C, De Lena M et al.
Comparing radical mastectomy with quadrantectomy, axillary dissection, and
radiotherapy in patients with small cancers of the breast. N Engl J Med. 1981;
305:6-11.
336. Vihko RK, Apter DL. The epidemiology and endocrinology of the menarche in
relation to breast cancer. Cancer Surv 1986; 5:561-571.
337. Vignon F, Terqui M, Westley B, Derocq D, Rochefort H. Effects of plasma
oestrogen sulfates in mammary cancer cells. Endocrinology 1980; 106:1079-
1086
338. Waard F. This may result from the reduced frequency of ovulatory menstrual
cycles associated with high body weight. Cancer 1977; 40:1269-1275.
339. Ward E1WC, Arthur K, Banks AJ, et al. Anti-oestrogen therapy for breast cancer
- report on 300 patients treated with tamoxifen. Clin Oncol 1978; 4:11-17
340. West CP, Baird DT. Suppression of ovarian activity by Zoladex depot (ICI
118630), a long-acting luteinizing hormone releasing hormone agonist analogue.
Clin Endocrinol 1987; 26:213-220.
341. Weippl SK, Goss PE. Advances in Adjuvant Hormonal Therapy for
Postmenopausal Women. J Clin Oncol 2005; 23:1751-1759
342. Wolf D, Fuqua S. Mechanisms of action of antioestrogens. Cancer Treat Rev
1995; 21:257-271.
223
343. Woodward TL, Xie JW, Fendrick JL, Haslam SZ: Proliferation of mouse
mammary epithelial cells in vitro: interactions among epidermal growth factor,
insulin-like growth factor-I, ovarian hormones and extracellular matrix proteins.
Endocrinology 2000; 141:3578-3586
344. Woodward TL, Xie JW, Haslam SZ. The role of mammary stroma in
modulating the proliferative response to ovarian hormones in the normal
mammary gland. J Mammary Gland Biol Neoplasia 1998; 3:117-131
345. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology
technology assessment on the use of aromatase inhibitors as adjuvant therapy for
postmenopausal women with hormone receptor-positive breast cancer: status
report 2004. J Clin Oncol 2005; 23:619-29.
346. Wysowski DK, Honig S, Beitz J. Uterine sarcoma associated with tamoxifen use.
N Engl J Med 2002; 346:1832-3.
347. Xie J, Haslam SZ: Extracellular matrix regulates ovarian hormone-dependent
proliferation ofmouse mammary epithelial cells. Endocrinology 1997; 138:2466-
2473
348. Yamamoto KR. Steroid receptor transcription of specific genes and gene
networks. Amer Rev Genetics 1989; 19:209-252.
349. Yee D, Lee AV. Cross talk between the insulin-like growth factors and
oestrogens in breast cancer. J Mammary Gland Biol Neoplasia 2000; 5:107-115.
350. Zhao Y, Nichols JE, Bulun SE, Mendelson CR, Simpson ER. Aromatase P450
gene expression in human adipose tissue. Role of a Jak/STAT pathway in
regulation of the adipose-specific promoter. Biol Chem 1995; 270:16449-16457.
351. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Oestrogen biosynthesis
proximal to a breast tumor is stimulated by PGE2 via cyclic AMP, leading to
activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996;
137:5739-5742
352. Zhang Z, Yamashita H, Toyama T, Omoto Y, Sugiura H, Hara Y et al.
Quantitative determination by real-time reverse transcription polymerase chain
224
reaction of aromatase mRNA in invasive ductal carcinoma of the breast. Breast
Cancer Res 2003; 5:250-256.
353. Zhou C, Zhou D, Esteban J, Murai J, Siiteri PK, Wilczynski S, Chen S.
Aromatase gene expression and its exon I usage in human breast tumors.
Detection of aromatase messenger RNA by reverse transcription-polymerase
chain reaction. J Steroid Biochem Mol Biol. 1996; 59:163-171.
354. Zhou J, Gurates B, Yang S, Sebastian S, Bulun SE. Malignant breast epithelial
cells stimulate aromatase expression via promoter II in human adipose
fibroblasts: an epithelial-stromal interaction in breast tumors mediated by
CCAAT/enhancer binding protein beta. Cancer Res 2001; 61:2328-2334.
225
ABBREVIATIONS USED IN TEXT
Cyclic AMP cyclic adenosine monophosphate
UK United Kingdom




EGF epidermal growth factor
IGF insulin-like growth factor
FGF fibroblast growth factor
TGF transforming growth factor
LHRH luteinizing hormone-releasing hormone
FSH follicle stimulating hormone
LH luteinizing hormone
NATO Nolvadex Adjuvant Trial Organisation
EBCTCG Early Breast Cancer Trialist's Collaborative Group
NSABP National Surgical Adjuvant Breast and Bowel
Project
SERMS selective oestrogen receptor modulators
PGE prostaglandin
RACE rapid amplication of cDNA ends
GAS gamma activating sequence
STAT signal transducer and activator of the transcription
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MA megestrol acetate
PBS phosphate buffered saline
MEM minimal essential medium




PCR polymerase chain reaction










#22571-020 LIFE TECHNOLOGIES [UK]
Foetal Bovine Serum
(heat inactivated)
#F9665 SIGMA ALDRICH [UK]
Dulbecco's Phosphate Buffered
Saline
#D5652 SIGMA ALDRICH [UK]
Penicillin & Streptomycin
(10,000 units/lOmg)
#P0781 SIGMA ALDRICH [UK]
Culture plates - 6 well plates
(polystrene)
#C3516 MACKAY AND LYNN [UK]
Collagenase type VIII #C2139 SIGMA ALDRICH [UK]
Syringe Filter 0.2pm #S2052-025 MACKAY AND LYNN [UK]
Pasette 1ml (plastic) #Z350591 SIGMA ALDRICH [UK]
Glass pipettes -10ml #PP280-53 STERILIN [UK]
Glass test tubes (ground socket) # MF24/1 MACKAY & LYNN [UK]
Petri dishes # P3924 MACKAY AND LYNN [UK]
Trypsin EDTA solution #T4299 SIGMA ALDRICH [UK]
Bio-freeze vials #C4166 COSTAR [UK]
Chloroform CDG # RH2009 RATHBURN CHEMICALS [UK]
228
IB- Androst-4ene-3, 17-dione NET-926
4-Androst-4ene-3, 17-dione #A9630
Charcoal (activated USP) #C7606
New-born calf serum
Liquid scintillant

















# BD 753-62 MACKAY & LYNN [UK]






Adenosine 5' Triphosphate [ATP]




























































Collagenase dissolved at lmg/ml of alpha MEM.
Filtered through a millex-GS sterile 0.22 pm filter and stored in 5ml aliquots at -20°C.
Freezing mixture
90% New-born calf serum [heat inactivated]
10% Dimethyl sulphoxide
Phosphate buffer
Phosphate buffer was prepared as follows:
Phosphate buffer [0.1 M, pH 7.4 containing 5mM MgCl2]
A. 0.2M Na2HPO4.2H20 8.90g/250ml
B. 0.2M NaH2P04.2H20
3.12g/100ml
202.5ml of solution A }
47.5 ml of solution B } to 500 ml
509.5 mg ofMgC12.6H20 }
Precursor mixture
10 pi of 6Glucose phosphate dehydrogenase
10 pi of 1 (3 3H androst-4-ene-3, 17- dione
100 pi of inhibitor [letrozole]
0.5 ml of cofactor mixture
0.5ml of particulate fraction
0.5ml of buffer to the blanks for the particulate fraction
80 pi of cold 1 B 3H androst-4-ene-3, 17- dione
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The cofactors were prepared as detailed below:
Cofactors mg/ml
• Adenosine 5'Triphosphate [ATP], 22 mM 13.31
• B Nicotinamide adenine dinucleotide [NAD], 22 mM 14.59
• B Nicotinamide adenine dinucleotide phosphate [NADP], 22 mM 18.66
• Nicotinamide, lOOmM 13.43
• Glucose 6 phosphate, 110 mM 39.39
• Glucose 6 phosphate dehydrogenase 250 units/ml of buffer
SOLUTION VOLUME / INCUBATION FINAL
ATP [22 mM] 100 pi 2 mM
NAD 22mM] 100 pi 2 mM
NADP [22mM] 100 pi 2 mM
NICOTINAMIDE [llOmM] 100 pi 10 mM
GLUCOSE 6 PHOPHATE [ 11 OmM] 100 pi 10 mM
G6PDH [250 units/ml] 10 pi 2.3
1B-3H- ANDROST-4-ENE-3,17-DIONE 10 pi lpCi
[lOOuCi/ml, 3.65nmol/ml]





Charcoal 5g in 100ml buffer containing 0.05% Tween 80 [v/v].
Charcoal pellets were prepared by centrifuging 1ml [2000g for 15 min] in
12mmX 75 mm glass tubes and aspirating the supernatant.
Androst-4-ene-3, 17-dione
1 B 3H androst-4-ene-3, 17-dione, lOOuci/ml 3.61nmol/ml.
Purified by thin layer chromatography on silica gel using chloroform: acetone [185:15],
Dissolved in ethanol to a concentration of lOOuCi/ml. Duplicate aliquots [lOpl] were
transferred at the time of addition of the titrated to the incubation mixture, into
60x27mm glass counting vials containing 10ml NE260 liquid scintillator for
measurement of the specific activity of the precursor.
Androst-4-ene-3, 17-dione
Androst-4-ene-3, 17-dione, 22ng/ml in buffer.
Prepared from a lmg/ml ethanolic solution as follows:
1. Diluted 0.1 ml to 10 ml with buffer to give a 10 pg/ml solution
2. Diluted 0.1 ml of solution [1] to 4.4 ml with buffer to give a 227ng/ml solution.
Reaction Mixture
Reaction Mixture was prepared as detailed below.
10 pi of 1B-3H androst -4ene-3, 1-17 dione [2p Ci]
90 pi of cold anrost-4ene-3, 7 dione
3.9 ml of alphaMEM containing no FCS
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Charcoal suspension preparation
Charcoal [sigma C5260]: 5g in 100ml buffer containing 0.05% Tween 80 [v/v].
Charcoal pellets were prepared by centrifuging 1ml [2000g for 15 min] in 12mmX
75mm glass tubes and aspirating the supernatant.
RNA mix
0.5 pi of rRNasin ribonuclease inhibitor [40units/pl]
4 pi of 25 mM MgCL2
2 pi of 10 X reverse transcription buffer
2 pi of 1 OmM dNTP mixture
1 pi of oligo [dT] [0.5 pi]
0.6 pi ofAMV reverse transcriptase [HC: 25 units / pi]
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